The Integrative Cardiologist

Nitric Oxide: Your Body’s Natural Blood Pressure Biohack

Dr. Sameer Azhak — Tue, 27 Oct 2026 11:03:50 GMT

The Integrative Cardiologist · By Sameer Azhak, MD, FACC

At a Glance

Your artery lining makes nitric oxide, a gas that helps the surrounding muscle relax. Your body produces it through an enzyme pathway and through a second pathway that uses nitrate from foods such as leafy greens and beets.¹,²
Beetroot juice has lowered blood pressure in some trials. Results vary, and one favorable trial does not tell us how much benefit you should expect.³,⁴,⁵
Garlic & Garlic supplements can lower blood pressure in people with hypertension, but the evidence comes from specific preparations—not simply adding a clove to dinner.⁶,⁷,⁸
Excess added sugar, particularly in sweetened drinks, deserves attention. Ordinary portions of whole fruit are not the target.⁹,¹⁰,¹¹
Exercise helps your arteries make nitric oxide and supports vascular function. Its benefits extend well beyond this one pathway.¹²,¹³
These approaches belong in a broader plan. Their study results cannot be added together to predict your response, and none is a reason to stop prescribed treatment on your own.¹⁴

“Is there anything I can eat or do besides another pill?”

I hear this question often when we discuss high blood pressure.

You deserve a better answer than “eat healthy.”

We’ve already talked about magnesium, sleep, exercise, and other parts of a blood-pressure plan. This article builds on that foundation, taking a closer look at nitric oxide and how everyday choices can support the work your blood vessels are already doing.

Part of the answer begins inside your blood vessels. Their lining makes nitric oxide, a gas that tells the surrounding muscle to relax. Several foods and habits influence how much is available and how well that signal works.¹

Think of your artery lining as a pharmacy that produces some of its own medicine.

The comparison is not exact. Blood pressure depends on your kidneys, hormones, nervous system, arteries, medications, and more. But it captures something useful: your vessels do not simply carry blood. They actively help control the pressure.¹³,¹⁵

This article is about supporting that work—not replacing treatment you need.

Two roads to the same gas

The endothelium is the thin layer of cells lining your arteries.¹²

Those cells contain an enzyme called endothelial nitric oxide synthase, or eNOS. It converts the amino acid arginine into nitric oxide. The gas moves into nearby muscle cells and activates signals that help the artery relax.¹²

One important trigger is blood flow itself.

As blood moves along the lining, it creates a mechanical force called shear stress. That signal can activate eNOS. Repeated stimulation through exercise also helps the vessels adapt over time.¹,¹²,¹³

Your body has two routes:

The enzyme road: An enzyme called eNOS uses arginine to produce nitric oxide. Exercise supports this pathway. Cocoa flavanols and other dietary components may influence it too.¹,¹²,¹⁶
The nitrate road: Dietary nitrate becomes nitrite, which can then become nitric oxide. Leafy greens and beets supply nitrate. Bacteria in your mouth help with the conversion.²,¹⁷

Both routes contribute to nitric-oxide availability, but they are not interchangeable—and neither works in isolation from the rest of your health.¹²,¹⁷

Why the supply can falter

Nitric oxide is short-lived. Oxidative stress can reduce its availability before it delivers its signal.¹²,¹⁵

Pressure-raising pathways, including angiotensin II signaling, can increase production of reactive molecules in the vessel wall. These can interfere with nitric oxide and vascular relaxation.¹³,¹⁵

The enzyme itself can also malfunction.

eNOS needs supporting molecules to work properly. When those supports are disrupted, it can become “uncoupled,” producing more superoxide instead of nitric oxide.¹²

The pharmacy starts producing the wrong product.

This is one part of the relationship between hypertension and vascular dysfunction. High pressure can damage the lining, while impaired vessel relaxation can help sustain high pressure.¹³,¹⁵

The goal is not to flood your body with a gas. It is to support the pathways that make it and reduce the conditions that interfere with its action.

Beets and leafy greens: the nitrate road

The nitrate pathway starts with conversion—not with nitrate acting like a conventional drug.

After you eat nitrate-rich vegetables, nitrate enters your bloodstream. Some returns to your saliva. Bacteria on your tongue convert it into nitrite, which you swallow. Your body can then convert that nitrite into nitric oxide.²,¹⁷

In a 2008 experiment, beetroot juice lowered blood pressure within hours. When participants interrupted the saliva pathway by spitting rather than swallowing, the blood-pressure effect disappeared.²

The mouth was not optional.

What the blood-pressure trials found

One influential trial enrolled 68 adults with hypertension. Participants drank 250 mL of nitrate-rich beetroot juice or nitrate-depleted placebo juice daily for four weeks.³

The nitrate group had a reduction of about 7.7/5.2 mm Hg in 24-hour ambulatory pressure, alongside improved measures of vascular function. The effect faded after the intervention stopped.³

That is an encouraging result—not the result everyone should expect.

A separate one-week trial in people already receiving hypertension treatment found that beetroot juice increased nitrate and nitrite levels without lowering blood pressure.⁴

An earlier pooled analysis found an average systolic reduction of about 4 mm Hg. Later analyses have also highlighted differences between clinic and 24-hour measurements; improvement in one does not guarantee a significant change in the other.⁵,¹⁸

The practical conclusion: nitrate-rich beet products help some people, but the response varies.

Start with vegetables

You do not need a shot or powder to eat nitrate-rich foods.

Arugula, spinach, lettuce, and beets are useful sources. Their nitrate content varies with the vegetable and growing conditions.¹⁷,¹⁹

In a Danish study following more than 53,000 adults for about 21 years, higher vegetable-nitrate intake was associated with lower blood pressure and less cardiovascular disease. The association with lower cardiovascular risk appeared to level off at a moderate intake.²⁰

That was an observational study, not proof that nitrate alone caused the benefit. People eating more vegetables may differ in other ways.

Still, the direction is practical: put vegetables on the plate before building a supplement routine.

The source matters

Evidence about nitrate-rich vegetables does not justify eating more processed meat.

In a large French cohort, nitrite from food additives was associated with a higher risk of developing hypertension. That does not prove that the additive caused the outcome, and processed meat differs from vegetables in much more than nitrate or nitrite content.²¹

Treat the whole food as the intervention—not one chemical on its label.

What about mouthwash?

Because mouth bacteria help convert nitrate, researchers have asked whether antiseptic mouthwash disrupts the pathway.²²

In one small study, chlorhexidine mouthwash sharply reduced oral nitrite production and raised blood pressure by a few points.²²

Pooled studies have been less consistent. Reviews have not established a large, dependable blood-pressure increase from mouthwash use.²³,²⁴

Do not throw out a rinse your dentist prescribed.

If you use a strong antiseptic rinse every day out of habit, ask whether you need it. Oral health matters too.²³,²⁴

Concentrated products deserve a separate decision

A daily beet shot is not the same decision as eating a serving of spinach.

Research doses of concentrated nitrate can exceed the conservative acceptable daily intake used by food-safety authorities. That does not mean those doses have been shown to cause harm. It does mean short trials cannot establish the benefit and safety of taking a concentrated product indefinitely.⁵,¹⁷,¹⁹,²⁵

Vegetables remain the foundation.

If you consider juice, shots, or powders:

Check the serving size and sugar content. Unsweetened does not necessarily mean sugar-free.¹¹
Recognize that nitrate content varies among products.²⁶
Review it with your clinician if you already take blood-pressure medicine or have a condition that affects your dietary choices.
Use home readings to assess the response rather than assuming the product is working.

Beets can temporarily turn urine or stools pink or red. If discoloration is unexplained, persists, or comes with symptoms, do not automatically assume it is from beets.²,³

Garlic: food and extract are different interventions

Garlic has a long history in food and medicine. Its chemistry changes when you crush it, heat it, or age it.²⁷,²⁸

Those distinctions matter because the blood-pressure trials tested particular preparations—not an interchangeable substance called “garlic.”

What crushing does

An intact clove keeps alliin separate from the enzyme alliinase.²⁷

Crush or chew the clove, and the two meet. Allicin forms, then breaks down into other sulfur compounds.²⁷,²⁸

In laboratory experiments, some garlic-derived compounds release hydrogen sulfide, another gas involved in vascular relaxation.²⁹

Allicin may contribute through the compounds it generates rather than circulating unchanged. The mechanism is more complicated than “allicin enters the blood and lowers pressure.”²⁸,²⁹

Heat changes the chemistry too. Cooking can inactivate alliinase, and the order of crushing and heating affects the compounds produced.²⁸,³⁰

For cooking, the simple approach is to crush first and avoid prolonged heating when you want to preserve more of that chemistry.³⁰

That is a food-preparation choice, not a proven blood-pressure dose.

What aging does

Aged garlic extract develops a different mixture of compounds, including the more stable S-allylcysteine.²⁷,²⁸

Laboratory work suggests that some aged preparations can support nitric-oxide-dependent relaxation. But those experiments do not establish exactly how an oral product lowers pressure in a person.³¹

What human trials show

A 2025 meta-analysis reported pooled reductions of roughly 8/4 mm Hg in people with hypertension, although products and trials differed.⁸

Some individual trials found larger effects:

One dose-ranging trial reported an approximately 11.8 mm Hg systolic reduction with a particular aged garlic extract regimen.⁶
A trial of time-released garlic powder tablets reported reductions of about 7.0/3.8 mm Hg in men with mild-to-moderate hypertension.⁷
Another aged-extract trial found a much smaller blood-pressure change despite changes in a nitric-oxide measure.³²

These results are not interchangeable. Product composition, baseline pressure, study size, and trial methods matter.

The studies cited here do not establish that hydrogen sulfide explains garlic’s blood-pressure effects in people. Nor do they establish that a favorable change in a nitric-oxide marker necessarily produces a meaningful clinical benefit.²⁹,³¹,³²

Garlic preparations may lower blood pressure. They have not been shown to prevent heart attacks or strokes in people with hypertension.³³

Garlic safety

Garlic in ordinary meals and concentrated garlic supplements are different exposures.

Supplements can increase bleeding risk. Tell your surgeon and prescribing clinician well before a procedure, and follow their instructions about stopping them.³⁴

A small trial of aged garlic extract in people taking warfarin did not identify an increased bleeding risk. That result applies to the studied product and population; it is not permission to combine any garlic supplement with a blood thinner.³⁵

Garlic supplements have also substantially reduced levels of saquinavir, an HIV medicine.³⁶

If you take anticoagulants, antiplatelet drugs, or HIV treatment, review a proposed supplement with your clinician or pharmacist first. Large amounts of raw garlic can also upset your stomach.²⁷,³⁴

Added sugar: the subtraction side

Supporting vascular health is not only about adding foods. Sometimes the useful change is removing an excess.

A large fructose load can rapidly consume energy molecules in the liver and increase uric-acid production. Experimental research suggests several ways this may interfere with nitric-oxide signaling.⁹

The human studies need context.

In one trial, men consumed 200 g of fructose daily for two weeks—far more than most people ordinarily consume. Their 24-hour blood pressure rose by about 7/5 mm Hg. Allopurinol, a uric-acid-lowering medicine, blunted much of the rise.³⁷

That does not mean you should take allopurinol to offset sugary drinks.

In U.S. survey data, higher added-fructose intake was associated with greater odds of elevated blood pressure. But feeding trials in which fructose replaced other carbohydrates calorie for calorie did not show the same increase.¹⁰,³⁸

Calories, dose, and food source matter.

The practical target is excess added sugar, especially sweetened drinks—not ordinary portions of whole fruit.¹¹

An apple is not the problem.

Agave, sweetened teas, large juice servings, and other products with a health-oriented label can still add substantial sugar. Look at what you drink over a week, not just what you sprinkle on food.¹¹

Cocoa and watermelon: promising, not magic

Cocoa flavanols

Flavanols are plant compounds that can support vascular function.¹⁶,³⁹

A 2025 analysis of 145 randomized trials found that flavan-3-ol interventions lowered office pressure by about 2.8/2.0 mm Hg and improved flow-mediated dilation, a measure of how well an artery widens. Effects were larger in participants starting with higher pressure.³⁹

That analysis included different flavanol sources; it was not simply a study of chocolate.

A Cochrane review focused on cocoa found a smaller average reduction of about 2 mm Hg.¹⁶

A candy bar is not the high-flavanol intervention tested in these studies. Product composition, sugar, and portion size still matter.

Watermelon and citrulline

Citrulline can be converted into arginine, the raw material used by eNOS.¹²,⁴⁰

A pooled analysis of 15 small trials involving middle-aged and older adults found reductions of about 4/2.5 mm Hg across citrulline and watermelon interventions, including some regimens combining citrulline with arginine.⁴¹

That is a reason for further study—not proof that an ordinary serving of watermelon delivers the same effect as a supplement. Its worth noting that citrulline is more concentrated in the white pulp compared to the sweeter center. Citrullus lanatus, the yellow watermelon is regarded at the highest dietary source of L-Citrulline.

Enjoy the food. Discuss the concentrated product separately.

Exercise: train the lining, not just the muscles

Each brisk walk increases blood flow along your artery lining.

That mechanical signal helps activate eNOS. Repeated training supports longer-term vascular adaptation. Exercise also influences oxidative stress and other processes that affect nitric-oxide availability.¹,¹²,¹³

You are training the vessels as well as the muscles.

A review of exercise interventions in people with hypertension found improvements in nitric-oxide measures and flow-mediated dilation.⁴²

More importantly for everyday care, exercise lowers resting blood pressure.

A 2023 analysis of 270 randomized trials found average systolic reductions of about 4.5 mm Hg with aerobic exercise. Resistance and interval training also helped. Isometric exercise—holding a contraction without moving—showed larger average reductions in that analysis.⁴³

A ranking across studies does not make one exercise best for every person.⁴³

The exercise you can perform safely and repeat consistently matters more than chasing the largest number in a table.

Build an aerobic foundation

Brisk walking, cycling, swimming, and similar activities are useful starting points.

A moderate pace generally lets you talk but makes singing difficult. Start where your health and fitness allow, then build a repeatable routine. If you have symptoms, known cardiovascular disease, or poorly controlled pressure, agree on a starting plan with your clinician.⁴⁴

Add strength and consider isometrics

Resistance exercise supports strength and function. Isometric options include handgrip training and supported wall holds.⁴³,⁴⁴

Trials have found benefits from repeated handgrip training—not simply one squeezing session.⁴⁵

A small comparison trial found that both wall-squat and handgrip training lowered clinic systolic pressure, without a statistically significant difference between the two.⁴⁶

The effort level matters. A study protocol is not automatically your starting prescription.

If you have uncontrolled blood pressure, cardiovascular disease, dizziness, or joint limitations, ask your clinician or an exercise professional how to begin. During holds, breathe continuously. Do not strain while holding your breath.⁴⁴

You do not need to master every exercise category this week. You need a safe place to start.

Putting both roads into daily life

A practical pattern might look like this:

Add leafy greens or beets to meals regularly.
Use garlic in cooking because you enjoy it—not because dinner must deliver a supplement dose.
Replace sweetened drinks with water, unsweetened tea, or sparkling water.
Choose cocoa products thoughtfully rather than treating candy as therapy.
Walk or do another aerobic activity regularly.
Add appropriate strength work and, when suitable, guided isometric training.

You cannot add the beet, garlic, cocoa, and exercise trial averages together to predict your result.

The effects overlap. Studies differ. Your starting pressure and current treatment matter.

How to tell whether the plan is helping

Use a validated upper-arm monitor and a consistent measurement routine. Compare averages over several days rather than celebrating or fearing one reading.¹⁴

Record medication timing and major changes in your routine. A home log shows whether your pressure is improving, although it cannot prove which part of a combined plan caused the change.¹⁴

For a step-by-step approach, see Four Blood Pressure Stories in The Integrative Cardiologist and the plan in Lower Your Blood Pressure.

What this does not replace

If you need medication now, take it.

Food and exercise may create an opportunity to simplify treatment later. That decision follows measurements and a clinical review—not the purchase of a supplement.¹⁴

I explain that conversation in “Do I Have to Take Blood Pressure Medication for the Rest of My Life?”

Concentrated products at a glance

Aged garlic extract: Some preparations lower blood pressure in people with hypertension. Responses vary among products and trials. Before starting, consider bleeding risk, planned procedures, medication interactions, and whether the product matches a studied preparation.⁶,⁸,³²,³⁴,³⁶
Beet juice, shots, or powders: Some trials show benefit. Average effects are generally modest and differ depending on how blood pressure is measured. Check nitrate content, serving size, and sugar. Consider your existing treatment and the limited evidence on long-term concentrated use.³,⁴,⁵,¹⁸,¹⁹,²⁵,²⁶
L-citrulline: Small trials suggest a possible blood-pressure benefit in middle-aged and older adults. Long-term evidence is limited. Review your other medicines and whether the expected benefit justifies adding another product.⁴⁰,⁴¹

A supplement label that says “nitric oxide support” does not establish that the product lowers blood pressure or prevents cardiovascular events.³³,⁴⁰

Protecting what you already make

So, is there anything you can eat or do besides another pill?

Yes.

Eat more vegetables. Use garlic as food. Replace sugary drinks. Move regularly.

Some concentrated products may help selected patients, but they are not interchangeable with the foods—or the medicines—studied in trials.

You do not need to chase a nitric-oxide number. You need a plan you can sustain and blood-pressure measurements that show whether it is helping.

Keep taking treatment you need.

If your readings improve, bring the log. That is how we decide together whether the plan can become simpler.

This post is for general educational purposes only. It is not medical advice, is not a substitute for care from your own physician, and does not create a physician-patient relationship. Do not start, stop, or change any treatment based on what you read here. If you think you may have a medical emergency, call 911 or go to the nearest emergency department.

Also by Dr. Azhak: Lower Your Blood Pressure: Help Your Doctor Reduce Your Medication, by Sameer Azhak, MD, FACC.

References

Hong J, Park Y. Microvascular function and exercise training: functional implication of nitric oxide signaling and ion channels. Pulse (Basel). 2024;12(1):27–33. doi:10.1159/000538271. Full text.
Webb AJ, et al. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension. 2008;51(3):784–790. doi:10.1161/HYPERTENSIONAHA.107.103523. Article.
Kapil V, et al. Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study. Hypertension. 2015;65(2):320–327. doi:10.1161/HYPERTENSIONAHA.114.04675. Article.
Bondonno CP, et al. Absence of an effect of high nitrate intake from beetroot juice on blood pressure in treated hypertensive individuals: a randomized controlled trial. Am J Clin Nutr. 2015;102(2):368–375. doi:10.3945/ajcn.114.101188. Article record.
Siervo M, et al. Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: a systematic review and meta-analysis. J Nutr. 2013;143(6):818–826. doi:10.3945/jn.112.170233. Article record.
Ried K, Frank OR, Stocks NP. Aged garlic extract reduces blood pressure in hypertensives: a dose–response trial. Eur J Clin Nutr. 2013;67(1):64–70. doi:10.1038/ejcn.2012.178. Article.
Sobenin IA, et al. Time-released garlic powder tablets lower systolic and diastolic blood pressure in men with mild and moderate arterial hypertension. Hypertens Res. 2009;32(6):433–437. doi:10.1038/hr.2009.36. Article record.
Ma X, Zhang H, Jia J. The effect of garlic on the lowering of blood pressure in patients with hypertension: an updated meta-analysis and trial sequential analysis. Asian Biomed. 2025;19(3):131–140. doi:10.2478/abm-2025-0016. Full text.
Jia G, et al. Fructose and uric acid: is there a role in endothelial function? Curr Hypertens Rep. 2014;16(6):434. doi:10.1007/s11906-014-0434-z. Full text.
Ha V, Sievenpiper JL, de Souza RJ, et al. Effect of fructose on blood pressure. Hypertension. 2012;59(4):787–795. doi:10.1161/HYPERTENSIONAHA.111.182311. Article.
American Heart Association. Added sugars. Reviewed August 2, 2024. Accessed October 25, 2026. Guidance.
Michel T, Vanhoutte PM. Cellular signaling and NO production. Pflugers Arch. 2010;459(6):807–816. doi:10.1007/s00424-009-0765-9. Full text.
De Ciuceis C, Rizzoni D, Palatini P. Microcirculation and physical exercise in hypertension. Hypertension. 2023;80(4):730–739. doi:10.1161/HYPERTENSIONAHA.122.19465. Article.
American Heart Association. Home blood pressure monitoring. Reviewed August 14, 2025. Accessed October 25, 2026. Guidance.
Raddino R, et al. Nitric oxide and cardiovascular risk factors. Heart Int. 2007;3(1):18. doi:10.4081/hi.2007.18. Full text.
Ried K, Fakler P, Stocks NP. Effect of cocoa on blood pressure. Cochrane Database Syst Rev. 2017;(4):CD008893. doi:10.1002/14651858.CD008893.pub3. Full text.
d’El-Rei J, et al. Beneficial effects of dietary nitrate on endothelial function and blood pressure levels. Int J Hypertens. 2016;2016:6791519. doi:10.1155/2016/6791519. Full text.
Benjamim CJR, et al. Nitrate derived from beetroot juice lowers blood pressure in patients with arterial hypertension: a systematic review and meta-analysis. Front Nutr. 2022;9:823039. doi:10.3389/fnut.2022.823039. Full text.
European Food Safety Authority. EFSA balances the consumer risks from nitrate in vegetables with the benefits of a balanced diet high in vegetables and fruit. 2008. EFSA statement.
Bondonno CP, et al. Vegetable nitrate intake, blood pressure and incident cardiovascular disease: Danish Diet, Cancer, and Health Study. Eur J Epidemiol. 2021;36(8):813–825. doi:10.1007/s10654-021-00747-3. Full text.
Srour B, et al. Nitrites, nitrates, and cardiovascular outcomes: are we living “La Vie en Rose” with pink processed meats? J Am Heart Assoc. 2022;11(24):e027627. doi:10.1161/JAHA.122.027627. Full text.
Kapil V, et al. Physiological role for nitrate-reducing oral bacteria in blood pressure control. Free Radic Biol Med. 2013;55:93–100. doi:10.1016/j.freeradbiomed.2012.11.013. Full text.
Farook FF, et al. Association between mouth rinse use and changes in blood pressure: a systematic review and meta-analysis with trial sequential analysis. Int J Dent Hyg. 2024;22(1):65–77. doi:10.1111/idh.12714. Article.
Toonen LSJ, et al. The effect of chlorhexidine mouthwash on blood pressure: a systematic review and meta-analysis. Int J Dent Hyg. 2026;24(3):390–403. doi:10.1111/idh.70035. Article.
European Food Safety Authority. EFSA confirms safe levels for nitrites and nitrates added to food. 2017. EFSA statement.
Bescos R, et al. Content of nitrate and nitrite in commercial and self-made beetroot juices and the effect of storage temperature. Food Sci Nutr. 2023;11(10):6376–6383. doi:10.1002/fsn3.3575. Full text.
Linus Pauling Institute. Garlic. Oregon State University. Evidence overview.
Lawson LD, Hunsaker SM. Allicin bioavailability and bioequivalence from garlic supplements and garlic foods. Nutrients. 2018;10(7):812. doi:10.3390/nu10070812. Full text.
Benavides GA, et al. Hydrogen sulfide mediates the vasoactivity of garlic. Proc Natl Acad Sci U S A. 2007;104(46):17977–17982. doi:10.1073/pnas.0705710104. Article.
Cavagnaro PF, et al. Effect of cooking on garlic (Allium sativum L.) antiplatelet activity and thiosulfinates content. J Agric Food Chem. 2007;55(4):1280–1288. doi:10.1021/jf062587s. Article.
Takashima M, et al. Aged garlic extract exerts endothelium-dependent vasorelaxant effect on rat aorta by increasing nitric oxide production. Phytomedicine. 2017;24:56–61. doi:10.1016/j.phymed.2016.11.016. Article record.
Serrano JCE, et al. Antihypertensive effects of an optimized aged garlic extract in subjects with grade I hypertension and antihypertensive drug therapy. Nutrients. 2023;15(17):3691. doi:10.3390/nu15173691. Full text.
Stabler SN, et al. Garlic for the prevention of cardiovascular morbidity and mortality in hypertensive patients. Cochrane Database Syst Rev. 2012;(8):CD007653. doi:10.1002/14651858.CD007653.pub2. Article record.
Memorial Sloan Kettering Cancer Center. Garlic. About Herbs. Safety resource.
Macan H, et al. Aged garlic extract may be safe for patients on warfarin therapy. J Nutr. 2006;136(3 Suppl):793S–795S. doi:10.1093/jn/136.3.793S. Article record.
Piscitelli SC, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis. 2002;34(2):234–238. doi:10.1086/324351. Article.
Perez-Pozo SE, et al. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. Int J Obes. 2010;34(3):454–461. doi:10.1038/ijo.2009.259. Article.
Jalal DI, et al. Increased fructose associates with elevated blood pressure. J Am Soc Nephrol. 2010;21(9):1543–1549. doi:10.1681/ASN.2009111111. Full text.
Lagou V, et al. Impact of flavan-3-ols on blood pressure and endothelial function in diverse populations: a systematic review and meta-analysis of randomized controlled trials. Eur J Prev Cardiol. 2025;32(14):1322–1334. doi:10.1093/eurjpc/zwaf173. Article.
National Institutes of Health, Office of Dietary Supplements. Dietary supplements for exercise and athletic performance: fact sheet for health professionals. Updated April 1, 2024. Accessed October 25, 2026. Guidance.
Luo P, et al. Does L-citrulline supplementation and watermelon intake reduce blood pressure in middle-aged and older adults? A systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2025;69:653–664. doi:10.1016/j.clnesp.2025.07.1130. Article record.
Liang C, et al. Exercise interventions for the effect of endothelial function in hypertensive patients: a systematic review and meta-analysis. J Clin Hypertens. 2024;26:599–614. doi:10.1111/jch.14818. Full text.
Edwards JJ, et al. Exercise training and resting blood pressure: a large-scale pairwise and network meta-analysis of randomised controlled trials. Br J Sports Med. 2023;57(20):1317–1326. doi:10.1136/bjsports-2022-106503. Full text.
American Heart Association. Getting active to control high blood pressure. Reviewed August 14, 2025. Accessed October 25, 2026. Guidance.
Oliveira PC, et al. Isometric handgrip training, but not a single session, reduces blood pressure in individuals with hypertension: a systematic review and meta-analysis. J Hum Hypertens. 2023;37(9):844–853. doi:10.1038/s41371-022-00778-7. Article record.
Edwards JJ, et al. Haemodynamic adaptations to isometric handgrip versus isometric wall squat exercise training: a randomised crossover study. Eur J Appl Physiol. 2026;126:4205–4214. doi:10.1007/s00421-026-06246-1. Article.

Blood Pressure and Sleep Apnea: What Happens While You Sleep Matters

Dr. Sameer Azhak — Tue, 20 Oct 2026 11:01:44 GMT

The Integrative Cardiologist · By Sameer Azhak, MD, FACC

At a Glance

Sleep apnea can contribute to high blood pressure, particularly when pressure stays elevated at night or remains difficult to control despite treatment.¹ ²
You do not have to feel sleepy—or remember waking—to have it.² ³
Morning readings, snoring, witnessed breathing pauses, and your broader medical history can prompt a sleep evaluation. None diagnoses sleep apnea on its own.¹ ² ³
CPAP can improve breathing, symptoms, and blood-pressure control. The average BP reduction is modest, and many people still need medication.¹
Treatment can include airway support, weight management when appropriate, and selected medicines or devices. Do not stop CPAP or blood-pressure treatment without reassessment.

The preoperative visit that became a sleep conversation

He came to me before shoulder surgery. He was 54, worked at a desk, and had torn his left rotator cuff playing catch with his son. He was 5 feet 10 inches tall and weighed 320 pounds.

His office blood pressure looked reassuring: 130/80 mm Hg. He was taking olmesartan 20 mg, chlorthalidone 25 mg, and nebivolol 10 mg.

It would have been easy to focus on that number and move on.

But his heart scan raised questions. His heart pumped normally, with an ejection fraction of 65%, yet the muscle wall was mildly thickened. His aortic root—the beginning of the body’s main artery—measured 4.3 centimeters, and the estimated pressure in his lung arteries was elevated.

Those findings did not diagnose sleep apnea. They made one office reading an incomplete account of his cardiovascular history.

His home journal added the contrast. Evening readings averaged about 128/75. Morning readings ran 150 to 160 over 90.

That pattern made me ask what was happening while he slept.

The shoulder observation

In my practice, I often see shoulder problems alongside obesity and previously unrecognized sleep apnea. That has made me curious about sleeping position.

Some people with sleep apnea breathe worse on their backs.⁴ I wonder whether years of favoring the side could contribute to shoulder symptoms in some patients.

That is a clinical observation and a question worth studying—not an established cause of rotator cuff tears. In this patient’s case, the reported injury occurred while playing catch; I would not attribute his tear to sleep apnea.

Researchers have examined sleep position in relation to shoulder pain and rotator cuff tendinopathy, and others have studied surgical complications in patients who already have sleep apnea and rotator cuff disease. These studies do not establish the pathway I am describing.⁵ ⁶

A shoulder injury does not diagnose sleep apnea. In the right context, it can prompt another question: “How do you sleep?”

Why this story matters to you

If your blood pressure stays high despite medication—or your morning readings tell a different story from the office—sleep belongs in the conversation.

The 2025 American Heart Association and American College of Cardiology guideline estimates that obstructive sleep apnea is present in 25% to 50% of people with hypertension.¹

Here is how a breathing problem at night can become a pressure problem during the day, how we investigate it, and what treatment can change.

What obstructive sleep apnea actually is

Picture the back of your throat as a soft, flexible tube. While you are awake, surrounding muscles help hold it open. During sleep, those muscles relax. In obstructive sleep apnea, the airway repeatedly narrows or closes.

A partial closure reduces airflow. A complete closure stops it, even while your chest and belly keep trying to pull air in. These episodes can lower oxygen, activate the nervous system, and break up sleep—many times an hour.²

In this article, “sleep apnea” means the obstructive kind.

Why you may not know

You can have repeated breathing interruptions and remember none of them. Your brain briefly rouses you enough to reopen the airway, often without a waking memory.

Feeling as if you slept through the night does not prove that you breathed normally.

Snoring is a clue, not a diagnosis

Snoring is the sound of air moving through a narrowed airway. Many people snore without sleep apnea, and some people with sleep apnea barely snore.

Symptoms and risk factors tell us when to investigate. An appropriate evaluation and sleep test establish the diagnosis.³

How disrupted breathing raises pressure

Follow one episode:

Your airway narrows or closes. Breathing muscles keep working, but air does not move freely.
Oxygen may fall while breathing effort rises. Your chest pulls harder against the obstruction.
Your brain responds. You rouse enough to reopen the airway.
The fight-or-flight system activates. Blood vessels tighten, and heart rate and pressure can surge.
You return to sleep. The cycle may repeat minutes—or seconds—later.²

The problem is not just interrupted sleep. It is what your body repeatedly does to get you breathing again.

There is mechanical stress too. Trying to inhale against a closed airway creates large pressure swings inside your chest, changing the forces acting on your heart and blood vessels.²

Over time, repeated alarms can contribute to persistent sympathetic activation and high blood pressure, including during waking hours.¹ ²

The missing nighttime dip

Blood pressure usually falls during sleep. Clinicians call this “dipping.” Sleep apnea can disrupt that pattern, and nighttime hypertension can be missed by ordinary office checks.¹

But morning and evening home readings cannot tell us exactly what happened overnight.

My patient’s high morning readings raised suspicion. They did not prove that his pressure failed to dip. A 24-hour ambulatory blood-pressure monitor could answer that question, while a sleep evaluation could assess whether breathing interruptions were contributing.

When sleep apnea moves higher on my list

What you or your partner may notice

Mention these symptoms:¹ ²

Habitual loud snoring.
Pauses in breathing, often followed by a snort or gasp.
Waking with choking or gasping.
Unrefreshing sleep or morning headaches.
Daytime sleepiness or difficulty staying asleep.

A partner may notice the breathing changes before you do.

What your medical history may show

Obesity, a large neck, a crowded airway, and difficult-to-control hypertension raise suspicion. So does a 24-hour monitor showing elevated nighttime pressure or loss of the normal dip.¹

People of every size can have sleep apnea. A larger body is not a diagnosis, and the absence of sleepiness does not rule it out.² ³

When the heart scan adds a question

A thickened heart muscle or enlarged aorta may reflect years of pressure exposure. Studies have also found a small association between sleep apnea and a larger thoracic aorta, but the evidence is limited.⁷

When these findings accompany reassuring office readings, I look beyond the office. They are reasons to investigate—not proof of the cause.

An elevated estimate of lung-artery pressure deserves its own assessment. Sleep-disordered breathing may be relevant, but heart disease, lung disease, and underbreathing can also contribute. Isolated obstructive sleep apnea does not usually explain pulmonary hypertension by itself.⁸

You do not need to sort out those possibilities yourself. The point is to avoid assuming that one reassuring cuff reading answers every question.

What “resistant hypertension” means

Blood pressure is considered resistant when it remains above goal despite three complementary medicines, including a diuretic, at the highest tolerated doses—or when control requires four or more medicines.¹

Taking three medicines does not establish resistance by itself. Before using that label, I check measurement technique, out-of-office readings, medication use, and substances that may raise pressure. Then we investigate contributors such as sleep apnea, excess aldosterone, and kidney-related conditions.¹

My patient’s morning readings needed attention. His visit alone did not establish resistant hypertension.

How we find out

Do you have to sleep in a laboratory?

Not always.

A clinician-ordered home sleep apnea test uses a device you wear in your own bed. For selected adults without major complicating conditions who appear likely to have moderate to severe OSA, a technically adequate home test can establish the diagnosis.³ ⁹

An overnight laboratory study, called polysomnography, records more information, including brain waves, sleep stages, breathing, oxygen, and heart rhythm.

Your clinician may recommend the laboratory if you have significant heart or lung disease, suspected underbreathing, prior stroke, chronic opioid use, severe insomnia, or certain neuromuscular conditions.³

The choice depends on the question we need the test to answer—not simply which test is more convenient.

A negative home test may need follow-up

A home test can miss sleep apnea. If it is negative, inconclusive, or technically inadequate, a laboratory study may be the next step.³

Questionnaires, overnight oxygen recordings, and watch alerts can raise suspicion. They are not interchangeable with a diagnostic sleep evaluation.³

If surgery is coming up

Tell your surgeon and anesthesiologist if you snore, stop breathing during sleep, have suspected sleep apnea, or use CPAP. The team can plan appropriate monitoring and precautions.¹⁰

A preoperative visit can uncover a problem worth addressing even when it was not the reason you made the appointment.

What CPAP can—and cannot—do

CPAP means continuous positive airway pressure. A bedside machine sends air through a mask, helping hold your airway open while you sleep.

Its first job is to treat the breathing obstruction.

The next question is usually: “Will I still need blood-pressure medicine?”

For most people, yes.

The 2025 guideline summarizes randomized trials showing average reductions of about 2 to 5 mm Hg in office or ambulatory blood pressure with short-term CPAP. Individual responses vary.¹

What HIPARCO showed

In HIPARCO, researchers at 24 Spanish hospitals randomized 194 patients with sleep apnea and resistant hypertension to CPAP or no CPAP for 12 weeks. Everyone continued usual blood-pressure medication.¹¹

Compared with the control group, CPAP produced an additional reduction of 3.1 mm Hg in 24-hour mean pressure and 3.2 mm Hg in diastolic pressure. The systolic difference did not reach statistical significance. CPAP also improved the nighttime dipping pattern.¹¹

This was not a cure for hypertension. It was an additional benefit alongside medication.

What longer follow-up suggested

HIPARCO-2 followed 161 patients for a median of about five years. It compared people who used CPAP consistently with a comparison group who did not; it was observational, not a new randomized trial.¹²

Consistent users had more favorable blood-pressure changes, particularly at night, and used an average of 1.1 fewer blood-pressure medicines. More nightly use was associated with greater systolic improvement.¹²

Those findings are encouraging, but they do not prove that CPAP alone caused the differences. The overall systolic estimate was uncertain, and people who use treatment consistently may differ in other ways.

For you, the practical lesson is simple: use treatment consistently, then reassess rather than guess.

Do not stop blood-pressure medicine because you have started CPAP. If readings improve, your clinician can decide whether the regimen can be simplified while preserving control and any other benefits of your medicines.

What about heart attacks and strokes?

CPAP treats airway obstruction and can improve symptoms and blood-pressure control. Randomized trials have not consistently demonstrated fewer cardiovascular events or deaths in the populations studied.¹

I would not promise that the mask prevents a heart attack. I also would not use that uncertainty as a reason to leave clinically important sleep apnea untreated.

If the mask is difficult

Struggling with CPAP is not a personal failure.

Tell your sleep clinician. Mask fit, pressure settings, humidity, nasal symptoms, and the overall approach may need adjustment. A machine sitting unused cannot deliver the benefit we are trying to achieve.

Treat the whole problem

Airway treatment, weight management when appropriate, and blood-pressure medication are not competing choices.

Extra tissue around the airway and changes in lung volume can contribute to OSA in people with obesity.¹³ The AHA recommends considering behavioral changes and weight management as part of treatment when appropriate.²

A meta-analysis found that combining weight-loss interventions with CPAP lowered systolic blood pressure more than CPAP alone. Adding CPAP to weight loss alone did not produce a statistically significant additional blood-pressure reduction.¹⁴

This is not an instruction to lose weight before receiving airway treatment. It is a reason to address both when both matter.

An FDA-approved medication option

On December 20, 2024, the FDA approved tirzepatide, sold as Zepbound, for moderate to severe OSA in adults with obesity, alongside a reduced-calorie diet and increased physical activity. It was the first medication approved for this indication.¹⁵

The approval drew on two trials involving 469 adults without type 2 diabetes: one trial included PAP users, while the other included people unable or unwilling to use PAP.¹⁵ ¹⁶

After 52 weeks, breathing interruptions fell by about 25 to 29 events per hour with tirzepatide, compared with about 5 with placebo. Participants also lost substantial weight.¹⁶

The 2025 guideline reports additional systolic reductions versus placebo of 7.6 mm Hg in the trial without PAP use and 3.7 mm Hg in the trial with PAP use.¹

Tirzepatide is an option for a defined group, not a universal treatment. It can cause gastrointestinal adverse effects and should not be used with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. Other warnings and medication considerations also matter.¹⁵

Whether it fits your situation depends on your history, tolerability, access, and goals. Improvement or weight loss does not automatically mean you can stop CPAP; that requires reassessment.

Other approaches

A custom oral appliance may be an option for selected patients, including some who cannot tolerate CPAP. Selected patients may also qualify for other airway treatments or implanted nerve-stimulation devices. These options require individualized assessment, and their blood-pressure benefits should not be assumed to match CPAP’s.¹ ²

An investigational nightly pill, AD109, is also under FDA review. According to the manufacturer’s announcement, the agency assigned a target decision date of February 28, 2027. That is a review deadline—not a promise of approval. AD109 is not an approved treatment as of this article’s October 13, 2026 preparation.¹⁷

You do not have to wait for a future drug to investigate a breathing problem you may have now.

What to bring to your appointment

You do not need to diagnose yourself. Bring observations that help us ask better questions:

“My partner says I snore or stop breathing.”
“My pressure is still high on medication.”
“My readings are highest in the morning.”
“My 24-hour monitor showed high pressure at night.”
“I wake whenever I roll onto my back.”
“I have shoulder discomfort and sleep mostly on one side.”
“My heart scan raised questions despite reassuring office readings.”
“I have CPAP, but I am struggling to use it.”
“When will we reassess my pressure after treatment?”

Bring the numbers

Bring a week or two of home readings, including morning measurements, and note medication timing.

If you use CPAP, bring its report of nightly use and remaining breathing events. Those data add context that one office reading cannot provide.

Make follow-up part of the plan

After treatment starts, agree on when to reassess symptoms and home or ambulatory pressure. If your readings improve, we can review the medication plan. If they do not, we keep looking. Sleep apnea can be one contributor among several.¹

And if you have stopped using CPAP, say so. That information is more useful than a polite silence.

The lesson to keep

If your blood pressure is difficult to control—or morning readings tell a different story from the office—ask about sleep.

A clinical observation can open a question. It does not need to become a diagnosis before we investigate it.

Finding sleep apnea gives us another part of the problem to treat. Good blood-pressure care continues after the sleep study, the mask fitting, or the first improved reading.

Free resource: Download my Lowering Blood Pressure guide (PDF).

Also by Dr. Azhak: Lower Your Blood Pressure: Help Your Doctor Reduce Your Medication, by Sameer Azhak, MD, FACC. Available now in paperback and on Kindle. Buy the paperback · Read on Kindle.

References

Jones DW, Ferdinand KC, Taler SJ, et al. 2025 guideline for the prevention, detection, evaluation and management of high blood pressure in adults. Hypertension. 2025. doi:10.1161/HYP.0000000000000249. Hypertension guideline
Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;144:e56–e67. doi:10.1161/CIR.0000000000000988. AHA scientific statement
Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea. J Clin Sleep Med. 2017;13:479–504. doi:10.5664/jcsm.6506. AASM diagnostic guideline
Jereisat RA, Qaryouti H, Alsawalha H, et al. The Effect of Different Sleep Positions on the Severity of Obstructive Sleep Apnea: A Retrospective Study. Nat Sci Sleep. 2026;18. doi:10.2147/NSS.S627693. Sleep-position study
Holdaway LA, Hegmann KT, Thiese MS, Kapellusch J. Is sleep position associated with glenohumeral shoulder pain and rotator cuff tendinopathy: a cross-sectional study. BMC Musculoskelet Disord. 2018;19:408. doi:10.1186/s12891-018-2319-9. Full text
Cancienne JM, Brockmeier SF, Deasey MJ, Werner BC. Obstructive Sleep Apnea and Arthroscopic Rotator Cuff Repair—Are Complication Rates Really Increased? J Am Acad Orthop Surg. 2019;27:486–492. doi:10.5435/JAAOS-D-18-00069. Rotator-cuff surgery study
Gherbesi E, Tadic M, Faggiano A, et al. Sleep Apnea Syndrome and Large Artery Subclinical Damage: Targeting Thoracic Aortic Dilatation. Am J Hypertens. 2022;35:543–550. doi:10.1093/ajh/hpac006. Aortic-dilatation study
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61:2200879. Pulmonary-hypertension guideline
American Academy of Sleep Medicine. AASM publishes new guideline for diagnostic testing for adult sleep apnea. AASM guideline announcement
Chung F, Memtsoudis SG, Ramachandran SK, et al. Society of Anesthesia and Sleep Medicine Guidelines on Preoperative Screening and Assessment of Adult Patients With Obstructive Sleep Apnea. Anesth Analg. 2016;123:452–473. doi:10.1213/ANE.0000000000001416. Preoperative guideline
Martínez-García MA, Capote F, Campos-Rodríguez F, et al. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. JAMA. 2013;310:2407–2415. doi:10.1001/jama.2013.281250. HIPARCO trial
Navarro-Soriano C, Torres G, Barbé F, et al. The HIPARCO-2 study: long-term effect of continuous positive airway pressure on blood pressure in patients with resistant hypertension: a multicenter prospective study. J Hypertens. 2021;39:302–309. doi:10.1097/HJH.0000000000002664. HIPARCO-2 study
Patil SP, Schneider H, Schwartz AR, Smith PL. Adult Obstructive Sleep Apnea: Pathophysiology and Diagnosis. Chest. 2007;132(1):325–337. doi:10.1378/chest.07-0040. Full text
Kovács DK, Gede N, Szabó L, et al. Weight reduction added to CPAP decreases blood pressure and triglyceride level in OSA: Systematic review and meta-analysis. Clin Transl Sci. 2022;15(5):1238–1248. doi:10.1111/cts.13241. Weight-loss and CPAP meta-analysis
U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea. December 20, 2024. FDA approval announcement
Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193–1205. doi:10.1056/NEJMoa2404881. SURMOUNT-OSA trials
Apnimed. Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea. July 14, 2026. Manufacturer announcement. Manufacturer announcement

The Mineral in the Muscle of Your Arteries

Dr. Sameer Azhak — Tue, 13 Oct 2026 11:15:32 GMT

At a Glance
Magnesium helps the muscle in your artery walls relax. It works partly by limiting how much calcium enters those muscle cells, which is the same basic idea behind a common class of blood-pressure medicines.¹
In a recent analysis of randomized trials, magnesium supplements lowered blood pressure by about 3/2 mm Hg on average. Larger average reductions were reported in subgroups already treated for hypertension and in those with low magnesium, but these findings need confirmation. The effect was not statistically significant in people with normal blood pressure.²
In U.S. survey data from 2013–2016, nearly half of Americans consumed less magnesium from food and beverages than their estimated average requirement. That is not the same as diagnosed magnesium deficiency.³
A normal serum magnesium result does not reliably exclude depleted body stores. Most magnesium is in bone and other tissues, including muscle—not in serum.³
Food is the long-term foundation. In clinically appropriate patients, I may use a short supplement trial, reassess, and actively transition toward magnesium-rich foods when the trial is helpful.

It is one of the most common questions I hear once a patient learns their blood pressure is high:

“Should I be taking magnesium?”

Sometimes it comes from a friend’s recommendation. Sometimes it comes from a social media video promising that one mineral can fix sleep, stress, cramps, and blood pressure all at once. And sometimes it comes from a patient who has quietly been taking it for months and wants to know whether it is doing anything.

It is a fair question, and it deserves a better answer than “it can’t hurt” or “there’s no evidence.” The truth is more interesting than either. Trials suggest magnesium supplements can produce a small average reduction in blood pressure, although results vary. Some subgroups have shown larger reductions, and magnesium belongs in a plan rather than replacing one.²

To understand why, we need to look inside the wall of an artery.

The muscle inside every artery

Your arteries are not passive pipes. Wrapped around them is smooth muscle that constantly tightens and relaxes. When that muscle tightens, the vessel narrows. When it relaxes, the vessel widens. Across the circulation, these changes help regulate blood pressure.

What makes that muscle contract is calcium. When calcium enters a smooth-muscle cell through tiny gates in its surface—or is released from internal stores—the cell can contract. When calcium is cleared or stored away, the cell can relax.

Magnesium is calcium’s natural counterweight. It influences calcium entry through those gates, called L-type calcium channels, and supports the energy-dependent processes that regulate calcium inside cells. Magnesium depletion can disturb that balance and favor increased vascular tone.¹

If that sounds familiar, it should. Many of my patients take amlodipine or another calcium-channel blocker. Those medicines work by limiting calcium entry into vascular smooth muscle. Magnesium interacts with some of the same machinery, although an oral supplement is not equivalent to a prescription calcium-channel blocker.

Calcium handling is not the whole story. Laboratory and human studies suggest magnesium also supports the artery’s lining, called the endothelium. It participates in pathways involving nitric oxide and prostacyclin, signals that help vessels relax.¹ In one small trial involving 50 people with stable coronary artery disease, oral magnesium improved flow-mediated dilation, a measure of how well an artery widens on demand.⁴

Researchers have also linked magnesium depletion to sympathetic “fight-or-flight” activity, the renin-angiotensin-aldosterone system, sodium and potassium balance, and inflammation.¹

So the biology is plausible. The more important question is what happens when people actually take magnesium.

What the trials show

The best answer comes from randomized, placebo-controlled trials, where some people receive magnesium and others receive a placebo.

In 2016, a meta-analysis in Hypertension combined 34 trials with 2,028 participants. Over a median of about three months, magnesium lowered systolic pressure by 2.00 mm Hg and diastolic pressure by 1.78 mm Hg compared with placebo. It also raised blood magnesium slightly.⁵

In 2025, a larger analysis in the same journal pooled 38 trials with 2,709 participants. On average, magnesium lowered blood pressure by 2.81/2.05 mm Hg.²

The subgroup findings were particularly interesting:

People with hypertension already taking blood-pressure medicine: systolic pressure fell by about 7.7 mm Hg.
People with low magnesium, or hypomagnesemia: pressure fell by about 6.0/4.8 mm Hg.
People with normal blood pressure: the effect was not statistically significant.

The authors found no clear dose-response pattern and considerable variation between trials. They urged caution and called for larger, better-designed studies.²

Newer reviews reinforce the need for modest expectations. A 2026 cardiometabolic review found average reductions of about 2.5/1.6 mm Hg, while a smaller review focused on vascular function found no statistically significant overall improvement in blood pressure or flow-mediated dilation. The studies differ, so these are not identical comparisons.⁶,⁷

That pattern makes clinical sense. Magnesium may help most when there is a deficit to correct and a pressure problem to correct. But subgroup averages do not predict exactly what an individual will experience.

The FDA reached a cautious conclusion as well. In 2022, it allowed a qualified health claim that diets with adequate magnesium may reduce the risk of high blood pressure, while stating that the evidence is inconsistent and inconclusive.⁸

Why a few points still matter

A 3-point drop can sound unimpressive. If your reading is 148/92, it will not single-handedly bring you to target.

But blood pressure works on a gradient, and most people do not lower it through one change. They lower it through several smaller changes, each contributing to the plan.

The 2025 AHA/ACC high blood pressure guideline discusses dietary magnesium within the broader nutritional picture. Its principal dietary recommendations emphasize a heart-healthy eating pattern, sodium reduction, appropriate potassium intake, and alcohol reduction. It does not make a specific recommendation for magnesium supplements.⁹

That is how I think of magnesium in practice: a contributor within a broader plan, not the center of it.

Who tends to run low

In national survey data from 2013 to 2016, 48% of Americans consumed less magnesium from food and beverages than their estimated average requirement. Inadequate intake is not identical to laboratory-confirmed deficiency, but it is a reason to look at the diet.³

Recommended total daily intake is 400–420 mg for adult men and 310–320 mg for nonpregnant adult women, preferably met primarily through food.³

Some people are more likely to run low:

People taking certain diuretics. Thiazide-type diuretics and loop diuretics increase urinary magnesium loss. Potassium-sparing medicines such as spironolactone and amiloride tend to conserve it.³
People taking long-term proton-pump inhibitors, such as omeprazole and esomeprazole. The FDA has warned that these medicines can cause low magnesium, often after prolonged use. In about a quarter of the cases it reviewed, supplementation alone did not correct the problem and the PPI had to be discontinued under medical supervision.¹⁰
People with diabetes, heavy alcohol use, or gastrointestinal conditions that impair absorption.³
People whose diets are low in whole plant foods. Refining grains removes much of their magnesium.³

The diuretic point deserves emphasis. A useful blood-pressure medicine can also increase magnesium loss. That is not a reason to stop it. It is a reason to ask whether magnesium status has been considered.

Why a normal blood test does not settle it

Patients often tell me, “My magnesium was normal on my labs.”

That is useful information, but it does not settle the question of whole-body magnesium adequacy.

Think of calcium. Most of your body’s calcium is stored in bones and teeth—not circulating in the bloodstream. The body regulates blood calcium tightly, so a normal result does not tell us whether dietary intake is adequate or skeletal reserves are being depleted. A blood calcium test is not an inventory of the calcium in your bones.¹¹

Magnesium follows a similar principle, although its distribution and regulation are not identical. About 50–60% is in bone, most of the rest is in other tissues, including muscle, and less than 1% is in serum. The magnesium measured in a routine blood test represents a small, closely regulated compartment—not the body’s entire supply.³

A normal serum magnesium level therefore does not reliably exclude depleted magnesium stores. A low result, however, is clinically important and deserves evaluation. The test is useful; it simply answers a narrower question than many people assume.¹²,¹³

Other tests have limitations too. RBC magnesium measures magnesium inside red blood cells, but it is not a definitive measure of whole-body stores. Magnesium-loading tests administer a measured dose, sometimes intravenously, and collect urine, commonly over 24 hours, to estimate retention. Kidney function, collection accuracy, and the protocol affect interpretation.¹²,¹⁴

I do not routinely use RBC magnesium testing or intravenous magnesium-loading tests with 24-hour urine collection. I assess dietary intake, medication exposures, gastrointestinal losses, alcohol use, diabetes, kidney function, symptoms, and laboratory findings when appropriate.

A blood test measures the circulating compartment—not the whole-body inventory.

What happens in the soil matters

Magnesium intake depends partly on what we eat—and partly on what plants had available while growing.

Plants obtain magnesium through their roots. Availability depends on soil type, acidity, rainfall, irrigation, competing nutrients, and fertilizer management.¹⁵

Ammonium-based nitrogen fertilizers can contribute to soil acidification. As microbes convert ammonium to nitrate, they generate acidity. Under conditions favoring leaching, magnesium can be carried downward with drainage water, sometimes beyond the effective root zone. High ammonium levels can also interfere with root magnesium uptake.¹⁵,¹⁶

This is particularly relevant in acidic, sandy soils and areas with substantial rainfall or irrigation. Inadequate magnesium replacement and imbalanced fertilization can further limit what crops absorb.¹⁵

That does not mean every fertilized crop is magnesium-poor. Soil testing, management of acidity, and balanced nutrient replacement can help maintain availability. Nor can we attribute a particular person’s deficiency to farming practices alone.

But growing a plant successfully and maximizing its mineral content are not necessarily the same task. Soil fertility deserves attention alongside the more immediate causes of inadequate intake: too few magnesium-rich foods, grain refining, and heavily processed diets.³,¹⁵

Food before bottles

Magnesium arrives in food alongside fiber, potassium, plant protein, and other nutrients that support cardiovascular health. That is why the plate remains the foundation of my long-term plan.

Some rich sources are:³

Roasted pumpkin seeds: about 156 mg per ounce
Chia seeds: about 111 mg per ounce
Dry-roasted almonds: about 80 mg per ounce
Dry-roasted cashews: about 74 mg per ounce
Boiled spinach: about 78 mg per half cup
Cooked black beans: about 60 mg per half cup
Shelled, cooked edamame: about 50 mg per half cup
Whole grains, including shredded wheat, brown rice, and oatmeal
Potatoes with the skin, plain yogurt, avocado, and bananas

These foods fit naturally into an anti-inflammatory, heart-healthy eating pattern built around vegetables, fruit, legumes, whole grains, nuts, seeds, olive oil, and fish when appropriate.

In the original DASH trial, a diet rich in fruits, vegetables, and low-fat dairy, with less saturated and total fat, lowered blood pressure by 5.5/3.0 mm Hg more than a typical American diet. Among participants with hypertension, the reduction was 11.4/5.5 mm Hg.¹⁷

DASH changes several nutrients together, including magnesium, potassium, and calcium. We cannot assign its benefit to magnesium alone.³ That is the point: the whole dietary pattern matters.

Where a supplement trial fits

Food first does not mean food only.

When a patient presents with symptoms that could be consistent with magnesium depletion, I consider their diet, medications, kidney function, gastrointestinal losses, and other possible explanations. A normal serum magnesium result does not automatically rule out depleted stores.

In clinically appropriate patients, I may use a one-month trial of an over-the-counter chelated magnesium supplement, such as magnesium glycinate. I do not use magnesium oxide in my practice.

Then I reassess. Have symptoms changed? Is it well tolerated? Has average home blood pressure changed, if that was part of the reason for the trial? Does the picture support continuing, adjusting, or stopping it?

When the trial is successful, we actively transition toward magnesium-rich foods within the broader anti-inflammatory dietary pattern. I want improvement to become an opportunity to change daily eating—not simply a reason to buy another bottle.

That does not always mean stopping supplementation immediately. Ongoing medication-related losses, gastrointestinal conditions, documented deficiency, and dietary limitations may justify continuing. The aim is to make food the long-term foundation and retain the supplement when it continues to serve a clinical purpose.

This is my clinical approach, not a recommendation that everyone with cramps, fatigue, palpitations, or high blood pressure should take magnesium. These symptoms have many causes. Improvement during a trial can inform the next decision, but does not by itself prove deficiency.

If you and your clinician consider a supplement

This article does not recommend a dose. Here is what makes the conversation more informed.

Forms differ. Small studies suggest citrate, chloride, lactate, and aspartate are absorbed more completely than oxide and sulfate. Labels list elemental magnesium—the amount of magnesium itself—not the full compound’s weight.³

Trial doses and the upper limit. In the 2025 analysis, daily doses ranged from about 82 to 637 mg of elemental magnesium, with a median of 365 mg.² The adult upper limit is 350 mg daily from supplements and medicines; food magnesium does not count. The limit is principally based on gastrointestinal adverse effects. Higher amounts may be used with clinical guidance, but a research dose is not a self-prescribing instruction.³

The kidneys matter. Reduced kidney function can allow magnesium to accumulate. Toxicity can cause low blood pressure, nausea, weakness, breathing difficulty, and dangerous heart rhythms. People with chronic kidney disease should not start supplements on their own.³

Medication timing. Magnesium can reduce absorption of certain antibiotics, including doxycycline and ciprofloxacin, and oral bisphosphonates such as alendronate. These generally need separation; your pharmacist can give medication-specific instructions.³

Digestive effects. Diarrhea, nausea, and cramping are common at higher supplemental intakes. Include magnesium-containing antacids, laxatives, multivitamins, and combination products when reviewing total intake.³

Quality. Look for independent third-party testing and transparent labels. A quality seal does not prove clinical benefit. See Yes, I Recommend Supplements. Here’s What I Wish Every Patient Knew About the Label.

Questions for your next appointment

Could my diet or medicines be lowering my magnesium?
Would assessing magnesium status help, and would a serum level be useful?
Does my kidney function affect supplement safety?
Would a short, monitored trial be appropriate?
How should it be timed around other medicines?
What symptoms and home blood-pressure averages should we reassess after a month?
If it helps, how can we transition toward magnesium-rich foods, and do I still need the supplement?

The integrative answer

So should you be taking magnesium?

For many people, start by eating more of it. Seeds, nuts, greens, beans, and whole grains bring magnesium alongside other nutrients that support cardiovascular health.

Food first does not mean food only. In my practice, symptoms, intake, medications, kidney function, and the clinical picture may justify a monitored trial—even when serum magnesium is within the reference range.

I generally use a chelated form, such as magnesium glycinate, for about one month and reassess. I do not use magnesium oxide.

When the trial is successful, we actively transition toward magnesium-rich foods within an anti-inflammatory, heart-healthy dietary pattern. The goal is not indefinite supplementation by default. It is to use the trial as a bridge to better nutrition while continuing supplementation when there is an ongoing clinical reason.

Magnesium remains a supporting player. It does not replace accurate measurement, appropriate evaluation of symptoms, or prescribed treatment when needed.

My forthcoming companion piece in The Menopause Heart, “Magnesium at Midlife,” examines the hot-flash, sleep, and bone claims that often travel with magnesium.

Also by Dr. Azhak: Lower Your Blood Pressure: Help Your Doctor Reduce Your Medication, by Sameer Azhak, MD, FACC. Available now on Kindle. Paperback launches October 20, 2026. Buy on Kindle.

References

AlShanableh Z, Ray EC. Magnesium in hypertension: mechanisms and clinical implications. Front Physiol. 2024;15:1363975. doi:10.3389/fphys.2024.1363975. Full text.
Argeros Z, Xu X, Bhandari B, Harris K, Touyz RM, Schutte AE. Magnesium Supplementation and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Hypertension. 2025;82(11):1844–1856. doi:10.1161/HYPERTENSIONAHA.125.25129. Article record; full text.
NIH Office of Dietary Supplements. Magnesium: Fact Sheet for Health Professionals. Accessed October 7, 2026. Fact sheet.
Shechter M, Sharir M, Labrador MJ, Forrester J, Silver B, Bairey Merz CN. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation. 2000;102(19):2353–2358. doi:10.1161/01.CIR.102.19.2353. Article record.
Zhang X, Li Y, Del Gobbo LC, et al. Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials. Hypertension. 2016;68(2):324–333. doi:10.1161/HYPERTENSIONAHA.116.07664. Publisher record.
Mohammadi S, Palermo A, Ojani P, et al. Comprehensive Effects of Magnesium Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose–Response Meta-Analysis. Nutrients. 2026;18(15):2435. doi:10.3390/nu18152435. Full text.
Amiri A, Gholami-Chahkand MS, Javazm AK, et al. The effects of oral magnesium supplements on vascular and endothelial function: an updated systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. Published September 15, 2026. doi:10.1186/s12872-026-06476-3. Publisher record.
U.S. Food and Drug Administration. FDA Announces Qualified Health Claim for Magnesium and Reduced Risk of High Blood Pressure. January 10, 2022. Accessed October 7, 2026. FDA announcement.
Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025;82(10):e212–e316. doi:10.1161/HYP.0000000000000249. Guideline.
U.S. Food and Drug Administration. FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). March 2, 2011. Archived communication; page last updated April 7, 2016. Archived FDA text.
NIH Office of Dietary Supplements. Calcium: Fact Sheet for Health Professionals. Accessed October 7, 2026. Fact sheet.
Workinger JL, Doyle RP, Bortz J. Challenges in the Diagnosis of Magnesium Status. Nutrients. 2018;10(9):1202. doi:10.3390/nu10091202. Full text.
Mayo Clinic Laboratories. Magnesium, Serum. Test ID MGS; Clinical Information and Cautions. Accessed October 7, 2026. Laboratory guidance.
Razzaque MS. Magnesium: Are We Consuming Enough? Nutrients. 2018;10(12):1863. doi:10.3390/nu10121863. Full text.
Senbayram M, Gransee A, Wahle V, Thiel H. Role of magnesium fertilisers in agriculture: plant–soil continuum. Crop Pasture Sci. 2015;66(12):1219–1229. doi:10.1071/CP15104. Full text.
Wortmann CS, Mamo M, Shapiro CA. Management Strategies to Reduce the Rate of Soil Acidification. University of Nebraska–Lincoln Extension. NebGuide G1503. Issued February 2003; revised March 2009. Extension publication.
Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336(16):1117–1124. doi:10.1056/NEJM199704173361601. Article record.

Do I Have to Take Blood Pressure Medication for the Rest of My Life?

Dr. Sameer Azhak — Fri, 09 Oct 2026 00:55:38 GMT

Starting treatment does not close the door on improving your blood pressure—or reassessing what you need.

“Do I have to take medication for my blood pressure?”

Sometimes that question is about the medication itself. But sometimes the question underneath it is:

If I start, does that mean I can never stop?

That is the part of the conversation I want to slow down.

Starting a blood pressure medication is a decision about what your body needs now. It is not a prediction of everything your body will need for the rest of your life.

I cannot promise that you will eventually come off it. But taking medication does not close the door on improving your health, and it does not mean the work you put into your food, activity, sleep, and stress has stopped mattering.

So the question I want us to answer is not, “How do we avoid medication?”

It is, “How do we protect you now while we work on what may be raising your blood pressure?”

What treatment is for

We treat high blood pressure to lower the risk of stroke, heart disease, and kidney damage. Current guidelines recommend lifestyle changes for everyone with elevated blood pressure, and add medication based on how high the blood pressure is and on each person’s overall cardiovascular risk.professional.heart+1

That distinction matters.

A person taking no medication is not automatically healthier than a person taking two. If the first person’s blood pressure stays too high and the second person’s is well controlled, counting pills tells us very little about who is better protected.

Medication burden still matters. Side effects, cost, and the daily hassle of taking pills deserve attention, and I want your plan to be both effective and manageable. But fewer medications should be the result of a safe plan, not the yardstick for every decision.

Room to improve

This is where I want to understand your daily life.

What does eating look like on an ordinary workday? How much salt is finding its way into your meals? How much do you move? Is alcohol part of the picture? Would weight loss help you? How are you sleeping? What happens to your routines when life gets stressful?

These questions are not meant to find something you have done wrong. They are meant to find where there is room to help.

A heart-healthy eating pattern, less sodium, regular physical activity, weight management when appropriate, less alcohol, and stress management are all recommended parts of blood pressure care. They matter whether or not you take medication.ahajournals+1

I also want to know what makes these changes hard to keep. A plan that looks excellent on paper is not much use if it does not fit the life you actually live.

You do not need to live perfectly. You need changes you can realistically make, keep making, and measure.

What “naturally” means

Many people ask whether they can lower their blood pressure naturally. I am interested in that question, but I want us to be precise about what it means.

If “naturally” means improving how you eat, moving more, cutting back on excess sodium, and finding a workable way to handle stress, those are central parts of treatment. They are not alternatives we try only after medication fails. The current guidelines even name approaches such as meditation, breathing exercises, and yoga as options for managing stress.ahajournals+1

If “naturally” means replacing a prescription with a collection of supplements, that is a different conversation.

Patients often ask me about magnesium, garlic, beets, omega-3s, and hibiscus. I do not want to dismiss those questions, but I do want to separate what has been studied from what has been established. The National Center for Complementary and Integrative Health describes the evidence for several of these, including garlic, omega-3 supplements, and hibiscus, as limited, with generally small effects on blood pressure. It also notes that no dietary supplement has been shown to match blood pressure medications.nccih.nih+1

That does not make every food or supplement useless. It means we should not treat all approaches as equally proven, or assume something can stand in for treatment just because it is called natural.

I would rather start with an eating pattern you can sustain than hand you a shopping list of supplements. And I would rather help you find a stress practice you will actually use than tell you to “just relax.” A positive outlook can help you stay engaged. It should never become another reason to blame yourself if your blood pressure stays high.

Waiting versus treating now

Do we have to wait for lifestyle changes to work before starting medication? Not always.

Some people with mildly elevated blood pressure and lower cardiovascular risk can begin with a monitored period of lifestyle changes alone. Others have blood pressure levels or medical risks that make medication appropriate alongside those changes from the start. The guidelines distinguish between these situations; they do not prescribe the same waiting period for everyone.professional.heart

So I do not see medication and lifestyle as competing choices. We may need to treat your blood pressure now while you work on what could improve it over time.

Taking a tablet does not cancel out a walk. It does not make a change in your eating meaningless. And it does not remove your role in your own care. It gives us another tool.

Could you need less medication someday?

Possibly. But I would rather leave room for that possibility than make you a promise.

First, I want to know whether there is something we can meaningfully improve. Then I want to see what happens when you work on it.

I want to see a consistent record over time, not one reassuring reading or one alarming one. Tell me what your days have been like, what you have changed, and how you have been feeling.

This is where your home blood pressure record becomes part of the conversation. Bring all the readings, not just the lowest number you remember. Tell me which changes have been sustainable and which have been difficult to keep.

If that pattern gives us a reason to reconsider your medication, we can talk about an adjustment together. Please do not cut back or stop on your own. A good reading while you are taking medication may simply mean the medication is doing its job. And some blood pressure medications also serve another purpose in your care, such as protecting the heart or kidneys, so we need to account for that too.

The real question becomes:

Does your current treatment still fit your current needs?

That is very different from deciding on day one that you must eventually come off everything.

If you still need medication

Then I do not want you to see that as failure.

We should look at what has improved, what is still difficult, and whether your treatment is effective and manageable—not simply whether we have crossed a prescription off the list.

You do not have to prove that you can do this naturally. You do not have to give up your interest in nutrition because you take a prescription. And you do not need to keep adding supplements just to feel that you are doing enough.

When I recommend medication, I am not saying, “There is nothing else you can do.”

I am saying, “Your blood pressure needs attention. Medication may be part of how we address it, and there is still work we can do together.”

That work should be specific enough to begin. Instead of sending you home with instructions to change everything, I would rather we choose a manageable starting point.

What can you change this week? What might get in the way? What will we review when you come back?

We build from there.

Protection, not a pill count

I understand why hearing that you need medication can feel like a door closing. You may hear the start of a lifelong obligation when you were hoping for a way to take back control.

But we are making a decision about where you are now. We can revisit that decision as we learn how you respond.

So when you ask, “Do I have to take blood pressure medication for the rest of my life?” my honest answer is:

“I cannot know that today. Let’s control your blood pressure, work on what we can improve, and reassess your treatment as we go.”

You may eventually need less medication. You may continue to need it. Neither outcome, on its own, tells us whether you have succeeded.

The number of medications is not the goal. Protecting your health is.

This article is for education and does not replace individualized medical care. Discuss medication changes with your treating clinician.

If this helped you think differently about blood pressure treatment, consider sharing it with someone who has asked the same question.

Four Blood Pressure Stories

Dr. Sameer Azhak — Tue, 06 Oct 2026 11:04:02 GMT

At a Glance
Normal blood pressure means a top number below 120 and a bottom number below 80 mm Hg. Under current U.S. categories, hypertension means an average systolic pressure of 130 or higher OR an average diastolic pressure of 80 or higher. Diagnosis rests on properly measured readings, usually obtained over more than one occasion and often confirmed outside the office.¹
A single office reading—even a very high one—does not always represent a person’s usual blood pressure. It still deserves prompt attention.¹
The opposite can also be true: normal office readings can miss elevated blood pressure at home, at work, in the early morning, or during sleep.¹
Over time, persistently elevated blood pressure can damage the heart, brain, kidneys, eyes, and aorta.¹
Persistent, disruptive urination or excessive thirst while taking a diuretic warrants a careful review. It is not proof of one cause, and it should not be self-treated by stopping the medicine.²,³
Accurate home blood-pressure readings can prevent both over-treatment and under-treatment.¹

Blood pressure is one of the most important numbers in medicine. Over time, persistently elevated pressure increases the risk of stroke, heart failure, atrial fibrillation, kidney disease, aortic disease, and vascular injury—often years before a person feels ill.¹

But blood pressure is not one number. It is a pattern measured across settings, days, sleep, work, illness, stress, medications, and ordinary life.

A high office reading can be real and urgent. It can also overestimate what happens the other 23 hours of the day. A normal office reading can be reassuring—or it can miss a problem that appears at home, overnight, or under stress. And sometimes the heart, kidneys, eyes, or blood vessels show accumulated effects before the cuff makes the pattern obvious.¹

The number matters. But the pattern matters more.

The following clinical stories illustrate why.

The patients described here are de-identified. Details have been modified where appropriate to protect privacy. These stories are for general education and are not individual medical advice.

When a high reading needs emergency attention
For adults who are not pregnant or recently postpartum: if the top number is above 180 OR the bottom number is above 120 mm Hg and you have chest pain, shortness of breath, new weakness or numbness, trouble speaking, vision changes, confusion, a sudden severe headache, fainting, or severe back pain, call 911. Do not drive yourself or wait for another reading before seeking help.¹,⁴
If either number is above that threshold and you do not have warning symptoms, stay seated quietly and repeat the measurement after at least one minute. If it remains this high, contact your clinician immediately for instructions. Do not take an extra dose of blood-pressure medication unless you have been specifically told to do so.¹,⁴
Pregnancy and the postpartum period require different guidance. A top number of 160 or higher OR a bottom number of 110 or higher needs immediate medical attention, even without symptoms. If you have severe headache, vision changes, abdominal pain, chest pain, significant swelling, or shortness of breath during pregnancy or after delivery, call 911.⁵
Serious symptoms can require emergency care even when blood pressure is below these thresholds. Do not use a lower reading to dismiss chest pain, stroke symptoms, or other emergency warning signs.¹

Story 1: The office reading that was not the whole story

A European man in his late sixties came to see me after a series of alarming office blood-pressure readings: 180/100, 180/90, and 170/90 mm Hg. His pulse was 90 beats per minute.

He worked in a high-stress position for a media conglomerate. The numbers were high enough that a low-dose ARB—a common family of blood-pressure medications—was started.

Soon afterward, he developed dizziness and passed out.

The story raised concern for medication-related hypotension and possible orthostatic hypotension: a fall in blood pressure after standing that can reduce blood flow to the brain. Orthostatic hypotension is formally defined by a sustained fall of at least 20 mm Hg systolic or 10 mm Hg diastolic within three minutes of standing, so symptoms alone do not establish the diagnosis. But his symptoms made it clear that office readings alone were not enough to guide the plan.⁶

We needed to know what his blood pressure was doing outside the medical setting.

His home systolic readings, particularly after the medication was started, were generally between 90 and 100 mm Hg. The ARB was discontinued. The discrepancy between repeated high office readings and much lower out-of-office readings raised strong concern for a white-coat effect and medication-related hypotension. It also showed why office readings alone were not enough to guide treatment.

Because these home readings were obtained mainly after treatment began, they did not establish what his untreated blood pressure had been. They did show that his treatment needed reassessment.¹

A properly performed home log or 24-hour ambulatory monitor can help determine whether someone has sustained hypertension, a white-coat pattern, or another pattern that deserves further evaluation.¹

This was not an argument for ignoring readings of 180/100. Repeated readings around that range require prompt clinical evaluation and should not be dismissed as anxiety. Repeated, correctly measured office readings this high generally warrant prompt treatment while the usual blood-pressure pattern is clarified. Symptoms, signs of acute organ injury, and out-of-office readings guide the urgency and treatment plan. Treatment must be reassessed if dizziness, fainting, or low home readings suggest hypotension.¹,⁶

It was an argument for treating the patient—not merely treating the most alarming number in the chart.

What is normal blood pressure?

Blood pressure is written as two numbers, such as 118/74 mm Hg.

The systolic pressure, the top number, is the pressure in the arteries when the heart contracts and pumps blood forward. The diastolic pressure, the bottom number, is the pressure while the heart relaxes and refills between beats.⁴

CategorySystolic, top numberDiastolic, bottom numberNormalLess than 120and less than 80Elevated120–129and less than 80Stage 1 hypertension130–139or 80–89Stage 2 hypertension140 or higheror 90 or higher

If either number falls into a higher category, the higher category applies. But a diagnosis should rest on an average of properly measured readings, not on one anxious moment, one rushed check-in, or one cuff placed over a sleeve.¹

Story 2: The normal office reading that missed the problem

Another patient’s office readings often looked reassuring. At routine visits, her numbers were in the 120s over 70s. These were below the office hypertension threshold, although technically in the “elevated” rather than “normal” category.¹ But she was waking with headaches, felt unusually tired during the day, and had been told that she snored loudly and sometimes stopped breathing at night.

Her home readings, taken correctly over several days, told a different story: repeated morning values in the 140s and 150s. A 24-hour ambulatory monitor confirmed that her blood pressure remained elevated outside the office, including overnight.

This pattern is called masked hypertension: office blood pressure is below the hypertension threshold, but blood pressure outside the office is elevated. In someone already taking medication, the related term is masked uncontrolled hypertension.¹

Masked hypertension matters because the body experiences the out-of-office pressure, not the reassuring clinic number. Masked hypertension is associated with conditions such as sleep apnea, chronic kidney disease, diabetes, and obesity, and with smoking and heavy alcohol use. Stress at work or home can also contribute to higher out-of-office readings.⁷ Separately, stimulants, NSAIDs, decongestants, and a high-sodium diet can raise blood pressure and deserve review.¹ None of these factors proves the diagnosis; they are reasons to ask better questions and consider home or ambulatory monitoring.

A normal office reading does not mean a person should monitor compulsively. It means that when symptoms, risk factors, home readings, or signs of organ effects do not fit the office number, the office number may not be the whole story.¹

White-coat, masked, and sustained hypertension

These terms are easy to confuse. They describe patterns, not character flaws and not a reason to dismiss blood pressure.

PatternIn-office blood pressureOut-of-office blood pressureWhat it meansWhite-coat hypertensionHighNormalHigh office readings in someone not taking treatment, with normal home or ambulatory readingsWhite-coat effectHigher in the officeLower outside the officeA clinic-related rise in readings, including in people already taking treatmentMasked hypertensionNormalHighNormal-looking office readings that miss hypertension outside the clinicMasked uncontrolled hypertensionNormal or controlled-lookingHighOut-of-office hypertension despite treatmentSustained hypertensionHighHighElevated blood pressure across settings

In this table, “normal” means below the hypertension threshold for that setting, not necessarily the “normal” office category shown earlier. Nighttime and 24-hour averages have different thresholds from office readings.¹

Twenty-four-hour ambulatory monitoring is the best way to capture daytime, nighttime, and 24-hour patterns. Home monitoring is more accessible and especially useful for tracking treatment over time.¹

Story 3: When the heart tells a longer story

A third patient came for evaluation after an echocardiogram ordered for a murmur and mild shortness of breath. His office blood pressure was often called “borderline”: usually in the 130s over 80s, occasionally lower. Under current U.S. categories, averages in the 130s over 80s are in the stage 1 hypertension range, even if they have previously been described as “borderline.”¹

But the echocardiogram showed mild thickening of the main pumping chamber of the heart, called left-ventricular hypertrophy, along with enlargement of the left atrium. Neither finding proves that blood pressure is the only cause. Athletic training, valve disease, obesity, sleep apnea, kidney disease, and other conditions can contribute.¹,⁸

Still, in the right clinical context, the heart can provide a longer record than a single cuff reading. Long-standing pressure overload can lead the left ventricle to thicken and the left atrium to enlarge. Over time, the heart may relax less efficiently, increasing the risk of atrial fibrillation and a form of heart failure in which the pumping strength is preserved but filling pressures are high.¹,⁸

The echocardiogram did not diagnose masked hypertension. It did something more useful: it made us take the question seriously. We reviewed his home technique, obtained a more complete set of out-of-office readings, assessed for sleep apnea and other contributors, and treated the broader cardiovascular risk rather than debating whether one “borderline” office number was important.

A cuff gives a snapshot. The heart sometimes provides a longer record. Left-ventricular thickening, enlargement of the left atrium, impaired relaxation of the heart muscle, changes in the aorta, albumin in the urine, kidney-function decline, or hypertensive retinal findings can be clues that blood pressure has been elevated more often or for longer than office readings suggest. None proves blood pressure is the only cause. Together with home readings and medical history, however, they can change how seriously we take a number that appears borderline.¹,⁸

How to get a useful home blood-pressure log

Accurate home readings are not about obsessing over every fluctuation. They are about collecting enough good information to see the pattern.

Use a validated automatic upper-arm monitor with the correct cuff size. If an upper-arm cuff cannot be used, ask your clinician which alternative is appropriate.⁹ Do not use smartwatch, ring, or other cuffless blood-pressure estimates to diagnose hypertension or adjust medication.¹⁰
Avoid caffeine, nicotine, exercise, and alcohol for at least 30 minutes before measuring when possible.¹¹
Empty your bladder, sit quietly for five minutes, and do not talk, text, scroll, or watch the reading anxiously while it is being taken.¹¹
Sit with your back supported, feet flat and uncrossed, and your arm supported at heart level. Place the cuff on your bare upper arm, not over clothing.¹¹
Take two readings one minute apart. Record both.¹¹
Measure in the morning and evening for several days—often a week—unless your clinician gives different instructions.¹²
Bring the cuff and your written or digital log to an appointment so the device and technique can be checked.⁹
Look for averages and patterns, not one unusually high or low result.¹²

Home monitoring can prevent overtreatment in a person with a large white-coat effect. It can also uncover undertreatment in a person with masked hypertension. It is a tool for better decisions, not a substitute for medical care.¹,⁹

Story 4: The salt intake that changed the conversation

A 57-year-old Hispanic woman had been started on a diuretic to treat hypertension. She returned with a complaint that had persisted for weeks: she felt she was constantly urinating.

At that follow-up, we went through her diet in more detail. The dietary inventory revealed that she was taking in a substantial amount of salt every day. We had discussed salt before, but she had not fully appreciated how her own daily intake fit into the blood-pressure conversation.

This time, the discussion became more concrete. After reviewing her intake, she was more willing to curb the salt in her diet than to continue the diuretic.

The lesson was not simply that she needed to be told to eat less salt. It was that a general recommendation had not become meaningful until we connected it to what she was actually consuming and what mattered to her.

The dietary history gave us a concrete treatment target, but it did not establish salt as the cause of her urinary symptoms. Reducing sodium can help lower blood pressure; persistent urinary symptoms still deserve a broader review.¹,²

Diuretics, often called “water pills,” commonly increase urination when they are first started or when the dose changes. That effect is expected, which is why dose timing matters. How much and how long the effect lasts depends on the particular medicine, dose, and condition being treated.¹,²,³

But persistent, disruptive thirst or urination deserves a broader review. Frequent small trips to the bathroom are different from passing unusually large total volumes of urine. Medication effects, high fluid intake, poorly controlled diabetes, kidney conditions, and less common hormonal causes can increase urine volume; bladder or urinary problems can cause frequent trips without a large increase in total volume.²

Do not assume it is “just the water pill.” And do not abruptly stop a diuretic on your own, especially if it has been prescribed for heart failure, swelling, kidney disease, or difficult-to-control blood pressure. Contact the clinician who prescribed it so the cause and the safest adjustment can be considered.¹,³

What blood pressure treatment really means

Blood-pressure treatment is not just about a prescription. It is a plan built around the pattern that is actually present.

For some people, the central intervention is medication. For others, it is medication plus weight management, sodium reduction, a dietary pattern rich in vegetables, fruit, beans, whole grains, nuts, and unsweetened foods, regular activity, better sleep, treatment of sleep apnea, less alcohol, smoking cessation, or attention to medications and supplements that raise blood pressure.¹

Lifestyle changes are not a test of virtue, and high blood pressure is not a personal failure. Genetics, aging, kidney function, hormones, chronic pain, sleep disorders, stress, food access, work schedules, caregiving, finances, and medication effects all shape blood pressure. The goal is not perfection. It is a plan that is effective enough, safe enough, and realistic enough to sustain.¹

For most adults, the treatment goal is blood pressure below 130/80 mm Hg, with individualized decisions when side effects, orthostatic symptoms, frailty, pregnancy, complex illness, or other circumstances change the balance of benefit and risk.¹,¹³

What to bring to your next appointment

A home blood-pressure log with dates, times, and two readings each time.
Your home cuff, if possible, so it can be compared with the office device.
A complete medication, supplement, and over-the-counter list, including NSAIDs, decongestants, stimulants, hormone therapies, and alcohol or nicotine use.
A description of dizziness, fainting, headaches, chest symptoms, palpitations, shortness of breath, sleep problems, snoring, and changes in exercise tolerance.
Family history of early hypertension, stroke, kidney disease, or aortic disease.
Questions about whether ambulatory monitoring, sleep-apnea assessment, kidney testing, or an echocardiogram would change the plan.¹,⁹

The integrative answer

Blood pressure is not merely a number collected in a clinic. It is a signal from the cardiovascular system, shaped by arteries, kidneys, hormones, sleep, stress, movement, sodium, alcohol, medications, and the rhythm of daily life.¹

The right response to a high office number is neither panic nor dismissal. It is accurate measurement, prompt attention when needed, and a plan built around the pattern.

The right response to a normal office number is not always reassurance. When symptoms, home readings, risk factors, or evidence of organ effects do not fit, it is worth looking further.¹

A blood-pressure cuff gives a snapshot. Accurate home or ambulatory readings reveal the pattern, and the heart sometimes shows the history.

References

Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025;82(10):e212–e316. doi:10.1161/HYP.0000000000000249. Corrected online guideline.
Merck Manual Professional Edition. Polyuria. Clinical review. Accessed October 4, 2026.
NHS. Common questions about bendroflumethiazide. Patient guidance. Accessed October 4, 2026.
American Heart Association. Understanding Blood Pressure Readings. Patient guidance. Accessed October 4, 2026.
American Heart Association. Top 10 Things to Know About High Blood Pressure. Patient guidance, including pregnancy-specific thresholds. Accessed October 4, 2026.
Juraschek SP, Cortez MM, Flack JM, et al. Orthostatic Hypotension in Adults With Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2024;81(3):e16–e30. doi:10.1161/HYP.0000000000000236. Full text.
Franklin SS, O’Brien E, Thijs L, Asayama K, Staessen JA. Masked Hypertension: A Phenomenon of Measurement. Hypertension. 2015;65:16–20. doi:10.1161/HYPERTENSIONAHA.114.04522. Full text.
Raman SV. The Hypertensive Heart: An Integrated Understanding Informed by Imaging. J Am Coll Cardiol. 2010;55(2):91–96. doi:10.1016/j.jacc.2009.07.059. Full text.
American Heart Association. Home Blood Pressure Monitoring. Patient guidance. Accessed October 4, 2026.
Cohen JB, Byfield RL, Hardy ST, et al. Cuffless Devices for the Measurement of Blood Pressure: A Scientific Statement From the American Heart Association. Hypertension. 2026;83(3):e00254. doi:10.1161/HYP.0000000000000254. Full text.
American Heart Association. Measuring Your Blood Pressure at Home. Patient measurement handout. Accessed October 4, 2026.
Shimbo D, Artinian NT, Basile JN, et al. Self-Measured Blood Pressure Monitoring at Home: A Joint Policy Statement From the American Heart Association and American Medical Association. Circulation. 2020;142:e42–e63. doi:10.1161/CIR.0000000000000803. Policy statement.
American Heart Association. Top Things to Know: 2025 High Blood Pressure Guideline. Professional summary. Accessed October 4, 2026.

Five Elevated Lipoprotein(a) Levels, Five Different Outcomes

Dr. Sameer Azhak — Sun, 04 Oct 2026 13:02:41 GMT

Nearly fifteen years ago, a man in his late fifties came to see me for medication refills. His regular cardiologist was on vacation. It was supposed to be a short visit, but he had a question that would stay with me.

“Doctor, why did I have a heart attack? I don’t smoke. I exercise. I run marathons. I eat healthy. My cholesterol isn’t very high. I don’t have high blood pressure. I don’t have diabetes. All I have is a family history, and I’ve done everything I can to make up for that.”

He looked defeated. He had done the work, and the outcome seemed to tell him that the work had not mattered.

His question sent us beyond the usual cholesterol panel. The result that changed our conversation was his lipoprotein(a), usually shortened to Lp(a) and pronounced “L-P-little-a”: 245 mg/dL.

That result helped explain an inherited risk his running could not remove. It did not prove that Lp(a) alone caused his heart attack, or that his healthy habits had failed him.¹

Four more patients would deepen that lesson. One needed coronary stents at 45. Another reached 78 with a calcium score of zero. A welder sought a check-up at the age his father had died and discovered serious disease without symptoms. A travel agent had already been through repeated stent and bypass-graft closures.

Five elevated results. Five very different clinical courses. The number mattered in every story, but it did not finish any of them.

These clinical stories are shared for education, with identifying details omitted. They are not individual medical advice.

The runner: an explanation, not a verdict

The runner’s Lp(a) was not a small abnormality. It was a substantial inherited risk that needed to be considered alongside his family history and the heart attack he had already experienced.¹

Here is the biology you need for this discussion: Lp(a) is a mostly inherited cholesterol-carrying particle, and a high level increases cardiovascular risk.¹ Healthy eating and exercise generally do not substantially lower the level itself, but they remain part of cardiovascular prevention.¹

The practical question was not how to make him exercise harder. It was what protection still needed to be added to the effort he was already making.

Later, this patient took niacin and added fish to his diet. His repeat Lp(a) was around 120 mg/dL. At the time, we counted the lower number as a win. Looking back, that observation could not tell us which part of the change came from treatment, or whether it translated into fewer future events.

His first question was about why the heart attack happened. The next question was what would actually help him avoid another one. Those questions overlap, but they are not interchangeable.

The number does not tell us everything about the particle

Lp(a) is not one uniform particle. Its attached protein, apolipoprotein(a), or apo(a), comes in different inherited sizes. These variants, called isoforms, make Lp(a) structurally heterogeneous: the label describes a family, not identical copies.²

Smaller apo(a) forms often accompany higher Lp(a) concentrations.¹ Human-genetic research also suggests that size can influence coronary risk beyond concentration, but it does not establish the benefit of routine size testing.³

A standard Lp(a) result reports concentration, not a structural profile. A result in mg/dL reports mass, not particle number; similar mass results can represent different particle counts because the particles differ in size.² Some assays can also under- or overestimate results depending on apo(a) size.²

Reporting in nmol/L better represents particle concentration, ideally using a validated assay that minimizes size-related bias.¹ It still does not identify your isoforms, and no universal formula reliably converts between the units.²

That does not make an mg/dL result useless. Guidance considers accurate concentration measurement sufficient for routine Lp(a)-related risk assessment, without specialized isoform testing.¹ Current U.S. risk-enhancing thresholds are at least 50 mg/dL or 125 nmol/L, not an exact conversion between units.⁴

For these five patients, we have concentrations, not isoform measurements. We cannot claim that particle size explains their different outcomes. The practical step is to read the units, check the measurement method when needed, and interpret the result alongside the rest of the cardiovascular picture.¹

The 45-year-old: inherited risk with additional fuel

Another patient was 45 when he developed unstable angina, an acute coronary syndrome. Cardiac catheterization showed multivessel disease, and he underwent staged stenting of all three major coronary arteries.

His Lp(a) was 178 nmol/L. His father and uncles had suffered heart attacks in their forties and fifties. He also smoked and ate a poor-quality diet.

Here, the conventional risks were not absent. The family history and Lp(a) added to them. It would have been a mistake to discover the inherited particle and then treat smoking or the rest of his prevention plan as secondary concerns.¹,⁵

It would have been equally incomplete to say that smoking explained everything, so there was no reason to ask about inherited risk. His relatives’ early disease was part of the history, not background noise.

Once someone has coronary disease, prevention is no longer only about estimating the chance of a first event. It is about preventing the next event, with lipid lowering, smoking cessation, appropriate antiplatelet treatment, activity, nutrition, and management of other risks working together.⁵

A stent treats a particular narrowing; it does not remove the underlying tendency to develop atherosclerosis elsewhere.⁵ That is why the prevention conversation must continue after the procedure.

The runner’s story challenged the assumption that healthy habits guarantee protection. This patient’s story challenged the opposite assumption: that an inherited risk makes the habits we can change irrelevant.

The 78-year-old: a high result and a reassuring scan

Then there was the woman who keeps me humble. At 78, she had a strong family history of heart disease and a history of LDL cholesterol at 190 mg/dL.

After news coverage of Lp(a) treatments in development, her primary-care physician checked her level. It was 180 nmol/L, close to the 45-year-old’s result in the same units.

Her coronary calcium score was zero. Her exercise nuclear stress test showed excellent exercise tolerance and no inducible ischemia.

The contrast is the reason to tell these stories together. One person had required multivessel stenting at 45. Another, more than three decades older, had no detectable coronary calcium. Their Lp(a) values alone could not account for that difference.

Her findings were reassuring, not proof that her arteries contained no plaque: calcium scoring does not exclude noncalcified plaque, and a normal stress test does not establish plaque-free arteries.⁴,⁵ Her previous LDL of 190 still deserved attention rather than dismissal because the scan was reassuring.⁴

An observational analysis of MESA and the Dallas Heart Study found the highest risk when elevated Lp(a) accompanied substantial coronary calcium; with CAC zero, elevated Lp(a) did not identify a statistically significant increase in events during the reported follow-up.⁶ That supports putting the tests together, not promising that a zero erases lifetime risk.

She had never smoked. She also wanted her story to include gratitude, a positive outlook, and the ownership she had taken of her health. I wanted to honor that without claiming that positive thinking had prevented coronary disease.

Her result did not require us to manufacture an emergency. It required a proportionate conversation about what was reassuring, what remained relevant, and what prevention made sense at her age.

The welder: 52 was not just an age

For the welder, 52 had a particular meaning. His father had died at 52. When he reached that age himself, he came for a check-up because of that family history.

He was asymptomatic. He did not smoke, tried to eat healthfully, and had made an effort to take care of himself. His Lp(a) was 257 mg/dL.

His calcium score was in the 400s. A stress test was abnormal. Catheterization showed multivessel coronary disease involving the left main, and he was referred for coronary artery bypass surgery.

The important contrast was not simply between two laboratory values. The runner had already had a heart attack. The welder had serious disease discovered before a symptomatic event brought him to care.

I reassured him that his efforts had not been pointless. Perhaps, without them, his course would have been worse. But I could not tell him that his habits were the reason he had survived to 52, or promise that he otherwise would have shared his father’s fate.

What we did know was more useful: he had acted on his family history, and we had identified disease that changed his care. The next step was evaluation for bypass surgery.

There is a difficult emotional trap in prevention. A person can work hard and still develop disease, then interpret the diagnosis as evidence that the work failed. The runner had felt it. The welder’s experience raised the same question in a different form.

The answer cannot be a guarantee. It is that inherited risk and modifiable risk coexist, and addressing the second remains worthwhile even when the first is substantial.¹ Discovering advanced disease does not turn years of not smoking into a wasted effort.

Nor does his case mean that everyone with high Lp(a) needs a stress test or catheterization; testing decisions depend on the whole clinical picture, not this blood result alone.⁴,⁵

The travel agent: when the usual explanation was not enough

The fifth patient was a 55-year-old travel agent with an unusually aggressive course: coronary stents, stent closure, bypass surgery, bypass-graft occlusions, stents in the grafts, and then closure of those stents.

This was precisely the kind of patient in whom I looked beyond the standard risk factors. Not because the usual risks had disappeared, but because the extent and recurrence of disease demanded a broader look.

LDL readings were in the 170–180 range, and HDL had generally been in the 20s and 30s. Lp(a) was in the 190s mg/dL. Homocysteine was elevated, and testing identified two copies of the common MTHFR C677T variant.

This was before the AIM-HIGH trial changed how we viewed niacin. The regimen included rosuvastatin, ezetimibe, and niacin at 2,000 mg, with aspirin and an apple before the niacin. This is a historical account of supervised care, not a regimen for readers to reproduce.

Food was part of the prescription too: a daily blended salad of two handfuls of mixed greens, a cup of red grapes, a tablespoon of freshly ground flax seeds, and pomegranate juice. We also used methylfolate, vitamin B6, and vitamin B12.

Over three to six months, Lp(a) fell approximately 20–25%, homocysteine fell from 19 to 10, and HDL rose from 32 to 48. The patient remained angina-free for three to four years before being lost to follow-up.

That symptom-free interval mattered. It does not establish that the grafts stayed open, that no cardiovascular events occurred, or that any single ingredient in the plan caused the improvement. Several treatments changed together.

Later, AIM-HIGH found no incremental cardiovascular benefit from adding niacin to statin therapy.⁷ HPS2-THRIVE likewise found no significant major vascular-event benefit from niacin plus laropiprant and identified more serious adverse effects.⁸

Neither trial specifically selected patients for elevated Lp(a), but the results do not support reviving routine niacin treatment to chase an Lp(a) or HDL number.¹ The lesson I retain is the need to look broadly and treat comprehensively, not to turn an old regimen into a modern promise.

Why homocysteine belonged in that conversation

Before the newer broad Lp(a) testing recommendations, I did not screen all comers indiscriminately. I looked especially at people with family histories of premature coronary disease, personal histories of premature disease, failure of conventional therapy, coronary or peripheral or cerebrovascular disease, and recurrent cardiovascular events.

The recurring question was whether the amount or behavior of vascular disease was adequately explained by the standard risk factors. Lp(a) and, selectively, homocysteine were part of that expanded search.

An elevated homocysteine result raises questions about folate and B12 status, kidney function, and other contributors; it is not a specific diagnosis of a genetic processing problem.⁹ My food inventory asks a practical question: is this person regularly eating folate-rich foods, particularly leafy greens, rather than relying on fortified products?

When supplementation is appropriate, I prefer methylfolate and consider B12 and B6 alongside it. I sometimes consider MTHFR testing, although the result often does not change my plan; routine testing for common variants is generally not needed to guide care.¹⁰

Two copies of C677T do not establish why a particular stent or graft closed.¹⁰ My preference for methylfolate is a clinical choice, not proof of better cardiovascular outcomes.

B12 status needs attention before substantial folate supplementation, which can conceal the anemia of B12 deficiency without treating its neurological effects.¹¹ The practical step is to review food intake, possible deficiencies, and the reason for the elevated result rather than buying a supplement stack.

Most importantly, lowering homocysteine is not the same as proving fewer heart attacks: randomized B-vitamin trials have not established reductions in myocardial infarction or mortality, although a major pooled review found a small stroke reduction.¹² Excessive long-term B6 can also injure nerves.¹³

The travel agent’s response belongs in the story as an observation. It is not permission to substitute supplements for established coronary treatment.

Prevention and lowering Lp(a) are not the same decision

The 2026 ACC/AHA guideline recommends measuring Lp(a) at least once in adulthood, a broader approach than my earlier selective testing.⁴ That recommendation does not mean ordering every other proposed cardiovascular marker in everyone.

Three decisions need to remain separate: whether to measure Lp(a), whether its result should strengthen the prevention plan, and whether to prescribe a treatment specifically to lower Lp(a). Broader screening does not automatically establish a drug indication for each person with an elevated result.¹,⁴

There is good reason to take the rest of the risk profile seriously. In an observational MESA analysis, more favorable cardiovascular health was associated with lower event risk even among people with high Lp(a), although it did not eliminate the inherited risk.¹⁴ The study supports that direction of care; it is not a randomized promise about what a particular lifestyle change will accomplish.

Better prevention improves the odds. It does not give us complete control, and it does not make a heart attack a verdict on someone’s discipline.

The drug question requires its own evidence. On September 4, 2026, Novartis announced that pelacarsen’s Lp(a)HORIZON trial had not met its primary cardiovascular endpoint despite lowering Lp(a).¹⁵ In its September statement, the National Lipid Association noted that full clinical results were not yet available and continued to recommend Lp(a) testing and intensive management of other risks.¹⁶

These five cases cannot explain why that trial missed its endpoint. Nor does that topline result justify treating Lp(a) as irrelevant or assuming that every future approach will have the same result. It reminds us why a laboratory response and an outcome benefit must be tested separately.

What none of the five results could tell me

None could show how much narrowing was present. None could tell me whether the next decade would resemble the 45-year-old’s course or the 78-year-old’s. None could identify the cause of every recurrent closure in the travel agent.

The result belongs beside the history, symptoms, standard lipid measurements, blood pressure, glucose, and evidence of vascular disease, not above them.¹,⁴ Treatment should reflect that complete picture.

For someone with established coronary disease, that can mean substantial LDL lowering with a statin and additional medicines when needed, alongside nutrition, movement, smoking cessation, and other proven care.⁵ For someone without known disease, the discussion includes absolute risk, treatment benefit and burden, and whether further assessment would change the plan.⁴

That is the difference between a frightening result and a useful one. A useful result changes a decision, clarifies a priority, or tells us what question to ask next.

What to do with your result

You do not need to master the chemistry before taking the next step. Bring the actual report, your medication list, and the ages at which close relatives developed heart or vascular disease. Then work through a few concrete questions with your clinician.

Find out which prevention conversation you are having

Ask: “Are we trying to prevent a first event, or do I already have disease that requires treatment?” Prior heart attack, coronary stenting or bypass, and other established atherosclerotic disease change the treatment conversation substantially.⁴,⁵

The runner and travel agent did not need another risk marker to prove that prevention mattered. They already had coronary disease. The 78-year-old needed a different conversation, one that respected her reassuring tests without ignoring her history.

If further testing is proposed, ask what decision the result would change. A high Lp(a) result alone is not an instruction to collect scans or proceed to catheterization.⁴,⁵

Get a specific cholesterol plan

Ask: “What should my LDL cholesterol goal be, and am I there?” Elevated Lp(a) supports more intensive attention to LDL, but the goal and choice of medicines still depend on the person’s overall risk and treatment tolerance.⁴

For people with established cardiovascular disease at very high risk, current guidance generally recommends LDL-C below 55 mg/dL; that is not an automatic target for every otherwise healthy person with an elevated Lp(a).⁴ Ask how the proposed target was chosen for you.

Also ask when to repeat the standard lipid panel and how the plan will change if the response is inadequate. “Watch your cholesterol” is not as useful as a target, a treatment decision, and a follow-up date.

Put the daily work beside the prescription

Food and medication are not competing loyalties. A heart-healthy eating pattern, regular physical activity, avoiding tobacco, and appropriate control of blood pressure and diabetes belong alongside indicated medicines, not in place of them.⁵

Make food changes concrete: build more meals around vegetables, beans, whole grains, nuts, and other minimally processed foods, with fish when appropriate.⁵ The blended salad was one way of making food part of the travel agent’s routine; it was not a special antidote to Lp(a).

If you smoke, ask for a cessation plan rather than relying on willpower alone; if you have coronary disease, ask what activity is safe and whether cardiac rehabilitation is appropriate.⁵ Discuss blood-pressure and glucose goals when relevant, and identify the change you can realistically sustain.

The task is not to perform health perfectly. It is to make the next meal, the next week, and the next follow-up part of the same workable plan.

Let the information help your family

Ask whether parents, siblings, and children should be tested, with childhood testing discussed with the child’s clinician.⁴ Share the result and its units rather than telling relatives they are destined to have your outcome.

The welder acted because his father’s age at death mattered to him. Family information is most useful when it leads to timely assessment, not when it becomes a prediction everyone carries in silence.

Do not chase the number on your own

Do not start niacin, aspirin, or high-dose vitamins simply because the Lp(a) result is elevated; each has separate indications, limitations, or risks.¹,⁵,¹³ Ask what benefit is expected from any proposed treatment and what will be monitored for safety.

Ask for a follow-up plan that tracks what you are actually treating. The visit should not end with an isolated abnormal result and a vague instruction to worry less.

Before you close this

I still return to the runner’s question. He wanted an explanation, but he also needed to know that his effort had not been meaningless.

The answer is neither that genes decide everything nor that perfect habits can control everything. The inherited particle is one part of the story. The purpose of finding it is to build a better plan around the person who carries it.

This article is for general education and does not replace individualized medical advice. Do not start, stop, or change medication or supplements without discussing your circumstances with your clinician.

References

Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43:3925–3946. Full article and DOI.
Marcovina SM, Albers JJ. Lipoprotein(a) measurements for clinical application. J Lipid Res. 2016;57(4):526–537. doi:10.1194/jlr.R061648. Full article.
Saleheen D, Haycock PC, Zhao W, et al. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2017;5(7):524–533. doi:10.1016/S2213-8587(17)30088-8. Full article.
Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2025.11.016. Guideline.
Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. Circulation. 2023. doi:10.1161/CIR.0000000000001168. Guideline.
Mehta A, Vasquez N, Ayers CR, et al. Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk. J Am Coll Cardiol. 2022;79:757–768. PubMed record.
AIM-HIGH Investigators. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N Engl J Med. 2011;365:2255–2267. Trial.
HPS2-THRIVE Collaborative Group. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. N Engl J Med. 2014;371:203–212. Trial.
Bedz D, Forsyth C. Vitamin B12 deficiency: testing and treatment. Aust Prescr. 2026;49(2):55–60. doi:10.18773/austprescr.2026.012. Full article.
MedlinePlus. MTHFR Gene Test. Patient resource.
National Institutes of Health, Office of Dietary Supplements. Folate: Fact Sheet for Health Professionals. Folate guidance.
Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;8:CD006612. Systematic review.
National Institutes of Health, Office of Dietary Supplements. Vitamin B6: Fact Sheet for Health Professionals. Vitamin B6 safety guidance.
Razavi AC, Reyes MP, Wilkins JT, et al. Traditional risk factors, optimal cardiovascular health, and elevated lipoprotein(a). Eur J Prev Cardiol. Published online November 28, 2024. Full article.
Novartis. Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease. September 4, 2026. Sponsor announcement.
National Lipid Association. Top Line Results from the Phase 3 Lp(a)HORIZON Trial. September 16, 2026. Professional society statement.

Can My Blockages Get Better?

Dr. Sameer Azhak — Wed, 30 Sep 2026 11:16:05 GMT

At a Glance
Yes. With sustained prevention, coronary disease can improve in meaningful ways. Plaque burden may decrease modestly, plaque composition can shift toward greater stability, blood flow can improve, and the risk of future events can fall.
The change in the narrowing itself is usually small. The change in risk can be large, because treatment can stabilize the lipid-rich plaques that disproportionately trigger heart attacks.
The most consistent driver of plaque regression and stabilization is sustained lowering of atherogenic ApoB-containing particles. LDL cholesterol is the usual treatment target and a practical proxy in many people; ApoB can add information when the two are discordant.
Blood pressure, diabetes, smoking, physical activity, diet, sleep, and other parts of daily life help determine whether plaque keeps growing even when cholesterol looks good.
A stress test can improve without the blockage changing at all. In some people, collateral circulation and small-vessel function improve, while treatment can also lower the heart’s oxygen demand.
A rising calcium score on a statin does not necessarily mean treatment is failing. Calcium scoring is not a reliable report card for treatment response.
Improvement needs upkeep. For most people with established coronary atherosclerosis, prevention is long-term and should be reviewed and adjusted over time.

“Can my blockages get better?”

I hear this question in almost every conversation that follows a cardiac catheterization, a CT angiogram, or an abnormal stress test. Sometimes it comes out as a whisper. Sometimes it comes with a printout from the internet promising that a particular diet “melts plaque away.” Most often, it comes with a quieter question underneath: Is this damage permanent, or is there still something I can do?

The honest answer is yes: with sustained prevention, coronary disease can improve in meaningful ways. But the change is usually not a dramatic disappearance of a blockage. It is more often a shift toward plaque that is smaller, less lipid-rich, more stable, and less likely to trigger a heart attack.

Regression is possible, but it is usually partial—not a cure, not a reason to stop treatment, and not something that can be reliably demonstrated by repeating scans until a better number appears. Once you understand what actually changes in the artery, the answer becomes more hopeful, not less.

A note about symptoms: Do not use this article to interpret new or worsening chest pressure, shortness of breath, sweating, fainting, pain in the jaw, arm, back, or upper abdomen, or a sudden decline in exercise tolerance. Those symptoms need prompt clinical assessment. If they are severe, persistent, or concerning, call emergency services.

Plaque is not a clog in a pipe

Most of us imagine a coronary blockage the way a plumber would: grease building up inside a pipe until the water cannot get through. That picture is intuitive, and it is wrong in ways that matter.

Plaque does not sit on the inside surface of the artery. It grows within the wall. The closer image is a blister. A pocket of cholesterol, inflammatory cells, and dead-cell debris sits under a thin cap of tissue, tucked inside the artery wall itself.

For years, the artery makes room for that blister by bulging outward. In a classic autopsy study of the left main coronary artery in 136 hearts, the channel for blood did not narrow until plaque filled roughly 40% of the artery’s cross-section.¹ In other words, you can carry a substantial amount of plaque with a channel that still looks nearly normal on an angiogram.

This matters because many type 1 heart attacks occur when a lipid-rich plaque ruptures or erodes and a clot forms on top of it. In studies of people who had angiography before a later heart attack, many future culprit lesions had appeared only mild or moderate on the earlier angiogram.² A heart attack is often not the result of a slow clog finally sealing shut.

Other causes of myocardial infarction exist, including supply-demand mismatch, spontaneous coronary artery dissection, coronary spasm, and embolic disease. New symptoms always require clinical evaluation. But for atherosclerotic coronary disease, keep the blister in mind. It explains almost everything that follows.

What “regression” actually means

When cardiologists talk about regression, we can mean five different things. They are measured with different tools, and they change on different timelines:

What may improveWhat it can showWhat it cannot prove by itselfThe channel is widerAn angiogram can show the lumen, or channel, of a larger coronary arteryTotal plaque burden, plaque composition, or small-vessel functionThere is less plaque in the wallIntravascular ultrasound, specialized intracoronary imaging, or detailed CT plaque assessment can estimate plaque burdenThat a particular person will never have a future eventThe plaque is saferSome imaging can show changes in plaque volume and features associated with stabilityThat every dangerous plaque has been identified or eliminatedThe heart muscle gets more blood under stressNuclear stress testing, PET, and other stress imaging can show ischemia or perfusion reserveThat a particular blockage has shrunkThere are fewer events and better daily functionSymptoms, exercise capacity, hospitalizations, heart attacks, procedures, and survival show what matters mostWhich individual plaque changed, or exactly why

These layers often move in the same direction, but not always, and not at the same speed. A great deal of confusion about “reversing heart disease” comes from mixing them up.

Yes, regression has been documented, many times

Even before modern cholesterol medicines, repeat angiograms showed that coronary disease is not a one-way street. In older serial-angiography studies, untreated coronary disease more often progressed than regressed. Spontaneous angiographic improvement was uncommon.³

Treatment changed those odds. In the Familial Atherosclerosis Treatment Study (FATS), men with high ApoB and established coronary disease received intensive lipid-lowering therapy for two and a half years. Intensive lipid lowering increased the frequency of angiographic regression and was associated with fewer coronary events than conventional treatment.⁴

The POSCH trial followed survivors of heart attack after a surgical procedure that permanently lowered cholesterol. On repeat angiography over ten years, definite progression was less common and regression more common in the treated group; coronary death plus nonfatal heart attack also fell.⁵

These are important findings, but the main lesson is not that every blockage disappears. It is that atherosclerosis can be modified over time.

The surprising part: the channel barely moves

If regression is real, why does a follow-up angiogram not always look dramatically better?

Because the average change in the channel is often small. Yet coronary events can fall substantially.⁶

How can a change that small produce a benefit that large? The answer goes back to the blister. Intensive lipid lowering appears to work not only by reducing plaque burden, but also by changing plaque features linked to instability. These vulnerable features are disproportionately represented among plaques that trigger acute coronary events.

The channel may look almost the same, but what is inside the wall may have changed. The lipid core can shrink. The cap over plaque can become thicker. The plaque can become more fibrotic and less prone to rupture.

Modern imaging lets us watch parts of this happen. In PACMAN-AMI, patients who had just had a heart attack were treated with a PCSK9 inhibitor on top of a high-intensity statin. Over one year, adding alirocumab produced greater regression of nonculprit plaque and greater thickening of the fibrous cap than statin treatment alone.⁷

That is what “better” often looks like: not an artery restored to adolescence, but plaque that is less likely to rupture.

What makes plaque grow

If you want plaque to stop growing, it helps to know what feeds it.

ApoB-containing particles. ApoB-containing particles—including LDL and cholesterol-rich remnant particles—can enter and become trapped in the artery wall. Over years, that retained cholesterol helps build and sustain plaque. LDL-C and ApoB usually move together, but ApoB can be particularly useful when triglycerides are elevated or metabolic health is impaired and the two measurements do not match.

Blood pressure. In an imaging analysis of patients with coronary disease, lower achieved blood pressure was associated with less plaque progression over two years.⁸ This does not establish one universal blood-pressure target for everyone, but it reinforces that blood pressure is part of atherosclerosis treatment, not a separate issue.

Diabetes and insulin resistance. People with diabetes often have faster plaque progression. In pooled intravascular-ultrasound studies, diabetes remained associated with less favorable plaque change even when LDL lowering was substantial.⁹

Smoking. Smoking injures the artery lining and makes clots more likely. Smoking is associated with atherosclerotic cardiovascular disease, and cardiovascular risk falls after quitting.¹⁰

Other exposures and conditions. Some prescribed therapies, supplements, hormones, chronic inflammatory diseases, kidney disease, sleep disorders, and metabolic conditions can influence cardiovascular risk. For example, in one trial of older men with low testosterone, testosterone therapy increased noncalcified coronary plaque volume compared with placebo.¹¹ The study measured CT plaque over one year and was not designed to determine whether testosterone changed the risk of heart attack, stroke, or death. That finding does not mean that anyone should stop prescribed hormone therapy because of this article. It means all medications, hormones, supplements, and exposures deserve a thoughtful, individualized review when plaque is progressing despite otherwise good control.

Here is the finding I share with patients who have already worked hard to lower their LDL. Even when LDL cholesterol is lowered to very low levels, some people still show plaque progression on serial imaging. Diabetes, blood pressure, and other residual-risk features can help identify people whose plaque is more likely to continue progressing.¹² Cholesterol matters enormously, but it is not the whole story.

What helps plaque regress

Lower atherogenic particles, and keep them low. This is the single most consistent lever across imaging studies. In ASTEROID, high-intensity statin therapy brought average LDL-C to about 61 mg/dL, and many participants demonstrated plaque regression over two years.¹³ In GLAGOV, adding a PCSK9 inhibitor to a statin lowered LDL-C substantially further, and a larger proportion of participants had regression on intravascular ultrasound.¹⁴

Move your body, as if it were a prescription. In an older randomized German study of patients with coronary disease, greater leisure-time activity was associated with less progression and, at higher activity levels, more regression.¹⁵ The exact calorie thresholds from that study are not a universal prescription. For many people, a practical goal is to build toward regular aerobic activity plus resistance training, adjusted to symptoms, fitness, mobility, and clinician guidance.

Build a sustainable dietary pattern, not a search for one plaque-melting food or supplement. In the Lifestyle Heart Trial, a small randomized study, patients followed a very low-fat, plant-forward diet, exercised, practiced stress management, and received group support. After five years, average angiographic narrowing improved in the intensive-lifestyle group and worsened in the usual-care group; cardiac events were also fewer in the intensive group.¹⁶ It was a small study, and it was done before today’s cholesterol medicines were routine. Still, its central message holds: dietary quality, movement, stress management, and social support can be part of meaningful prevention.

An intensive Ornish-style program is one evidence-based model, not the only heart-healthy dietary pattern. Mediterranean-style, plant-forward, high-fiber eating patterns can also support cardiovascular prevention. The best pattern is one that is nutritionally sound and sustainable in the context of your culture, budget, schedule, caregiving responsibilities, symptoms, and preferences.

Treat blood pressure and blood sugar as if they were cholesterol. They feed the same disease process.

Be skeptical of “natural” plaque-reversal promises. No vitamin or supplement has been shown to reliably melt coronary plaque. In HATS, a specific antioxidant-vitamin combination did not add cardiovascular benefit and appeared to attenuate some favorable effects of simvastatin-niacin therapy. That finding does not answer the question for every supplement or every antioxidant formulation.¹⁷

Medication and lifestyle are not competing answers. Sustained lowering of atherogenic particles has the clearest evidence for plaque regression and stabilization, while exercise, dietary quality, smoking cessation, blood-pressure control, glucose management, sleep, and stress support the broader conditions in which cardiovascular risk falls.

When the stress test improves but the blockage does not

This is the part of the story most people have never heard, and it is one of my favorites.

A nuclear stress test does not photograph a blockage. It shows how well blood reaches the heart muscle when the heart is working hard. That can improve for several reasons, and only one of them is a smaller plaque.

In a selected randomized trial of people with stable coronary disease who were eligible for either approach, exercise training was compared with PCI. The trial should not be read as evidence that exercise replaces revascularization when revascularization is clinically indicated. In the exercise group, the narrowing barely changed. Yet blood flow to the heart muscle beyond the narrowing improved, and more people in the exercise group remained free of cardiac events during the year.¹⁸

How? In some people, regular exercise can improve collateral circulation: small alternate channels that may help supply blood beyond a narrowing. In a later trial, four weeks of moderate- or high-intensity exercise increased collateral flow compared with usual care.¹⁹ Better endothelial function in the small vessels, a lower heart rate and blood pressure during exertion, and medicines such as beta-blockers can also improve a stress test.

Improvement on stress imaging is genuinely good news. In a study of combined intensive lifestyle and pharmacologic lipid treatment, participants had fewer perfusion abnormalities and fewer coronary events than those receiving usual-care lipid treatment.²⁰ In the COURAGE nuclear substudy, less residual ischemia on follow-up imaging was associated with better outcomes, although that association weakened after adjustment for other risk factors.²¹ These studies support a useful conclusion: improvement in perfusion matters, but it does not prove that a particular blockage shrank.

Two surprises that can mislead you

Your calcium score may go up on a statin. This worries many patients, and it should not automatically be interpreted as failure. In serial intravascular-imaging studies, statin therapy has been associated with lower overall plaque burden alongside greater calcification within plaque.²² That pattern may reflect a shift in plaque composition, but a rising calcium score by itself cannot tell us whether an individual prevention plan is succeeding or failing. Calcium scoring is not designed to monitor whether treatment is working.

Not every “improved” angiogram is regression. An artery can look narrower or wider depending on its tone at the moment of the picture, whether nitroglycerin was given, the angle of the images, or healing of a prior tear or clot. Before I call a change regression, I compare like with like.

What this means for you

Here is how I approach this with patients:

Know your numbers. That means LDL cholesterol, and sometimes ApoB; Lp(a), measured at least once; A1C or other glucose assessment when appropriate; and home blood-pressure readings. Tell your clinician if you smoke or vape, take hormones, use supplements, or have a history of kidney disease, inflammatory disease, or sleep apnea.
Aim low, and stay there. Regression in trials occurred when LDL-C was lowered substantially and held low over years. Your target depends on your history, disease burden, other risks, tolerance, and personal goals, so it should be set with your clinician.
Think in years, not months. Plaque composition can change within a year. Changes in the channel and in clinical outcomes may take much longer. POSCH needed a decade to show its full picture.⁵
Do not seek repeat invasive procedures simply for a plaque “report card.” Repeat catheterization or other testing should be driven by symptoms, a change in functional status, prior findings, and your clinician’s assessment.
Do not change prescribed treatment based on a scan trend alone. A calcium score, CT plaque measurement, angiogram, or stress test is only one part of the picture. Decisions about antiplatelet therapy, lipid-lowering treatment, blood-pressure medicines, diabetes medicines, exercise intensity, or procedures should be made with the clinician who knows your history.
Keep going, but review the plan. For most people with established coronary atherosclerosis, prevention is long-term. Treatment is not a short course of antibiotics. The specific plan should be reviewed and adjusted for benefit, adverse effects, preferences, pregnancy planning when relevant, and changing circumstances.

The integrative answer

Can your blockages get better? Yes.

But the goal is not to make an angiogram look like a teenager’s. The goal is to reduce the chance that plaque will rupture, improve the blood supply to heart muscle, protect daily function, and prevent the next heart attack.

A recent European scientific statement emphasizes that average plaque-volume changes with treatment are usually limited and that calcified plaque is difficult to reverse.²³ That is true. It is also true that small changes in the right plaques, sustained for years, can translate into large changes in the lives of real people.

Meaningful prevention can begin at many stages of life and disease. The safest starting point depends on your health, symptoms, and current treatment. The medicine and the lifestyle are not competing answers; they are parts of the same long-term plan.

References

Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371–1375. https://pubmed.ncbi.nlm.nih.gov/3574413/
Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78:1157–1166. https://pubmed.ncbi.nlm.nih.gov/3180375/
Gotto AM Jr. Lipid lowering, regression, and coronary events: a review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council Meeting. Circulation. 1995;92:646–656. https://pubmed.ncbi.nlm.nih.gov/7634480/
Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289–1298. https://pubmed.ncbi.nlm.nih.gov/2215615/
Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia (POSCH). N Engl J Med. 1990;323:946–955. https://pubmed.ncbi.nlm.nih.gov/2205799/
Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781–1791. https://pubmed.ncbi.nlm.nih.gov/8504494/
Räber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327:1771–1781. https://pubmed.ncbi.nlm.nih.gov/35368058/
Sipahi I, Tuzcu EM, Schoenhagen P, et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol. 2006;48:833–838. https://pubmed.ncbi.nlm.nih.gov/16904557/
Nicholls SJ, Tuzcu EM, Kalidindi S, et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol. 2008;52:255–262. https://pubmed.ncbi.nlm.nih.gov/18634979/
Dawson LP, Lum M, Nerleker N, Nicholls SJ, Layland J. Coronary atherosclerotic plaque regression: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79:66–82. https://pubmed.ncbi.nlm.nih.gov/34991791/
Budoff MJ, Ellenberg SS, Lewis CE, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA. 2017;317:708–716. https://pubmed.ncbi.nlm.nih.gov/28241355/
Bayturan O, Kapadia S, Nicholls SJ, et al. Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol. 2010;55:2736–2742. https://pubmed.ncbi.nlm.nih.gov/20538166/
Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556–1565. https://pubmed.ncbi.nlm.nih.gov/16533939/
Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316:2373–2384. https://pubmed.ncbi.nlm.nih.gov/27846344/
Hambrecht R, Niebauer J, Marburger C, et al. Various intensities of leisure time physical activity in patients with coronary artery disease: effects on cardiorespiratory fitness and progression of coronary atherosclerotic lesions. J Am Coll Cardiol. 1993;22:468–477. https://pubmed.ncbi.nlm.nih.gov/8335816/
Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998;280:2001–2007. https://pubmed.ncbi.nlm.nih.gov/9863851/
Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease (HATS). N Engl J Med. 2001;345:1583–1592. https://pubmed.ncbi.nlm.nih.gov/11757504/
Hambrecht R, Walther C, Möbius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation. 2004;109:1371–1378. https://pubmed.ncbi.nlm.nih.gov/15007010/
Möbius-Winkler S, Uhlemann M, Adams V, et al. Coronary collateral growth induced by physical exercise: results of the EXCITE trial. Circulation. 2016;133:1438–1448. https://pubmed.ncbi.nlm.nih.gov/26979085/
Sdringola S, Nakagawa K, Nakagawa Y, et al. Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease. J Am Coll Cardiol. 2003;41:263–272. https://pubmed.ncbi.nlm.nih.gov/12535820/
Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the COURAGE trial nuclear substudy. Circulation. 2008;117:1283–1291. https://pubmed.ncbi.nlm.nih.gov/18268144/
Puri R, Nicholls SJ, Shao M, et al. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol. 2015;65:1273–1282. https://pubmed.ncbi.nlm.nih.gov/25835438/
Conte E, Perone F, Cosyns B, et al. Therapies leading to coronary atherosclerosis plaque regression: a scientific statement of the European Association of Preventive Cardiology, the European Association of Cardiovascular Imaging of the ESC, the ESC Working Group on Atherosclerosis and Vascular Biology, and the ESC Working Group on Cardiovascular Pharmacotherapy. Part 2: drugs’ specific effect on atherosclerosis. Eur J Prev Cardiol. 2025. doi:10.1093/eurjpc/zwaf654. https://pubmed.ncbi.nlm.nih.gov/41206215/

Statins, Muscle Pain, and CoQ10

Dr. Sameer Azhak — Tue, 29 Sep 2026 11:00:56 GMT

At a Glance
Muscle symptoms are common in adults who take statins, but a symptom occurring after a statin starts is not automatically caused by the medication.
Blinded studies show that many symptoms experienced during statin treatment also occur during placebo treatment. The symptoms are real; the cause is not always the statin.
A smaller group of people do have true statin-associated muscle symptoms or intolerance.
Severe weakness, dark or cola-colored urine, markedly reduced urination, fever, or intense muscle pain requires prompt medical evaluation.
Before giving up on statin therapy, clinicians can review interactions and other causes, change the dose or statin, use less-frequent dosing in selected cases, or use non-statin therapies.
Statins lower blood levels of CoQ10, but this does not prove that muscle cells become CoQ10-deficient or that supplements prevent muscle symptoms.
Current guidelines do not recommend routine CoQ10 for statin-associated muscle symptoms because trials have been small, mixed, and inconsistent.

In the first article, I made the case that the decision to take a statin should begin with your cardiovascular risk—not with fear of medication, and not with one cholesterol number.

But that leaves the question many readers asked in the poll:

If I need a statin and my muscles hurt, should I take CoQ10?

This deserves a better answer than either extreme.

It is not accurate to say that muscle symptoms on statins are imaginary, irrelevant, or simply “in your head.” It is also not accurate to assume that every ache that begins after a prescription is written must be caused by the statin, or that CoQ10 is a universal antidote.

The goal is to protect the heart while respecting the body.

That means taking symptoms seriously, being methodical about possible causes, recognizing the rare situations that require urgent attention, and using the evidence we have—not the marketing we are offered—to decide what comes next.

How statins work

Statins block an enzyme called HMG-CoA reductase in the liver. This enzyme is part of the pathway the body uses to make cholesterol.

When the liver produces less cholesterol internally, it responds by making more LDL receptors. Those receptors pull LDL and other ApoB-containing particles out of the bloodstream.

The result is fewer atherogenic particles circulating in the blood and fewer opportunities for those particles to enter the artery wall and contribute to plaque over time.

Depending on the medication and dose, statins can lower LDL cholesterol by roughly 30% to more than 50%. In people at meaningful cardiovascular risk, lowering LDL and ApoB-containing particles translates into fewer heart attacks, strokes, and other atherosclerotic events.¹

Statins also affect more than cholesterol production.

The same biochemical pathway contributes to the production of coenzyme Q10, or CoQ10, as well as other compounds involved in cellular signaling. That is the biologic basis for the concern that statins might affect muscle energy production and for the popular belief that everyone taking a statin should automatically take CoQ10.²

The biology is plausible. The clinical conclusion is less simple.

Muscle symptoms are real. The cause is often complicated.

Muscle pain is common in adulthood, whether or not someone takes a statin.

People develop soreness, cramps, fatigue, weakness, tendon problems, back pain, and joint pain for many reasons: exercise changes, aging, viral illness, poor sleep, dehydration, thyroid disease, vitamin deficiencies, inflammatory conditions, arthritis, alcohol use, new medications, and ordinary day-to-day life.

So when a symptom develops after a statin is started, timing alone cannot prove causation.

Large blinded trials are important here because neither the participant nor the clinician knows whether the person is receiving the statin or a placebo. In these studies, muscle symptoms are reported frequently in both groups, with only a small additional number attributable to the statin itself.³

In a large individual-participant meta-analysis of 19 placebo-controlled statin trials, 27.1% of people assigned a statin reported muscle pain or weakness, compared with 26.6% of people assigned placebo. The small excess was concentrated in the first year of treatment.³

The SAMSON study made this particularly vivid. It enrolled people who had stopped statins because of side effects and gave them alternating months of statin, placebo, and no tablets. Most of the symptom burden that occurred during statin months also occurred during placebo months.⁴

StatinWISE found a similar pattern: among people who had previously reported muscle symptoms with statins, symptom intensity was not meaningfully different during atorvastatin and placebo periods.⁵

This does not mean the symptoms were imagined.

Symptoms can be severe, disruptive, and completely real even when a drug is not the direct pharmacologic cause. Expectations, attention, prior experiences, natural changes in pain, and the understandable concern about a new medication can all influence what the body feels.

And a smaller group of people truly do experience statin-associated muscle symptoms.⁶,⁷

The clinical task is not to dismiss the person or to reflexively blame the medication. It is to determine the most likely explanation and find a treatment plan that remains both tolerable and protective.

What statin-related muscle symptoms usually look like

When muscle symptoms are related to a statin, they often involve aching, heaviness, cramping, tenderness, or fatigue in large, symmetrical muscle groups such as the thighs, buttocks, shoulders, or upper arms.⁶,⁷

Symptoms may begin within weeks to months of starting a medication or increasing a dose, though timing alone is not definitive. They may improve after stopping the statin and recur with a rechallenge, especially with the same medication and dose.⁶,⁷

But there is no single symptom pattern that proves the diagnosis.

Pain isolated to one shoulder, one knee, a single calf, or the low back may have another explanation. New severe weakness is different from soreness. Pain that started after a major change in exercise may be exercise-related. Cramping after illness, dehydration, or alcohol excess deserves a broader look.

That is why a careful history matters more than a generic online checklist.

Red flags: when to seek prompt care

Serious statin-related muscle injury is rare, but it is important to recognize.¹,⁶

Seek urgent medical evaluation for:

Severe or rapidly progressive muscle weakness
Intense or widespread muscle pain, especially if it is not explained by exercise or injury
Dark, tea-colored, or cola-colored urine
Markedly reduced urination
Fever, severe malaise, or dehydration along with muscle symptoms
Symptoms that occur with known kidney disease or after a major medication interaction
A significant elevation in creatine kinase, often called CK, if testing has been performed

These symptoms can suggest rhabdomyolysis, a rare condition in which muscle breakdown can injure the kidneys.¹

This is not a situation to treat with CoQ10, hydration alone, or internet reassurance. It needs timely clinical assessment.

Before blaming the statin, review the full context

If muscle symptoms develop, the next step is not necessarily to stop the medication permanently. It is to understand what else may be contributing.

A clinician may review:

The exact timing of symptoms relative to starting or changing the statin
Location, symmetry, severity, and whether there is true weakness
Recent increases in exercise, especially unfamiliar eccentric or strength training
Dehydration, viral illness, fever, or major changes in alcohol intake
Thyroid disease, kidney disease, liver disease, or other metabolic conditions
Other medications and supplements
Baseline and symptom-triggered laboratory tests when clinically appropriate

Testing is not required for every ache. But CK, thyroid studies, kidney and liver function, and other evaluation may be appropriate depending on the symptoms and medical context.⁷,⁸

Vitamin D deserves a measured discussion. Low vitamin D is common and can contribute to generalized muscle discomfort in some people, but routinely giving vitamin D solely to prevent statin muscle symptoms is not a proven solution. Test and treat when there is a clinical reason to do so, rather than turning it into another automatic supplement.⁷

Important medication interactions

Some cases of statin intolerance are not simply about the statin dose. They are about the statin dose plus another medication or substance that raises statin exposure.

Depending on the specific statin, relevant interactions can include:¹,⁷,⁹

Grapefruit products, especially with simvastatin and lovastatin, and sometimes with higher atorvastatin exposure
Certain macrolide antibiotics
Azole antifungal medications
Cyclosporine
Some HIV or hepatitis C antiviral therapies
Gemfibrozil and certain other triglyceride-lowering drugs
Some calcium-channel blockers
Other medications that affect liver enzymes or drug transport systems

This is one reason it is important to tell both the prescriber and pharmacist about prescription medications, over-the-counter products, and supplements.

It is also why “natural” does not always mean simpler.

Red yeast rice is a good example. Some preparations contain monacolin K, which is chemically identical to lovastatin. The amount can vary widely by product, quality control is inconsistent, and it can cause statin-like side effects and interactions.¹⁰,¹¹ Taking red yeast rice to avoid a prescription statin can mean taking an unpredictable, unmonitored version of one.

What to do if you think a statin is causing symptoms

If you have established coronary artery disease, a prior heart attack or stroke, peripheral artery disease, diabetes with high risk, very high LDL cholesterol, or other strong indications for lipid lowering, do not permanently discontinue treatment on your own.⁷

Contact the clinician who prescribed it. There are usually several options.

1. Pause and reassess when appropriate

For nonurgent symptoms, a clinician may recommend a brief pause to see whether symptoms improve. If they do, a carefully planned rechallenge can help determine whether the relationship is likely to be causal.⁷

This process is not meant to “prove you wrong.” It is meant to avoid permanently losing an effective therapy because of a coincidence—or continuing a medication that is genuinely not tolerable.

2. Try a different statin

Statins differ in dose, metabolism, potency, and how they are handled by the body.

A person who struggles with one statin may tolerate another. Some clinicians may choose a lower dose, a statin with fewer interaction concerns, or a more gradual titration.⁷,⁸

3. Consider less-frequent dosing in selected people

Because some statins have longer effects, intermittent dosing can be considered for selected patients who cannot tolerate daily therapy. It is not ideal for everyone, and the degree of LDL lowering may differ from standard daily treatment, but it can be better than abandoning lipid lowering altogether.⁷,⁸

4. Use combination or non-statin therapy when needed

Ezetimibe, bempedoic acid, PCSK9-targeting therapies, and other agents may be appropriate depending on your cardiovascular risk, LDL level, statin tolerance, other medical conditions, and insurance coverage.⁷,⁸

The right plan may be a lower statin dose plus another medication rather than an all-or-nothing choice.

The larger point is this: statin intolerance is not the same as lipid-lowering intolerance.⁷

Where CoQ10 fits into the story

CoQ10 is a naturally occurring compound involved in mitochondrial energy production. Mitochondria help cells convert oxygen and nutrients into ATP, the usable energy currency of the body. CoQ10 also functions as an antioxidant within cell membranes.

The body makes much of its own CoQ10, in part through the same biochemical pathway affected by statins.

Statins do lower circulating CoQ10 levels. But CoQ10 travels in the bloodstream largely on lipoproteins, including LDL particles. When statins lower LDL, blood CoQ10 levels may fall partly because there are fewer LDL particles carrying it.²

That observation alone does not establish that muscle cells are CoQ10-deficient.

Muscle-biopsy studies have not consistently shown that people taking statins have reduced CoQ10 inside muscle tissue, including among those who report symptoms.¹² Laboratory research has raised other plausible mechanisms, including effects of certain statin metabolites on mitochondrial energy production.¹³ Those findings are scientifically interesting, but they do not prove that most statin-associated symptoms result from CoQ10 depletion.

This distinction matters because plausible biology is not the same thing as a proven treatment.

Does CoQ10 prevent or treat statin muscle symptoms?

The short answer is: we do not know with enough confidence to recommend it routinely.

Clinical trials of CoQ10 for statin-associated muscle symptoms have been small, short, and inconsistent. Some analyses suggest a modest improvement in pain, cramping, weakness, or fatigue. Others find no meaningful benefit. The studies also differ in the type and dose of CoQ10 used, the statins involved, how symptoms were measured, and whether participants had symptoms that were clearly confirmed as statin-related.²,¹²,¹⁴

For those reasons, current guidelines do not recommend CoQ10 routinely to prevent or treat statin-associated muscle symptoms.⁸

That is not the same as saying no individual will ever feel better taking it.

For a person with persistent symptoms that have been thoughtfully evaluated, who has a meaningful need for lipid lowering, and who has already considered more established strategies—such as changing the statin, lowering the dose, adjusting frequency, or considering non-statin treatment—a clinician-supervised, time-limited trial of CoQ10 may be reasonable.² This is an individualized clinical judgment under uncertainty, not a guideline-endorsed treatment; the National Lipid Association does not currently recommend this strategy.⁷,⁸

But it should be a trial, not a lifelong assumption.

Define what symptom you are trying to improve. Decide how long you will test it. Keep other changes stable when possible. Then reassess honestly.

If it is not helping, there is no need to keep buying it.

CoQ10 safety and supplement reality

CoQ10 is generally well tolerated, but “generally well tolerated” is not the same as universally harmless or automatically appropriate.

It can cause gastrointestinal symptoms in some people.¹⁵ Supplements vary in formulation, dose, absorption, and quality. Labels do not always tell the full story.

CoQ10 may affect warfarin response in some people.¹⁵ If you take warfarin, do not start, stop, or substantially change CoQ10 without telling the clinician or anticoagulation service managing your INR.

If you are considering a CoQ10 product, choose one that has been independently tested when possible, and remember that a polished label is not proof of effectiveness.

Most importantly, do not use a supplement to delay evaluation of severe symptoms or to replace a lipid-lowering plan that is likely to protect you.

A practical path forward

If you are taking a statin and develop muscle symptoms, use this sequence:

Do not panic, but do not ignore severe symptoms. Seek prompt care for weakness, dark urine, reduced urination, fever, severe muscle pain, or other red flags.
Contact the prescriber before permanently stopping a statin, especially if you have known vascular disease, prior heart attack or stroke, diabetes with high risk, markedly elevated LDL cholesterol, or documented plaque.
Describe the symptoms precisely. When did they begin? Where are they? Is this soreness, cramping, fatigue, or actual weakness? Did your exercise, illness, hydration, alcohol intake, or medication list change?
Review possible contributors. This may include interacting medications, thyroid disease, kidney or liver disease, an exercise-related injury, or another cause of pain.
Use established medication strategies first. A pause and rechallenge, a different statin, a lower dose, intermittent dosing in selected patients, or a non-statin medication may all be reasonable depending on the situation.
Discuss CoQ10 afterward—not instead of assessment. If it is tried, treat it as a monitored, time-limited experiment rather than a guaranteed fix.

The integrative answer

Integrative medicine is often misunderstood as “natural instead of pharmaceutical.”

That is not how I think about it.

A genuinely integrative approach asks broader questions. What is driving this person’s risk? How do nutrition, movement, sleep, stress, metabolic health, medications, symptoms, family history, social circumstances, and personal preferences fit together? Which interventions are proven? Which are promising but uncertain? What is likely to help enough to justify the burden?

Sometimes the answer is a statin.

Sometimes it is a lower dose, a different statin, or a combination approach. Sometimes it is a non-statin therapy. Sometimes it is a serious commitment to lifestyle change alongside medication. Occasionally, after a careful evaluation, CoQ10 may be worth a monitored individual trial.

But the answer should not be reflexive.

You do not need to choose between being a thoughtful, health-conscious person and accepting appropriate medical treatment. And you do not need to accept side effects without asking for a better plan.

The goal is a prevention strategy you understand, trust, and can safely sustain.

References

Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39:e38–e81. https://pubmed.ncbi.nlm.nih.gov/30580575/
Zaleski AL, Taylor BA, Thompson PD. Coenzyme Q10 as treatment for statin-associated muscle symptoms—a good idea, but… Adv Nutr. 2018;9:519S–523S. https://pubmed.ncbi.nlm.nih.gov/30032220/
Cholesterol Treatment Trialists’ Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400:832–845. https://pubmed.ncbi.nlm.nih.gov/36049498/
Wood FA, Howard JP, Finegold JA, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med. 2020;383:2182–2184. https://www.nejm.org/doi/full/10.1056/NEJMc2031173
Herrett E, Williamson E, Brack K, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021;372:n135. https://www.bmj.com/content/372/bmj.n135
Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement. Eur Heart J. 2015;36:1012–1022. https://pubmed.ncbi.nlm.nih.gov/25694464/
Warden BA, Guyton JR, Kovacs AC, et al. Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association. J Clin Lipidol. 2023;17:19–39. https://pubmed.ncbi.nlm.nih.gov/36115813/
Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026;87:2624–2757. https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016
Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease. Circulation. 2016;134:e468–e495. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000456
Red yeast rice. National Center for Complementary and Integrative Health. https://www.nccih.nih.gov/health/red-yeast-rice
Red yeast rice. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements-red-yeast-rice/art-20363074
Kovacic S, Habicht SD, Eckert GP. Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis. J Nutr Sci. 2025;14:e72. https://pmc.ncbi.nlm.nih.gov/articles/PMC12554813/
Schirris TJJ, Renkema GH, Ritschel T, et al. Statin-induced myopathy is associated with mitochondrial complex III inhibition. Cell Metab. 2015;22:399–407. https://pubmed.ncbi.nlm.nih.gov/26331605/
Qu H, Guo M, Chai H, et al. Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e009835. https://www.ahajournals.org/doi/10.1161/JAHA.118.009835
Coenzyme Q10. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements-coq10/art-20362602

Do You Really Need a Statin?

Dr. Sameer Azhak — Sun, 27 Sep 2026 13:30:42 GMT

In response to a recent poll, this topic was chosen, “Statins and CoQ10: Who really needs them?” In order to do the topic justice, I’ve split them into two articles. My take on the CoQ question will arrive next tuesday.

At a Glance
A statin decision should not be based on one LDL cholesterol number alone.
The central question is your overall cardiovascular risk: not only your risk over the next 10 years, but your likely exposure to atherosclerosis over decades.
Blood pressure, smoking, diabetes, kidney function, family history, pregnancy-related risk factors, metabolic health, and lifestyle all help shape that risk.
ApoB can add useful information when LDL cholesterol and metabolic health do not tell the same story.
A coronary artery calcium score can sometimes clarify an uncertain decision, but it is not a universal test and a score of zero does not mean zero risk.
Lifestyle measures are foundational. They can substantially lower risk, but they do not always replace medication when risk is high or plaque is already present.

Readers chose this topic in a recent poll, and I understand why. A statin prescription can feel strangely impersonal: a lab result appears, a number is flagged, and suddenly you are being asked to take a daily medication for a disease you may not feel.

The question I hear is rarely, “Can a statin lower LDL cholesterol?” Most people already know that it can.

The real question is: Do I, personally, need one?

That is the right question. A statin is not a vitamin. It is not automatically appropriate because an LDL cholesterol number crosses a line on a laboratory report. But it is also not a medication to dismiss simply because you feel well, exercise, eat thoughtfully, or would prefer to avoid prescriptions.

The decision should start with the likelihood that atherosclerosis—the gradual buildup of plaque in arteries—will cause harm over time, and with how much a treatment is likely to reduce that risk for you.

The number that matters is not just LDL

LDL cholesterol matters. LDL-containing particles can enter the artery wall, contribute to plaque formation, and raise the risk of atherosclerotic cardiovascular disease over time. The evidence supporting that relationship comes from genetics, epidemiology, imaging, and randomized treatment trials.¹

But an LDL value is still only one piece of a larger clinical picture.

Two people can have the same LDL cholesterol and very different levels of cardiovascular risk.

A 42-year-old nonsmoker with normal blood pressure, no diabetes, no plaque, and no strong family history is not in the same situation as a 62-year-old with hypertension, insulin resistance, elevated triglycerides, a parent who had a heart attack at 52, and a calcium score showing coronary plaque—even if their LDL values are identical.

That distinction is why prevention has moved away from asking only, “What is your cholesterol?” and toward asking, “What is your overall risk?”

Risk estimates are imperfect.²,³ They are not crystal balls, and they are not instructions to treat yourself. They are structured ways to begin a better conversation.

They incorporate familiar factors such as age, blood pressure, cholesterol values, smoking, diabetes, and kidney function. Newer approaches may also consider metabolic health, long-term risk, and social conditions that affect cardiovascular health.⁴,⁵ The useful point is not the name of any particular calculator. It is that good prevention is individualized.

A calculated score should start a shared decision, not end one.

Why age can hide long-term risk

One limitation of short-term risk calculators is that age carries so much weight.

A younger person can have a reassuring 10-year estimated risk while still having meaningful lifetime exposure to high LDL cholesterol, high blood pressure, smoking, insulin resistance, or diabetes. Plaque does not usually develop because of one bad month or one isolated blood test. It develops through cumulative exposure over years and decades.¹,⁵

That does not mean every young person with an elevated LDL needs medication immediately. It does mean that “my 10-year risk is low” should not automatically become “there is nothing to address.”

The question becomes: What direction is this person heading?

For some people, the answer is to improve diet quality, activity, sleep, weight, blood pressure, alcohol use, and metabolic health; then repeat testing after a meaningful period of change. For others, the presence of markedly elevated LDL cholesterol, diabetes, familial hypercholesterolemia, kidney disease, established plaque, or a strong family history makes earlier medication more reasonable.

The goal is not to medicate everyone early. It is to avoid waiting until the first event reveals that the risk was real.

A brief history of risk

The idea that heart disease could be predicted was revolutionary when the Framingham Heart Study began following residents of Framingham, Massachusetts, in 1948. Investigators identified characteristics—high blood pressure, smoking, diabetes, and elevated cholesterol—that made future coronary disease more likely.⁶

That work gave medicine the language of “risk factors.”⁶

Over time, clinicians learned that risk factors should not be considered one at a time. Their effects overlap and compound. A person with modest abnormalities in several areas may face more risk than someone with a single striking laboratory value.

Risk equations evolved in response. They expanded beyond heart attack alone to include stroke and other cardiovascular outcomes, and newer models aim to account more fully for kidney function, metabolic factors, and longer time horizons.⁴,⁷

Still, no calculator sees everything.

It may not adequately capture a powerful family history, elevated lipoprotein(a), chronic inflammatory disease, prior pregnancy complications, metabolic dysfunction, or a person’s actual plaque burden. That is where clinical judgment—and sometimes additional testing—matters.

Risk enhancers that change the conversation

A “risk enhancer” is not a diagnosis by itself. It is information that can make a seemingly modest estimated risk more concerning, or make a discussion about treatment more urgent.⁵

Important examples include:

A parent or sibling with premature coronary disease or stroke
Persistently elevated LDL cholesterol, particularly when it is markedly high
Diabetes, prediabetes, insulin resistance, or elevated triglycerides
Chronic kidney disease
Cigarette smoking or ongoing nicotine exposure
Elevated lipoprotein(a), often written as Lp(a)
Chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, or lupus
A history of preeclampsia, gestational diabetes, premature menopause, or other pregnancy-related cardiovascular risk factors
Known plaque in the coronary arteries, carotid arteries, aorta, or peripheral arteries
Elevated high-sensitivity C-reactive protein in an appropriate clinical context

These factors do not mean a person has failed at prevention. They reflect biology, inherited risk, medical history, and the realities of a person’s environment and life circumstances.

They also explain why a good prevention visit should never be reduced to a five-minute discussion of total cholesterol.

ApoB: a useful measure when the story is unclear

LDL cholesterol tells us how much cholesterol is carried inside LDL particles. ApoB estimates the number of cholesterol-carrying particles that are capable of entering the artery wall.

Each atherogenic particle—LDL, very-low-density lipoprotein remnants, and lipoprotein(a)—carries one ApoB protein. Measuring ApoB therefore gives an estimate of the number of particles with the potential to contribute to plaque formation.⁸

For many people, LDL cholesterol and ApoB move together. If LDL is high, ApoB is usually high too. In those cases, ApoB may not change the plan very much.

But the two measurements can become discordant.

This is especially common in people with elevated triglycerides, insulin resistance, type 2 diabetes, obesity, metabolic syndrome, or fatty liver disease. A person may have an LDL cholesterol level that appears only mildly elevated while still carrying a larger number of smaller, cholesterol-poor atherogenic particles.⁸,⁹

In that setting, ApoB can refine the risk discussion.

It is not a replacement for LDL cholesterol. It is not automatically “better” for every person. And it is not a stand-alone reason to begin or intensify medication without considering the full clinical picture.

But when the usual lipid panel and the metabolic story do not match, ApoB can be a particularly useful additional piece of information.⁵,⁹

What a calcium score can—and cannot—tell you

A coronary artery calcium, or CAC, score uses a low-radiation CT scan to identify calcified plaque in the coronary arteries.¹⁰

For some people, it is one of the most helpful tests in preventive cardiology because it answers a different question from a blood test. Rather than estimating risk from risk factors alone, it looks for evidence that coronary plaque has already developed.

That can be clarifying when a statin decision remains uncertain after reviewing the usual clinical information.⁵

A calcium score may be most useful when:

You are in an intermediate or uncertain risk range
You and your clinician are genuinely undecided about starting a statin
You want more personalized information before committing to long-term medication
You have risk factors or a family history that make a simple calculator feel incomplete
You would be more likely to take a recommended treatment if there were objective evidence of plaque

But it is not a test that every person needs.

It is generally less useful when treatment is already clearly indicated—for example, after a heart attack or stroke, in established peripheral artery disease, with very high LDL cholesterol, or in certain high-risk diabetes or familial hypercholesterolemia situations. In those settings, delaying proven therapy to obtain another test often adds little.⁵

It also has limitations.

A calcium score detects calcified plaque. It does not see all plaque, particularly some earlier noncalcified plaque. A score of zero is reassuring in many contexts, but it does not mean a person has no cardiovascular risk.¹¹ It does not erase the importance of smoking, diabetes, markedly elevated LDL cholesterol, a strong family history, symptoms that need evaluation, or other high-risk conditions.

Think of it as a decision-refining tool—not as a cardiovascular report card, and not as a substitute for a clinical evaluation.

Why baseline risk changes the value of a statin

Statins lower LDL cholesterol and ApoB-containing particles. In appropriately selected people, they reduce heart attack, stroke, and other cardiovascular events.¹²

But the benefit is not the same for everyone.

A useful way to understand this is to separate relative benefit from absolute benefit.

If a treatment lowers cardiovascular events by a similar relative percentage across many groups, a person who begins at higher risk has more events available to prevent. That means the absolute benefit is larger.¹²

Here is an illustration, not a prediction for any one person:

If 100 people each have a 20% chance of a cardiovascular event over a given period, about 20 events might occur without treatment. A 20% relative reduction would prevent about 4 of those events.
If 100 people each have a 3% chance of an event, about 3 events might occur without treatment. The same relative reduction would prevent fewer than 1 event.

The medication may have a similar biologic effect in both groups. The practical value differs because the starting risk differs.

That is why statin decisions should feel more urgent in people with established atherosclerotic disease, clearly visible plaque, diabetes with high risk, markedly elevated LDL cholesterol, or a high overall estimated risk. And it is why the decision can be more preference-sensitive when short-term risk is low and the expected absolute benefit is smaller.

Lifestyle is treatment, not a consolation prize

There is a false choice that shows up constantly in prevention conversations:

Either I do lifestyle, or I take medication.

In reality, the most effective plan is often both.

Lifestyle is not something clinicians recommend because they have nothing else to offer. It affects blood pressure, insulin sensitivity, triglycerides, body composition, inflammation, sleep, mood, fitness, and vascular function. It can meaningfully improve cardiovascular risk, whether or not medication is eventually part of the plan.

The basics are familiar because they work:¹³

Do not smoke, and seek structured help if quitting has been difficult.
Build regular aerobic activity and resistance training around your actual health, mobility, and schedule.
Favor a Mediterranean-style or otherwise cardioprotective eating pattern centered on vegetables, fruit, legumes, nuts, seeds, high-fiber foods, unsaturated fats, and minimally processed protein sources.¹⁴
Treat high blood pressure thoughtfully and consistently.
Address diabetes, insulin resistance, and elevated triglycerides.
Prioritize sleep, including evaluation for sleep apnea when symptoms or risk factors point in that direction.
Reduce prolonged sedentary time.
Attend to depression, anxiety, loneliness, chronic stress, and the practical barriers that make healthy routines hard to sustain.

Stress is not a personal failure, and no one should be blamed for living in a body shaped by caregiving, financial strain, trauma, shift work, illness, or social isolation. The evidence for smoking cessation, blood-pressure treatment, and lipid lowering is more direct than the evidence for any single stress-reduction practice preventing heart attacks. Still, psychological health, social connection, sleep, and sustainable routines are part of real cardiovascular care—not decorative add-ons.¹⁵

Lifestyle can sometimes reduce or postpone the need for medication. It does not reliably remove the need for medication in every person with established plaque, familial hypercholesterolemia, markedly elevated LDL cholesterol, diabetes with high risk, or a high calculated risk.

So, who is likely to benefit from a statin?

A statin is most clearly supported when a person already has atherosclerotic cardiovascular disease: prior heart attack, coronary stent or bypass surgery, ischemic stroke or TIA caused by atherosclerosis, peripheral artery disease, or clearly documented plaque in an appropriate clinical context.⁵,¹²

It is also often appropriate in people without a prior event who have substantially elevated baseline risk because of factors such as:

Markedly elevated LDL cholesterol
Diabetes with additional risk factors or high overall risk
A high estimated cardiovascular risk
A strong family history together with unfavorable lipid or metabolic findings
A clearly elevated ApoB in a context where particle burden is likely underestimated by LDL cholesterol alone
Coronary artery calcium or other imaging evidence of plaque when the decision was previously uncertain

For a person at lower short-term risk, with modest LDL elevation, no plaque, and no major risk enhancers, a reasonable plan may be more lifestyle-focused with follow-up testing and a discussion of longer-term risk.

There is no virtue in taking a medication you do not need. There is also no prize for declining one that could meaningfully lower your chance of a heart attack or stroke.

The right answer is personal, evidence-based, and revisited over time.

Questions worth bringing to your visit

If you are unsure about a statin recommendation, these questions can make the conversation more useful:

What is my estimated short-term and longer-term cardiovascular risk?
What factors are driving that estimate?
Do I have risk enhancers that a calculator may not fully capture?
Would ApoB or Lp(a) change the way we understand my risk?
Is a calcium score likely to clarify a genuinely uncertain decision in my case?
What absolute benefit might I expect from a statin?
What lifestyle changes are most likely to help my risk profile?
If I develop side effects, what is the plan before we conclude that I cannot take any statin?

That last question matters. In the next article, I will address the second part of the poll question: what muscle symptoms on statins really mean, how they should be evaluated, and whether CoQ10 has a meaningful role.

Because the most integrative answer is not “take a statin” or “take CoQ10.”

It is to understand your actual cardiovascular risk, address the factors you can change, use medication when its likely benefit is meaningful, and remain appropriately skeptical about any supplement that promises to make a difficult decision simple.

Coming next

Statins, Muscle Pain, and CoQ10: What the Evidence Actually Says

We will cover:

Why statins can cause muscle symptoms in a minority of people
Why many symptoms occurring on statins are not pharmacologically caused by them
How to recognize red flags that need urgent evaluation
Medication interactions and common alternative explanations
Different statin strategies and non-statin options
What CoQ10 does, what the trials show, and when a supervised trial may be reasonable

References

Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–2472. https://pubmed.ncbi.nlm.nih.gov/28444290/
DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162:266–275. https://pubmed.ncbi.nlm.nih.gov/25686167/
Yadlowsky S, Hayward RA, Sussman JB, McClelland RL, Min YI, Basu S. Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk. Ann Intern Med. 2018;169:20–29. https://pubmed.ncbi.nlm.nih.gov/29868850/
Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067626
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026. https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016
Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J. Factors of risk in the development of coronary heart disease—six-year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33–50. https://pubmed.ncbi.nlm.nih.gov/13751193/
Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847. https://pubmed.ncbi.nlm.nih.gov/9603539/
Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4:1287–1295. https://pubmed.ncbi.nlm.nih.gov/31642874/
Marston NA, Giugliano RP, Melloni GEM, et al. Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content. JAMA Cardiol. 2022;7:250–256. https://pubmed.ncbi.nlm.nih.gov/34773460/
Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827–832. https://pubmed.ncbi.nlm.nih.gov/2407762/
Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease events: MESA. Eur Heart J. 2018;39:2401–2408. https://pubmed.ncbi.nlm.nih.gov/29688297/
Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397–1405. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61368-4/abstract
Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health. Circulation. 2022;146:e18–e43. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001078
Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2018;378:e34. https://www.nejm.org/doi/full/10.1056/NEJMoa1800389
Holt-Lunstad J, Smith TB, Layton JB. Social relationships and mortality risk: a meta-analytic review. PLoS Med. 2010;7:e1000316. https://pmc.ncbi.nlm.nih.gov/articles/PMC2910600/

The Cholesterol Transit Authority — Part 3

Dr. Sameer Azhak — Tue, 22 Sep 2026 11:04:07 GMT

Medications and Supplements: What Actually Lowers Risk

“Can I try something natural first?”

That question opens a conversation, not an argument. Before discussing a prescription or a supplement, I want to understand what the patient hopes to accomplish, what worries them, and how quickly we need to act.

My job is to explain what I recommend, how it might help, its limits, and the risks of waiting. The patient makes the decision with that information. Respecting their choice does not mean pretending every option is equally safe.

Some patients worry about side effects. Others dislike the idea of taking medicine for years, have had a difficult experience with treatment, or prefer an approach they see as more natural. I want those concerns on the table. An honest conversation is different from handing over a prescription the patient never intends to take.

The Short Version

My first prescription is food: I use Dr. Andrew Weil’s anti-inflammatory eating plan, with practical guidance and changes the patient feels ready to make.
Timing matters. Preventing another heart attack or stroke is a different conversation from preventing a first one in someone at lower risk.
At follow-up, we ask what changed in daily life and what changed in the blood tests. Both matter.
A supplement cannot automatically replace a prescription. Better blood-test results and fewer heart attacks or strokes are different findings.
We make decisions together and revisit them as the patient’s health, results, and wishes change.

A Brief Return to the Transit Map

In Parts 1 and 2, we explored how cholesterol travels through the body and what food and movement can change. This final installment turns to prescriptions and supplements.

The question is not simply which product lowers a number. It is whether that option belongs in this person’s plan to protect their health.

What Medications Can Do

Statins: Slow the liver’s cholesterol production. The liver responds by adding more LDL receptors, proteins that help remove LDL particles from the blood. LDL is the cholesterol carrier often called “bad cholesterol.” Studies show that statins reduce heart attacks and strokes in patients who stand to benefit. The medicine and dose depend on the person’s risk. (2026 guideline; Endotext)
Ezetimibe: Reduces the cholesterol absorbed through the intestine. In IMPROVE-IT, adding it to a statin reduced a combined measure of serious heart and circulation problems in people recently hospitalized with a heart attack or unstable heart-related chest pain. That is not the same as showing fewer deaths, or promising the same benefit to everyone. (Cannon et al.)
Medicines targeting PCSK9: This protein helps control how quickly LDL receptors are broken down. Evolocumab and alirocumab block it; inclisiran reduces how much the liver makes. More receptors remain available to clear LDL. FOURIER examined serious heart and circulation problems with evolocumab; ORION-10 and ORION-11 measured LDL lowering with inclisiran. Those studies answered different questions. (Sabatine et al.; Ray et al.)
Bempedoic acid: Reduces cholesterol production at a different step from statins. CLEAR Outcomes studied people unable or unwilling to take statins because of side effects. It reduced a combined measure of serious heart and circulation problems, but did not show a reduction in deaths overall. It is an option to discuss, not the automatic next choice for everyone. (Nissen et al.)
Icosapent ethyl: A prescription form of purified EPA, an omega-3 fat, not ordinary fish oil. REDUCE-IT found fewer serious heart and circulation problems in selected patients already taking statins who had raised triglycerides, another type of blood fat. Its role differs from simply lowering LDL. (Bhatt et al.)

The conversation should cover likely benefit, side effects, how the medicine could affect other treatments, cost, and follow-up. Knowing how a drug works is only part of the decision.

I also want patients to distinguish “What can this medicine do?” from “Why are you recommending it for me?” The first question is about the treatment. The second is about their circumstances and the goal we are trying to reach.

An Honest Tour of the Supplement Aisle

When patients ask about supplements, I want to know what they expect. Is the goal to improve a blood-test result, ease a symptom, or replace a prescription I have recommended?

These studies asked different questions and enrolled different kinds of patients. Improving a blood-test result does not, by itself, prove that a product prevents heart attacks or strokes. The 2026 cholesterol guideline does not recommend dietary supplements for lowering LDL or triglycerides because evidence is limited or inconsistent. The discussion below explains the evidence, not a shopping list. (2026 guideline)

I want to review the actual product label alongside the patient’s medicine list. We should know what we hope to gain, what remains uncertain, and what would make us stop. Otherwise, we may be adding another bottle without a clear plan.

Options studied for blood-test results or symptoms

Soluble fiber: Psyllium and beta-glucan, a fiber in oats and barley, belong in the food discussion before more elaborate products. A review combining controlled studies of psyllium found lower LDL, non-HDL cholesterol, and ApoB. The latter two tests look beyond LDL alone at cholesterol or particles linked to artery disease. Those blood-test improvements do not establish fewer heart attacks or deaths. (Jovanovski et al.)
Fish-oil supplements: EPA and DHA are two omega-3 fats. In STRENGTH, a high-dose EPA/DHA mixture did not reduce serious heart and circulation problems. REDUCE-IT studied a different prescription product and group of patients. Its results should not be applied to ordinary fish-oil supplements. (Nicholls et al.; Bhatt et al.)
Garlic products: Studies have looked at effects on blood pressure and cholesterol. The products and studies differ; their findings do not show that a garlic supplement can replace treatment someone needs. (Ried)
Coenzyme Q10: The question here is muscle symptoms, not lowering LDL. A 2025 review suggested possible relief, but studies were small and their results differed substantially. The 2026 guideline does not recommend routine CoQ10 to prevent or treat statin-related muscle symptoms. New muscle symptoms deserve evaluation, not just another supplement. (Kovacic et al.; 2026 guideline)

Products that deserve particular caution

Red yeast rice shows why “natural” does not settle the decision. Some products contain monacolin K, the same chemical as the prescription statin lovastatin. That means statin-type side effects and interactions with other medicines are possible, while the amount in the bottle can vary. (NCCIH)

There have been legal disputes about how these products should be regulated, including the Cholestin case. For patients, the practical question is what they are taking. An analysis of 28 brands found widely differing amounts of monacolin K, without those amounts listed on the labels. (Pharmanex v. Shalala; Cohen et al.)

Other substances in red yeast rice are of scientific interest. But according to the National Center for Complementary and Integrative Health, we do not know whether products with little or no monacolin K work. (NCCIH)

If someone wants to avoid a statin because it is a drug, that distinction matters. Calling a product a supplement does not remove its drug-like effects or the need to discuss safety and follow-up. (NCCIH)

Berberine has evidence of effects on cholesterol and other blood fats, but it can also interact with medicines. An improvement in LDL is not a reason to take it without reviewing those risks. (Ju et al.; NCCIH safety guidance)

Modest add-ons, with limits

Plant sterols and stanols: These plant substances reduce cholesterol absorption and can lower LDL modestly. That does not establish the same protection against heart attacks and strokes demonstrated for some prescription treatments. (Gylling et al.)
Bergamot: A small, six-month study of a specific extract reported improved cholesterol levels. That is not enough to promise the same result from another product or establish protection against heart attacks. (Toth et al.)
Green tea: A review combining several studies found modest changes in cholesterol. Drinking tea and taking a concentrated extract are not the same thing; I would not recommend either in place of needed treatment. (Zheng et al.)

Products I would not use instead of established treatment

Niacin: Added to statin-based treatment, niacin did not provide added protection against serious heart and circulation problems in AIM-HIGH and HPS2-THRIVE despite better cholesterol numbers. HPS2-THRIVE tested niacin with laropiprant and found more serious adverse events. Buying it without a prescription is not a way around the treatment discussion. (Boden et al.; Landray et al.)
Curcumin: A 2025 review found modest average improvements in cholesterol and triglycerides, but results varied widely and confidence in the evidence was low. Those findings do not establish fewer heart attacks or strokes, or justify replacing established treatment. (Unhapipatpong et al.)
Guggul: A controlled US study did not support the cholesterol-lowering claims and found side effects. (Szapary et al.)
Policosanol: A well-designed independent study did not reproduce the large improvements in cholesterol reported in earlier studies. (Berthold et al.)
Nattokinase: The cholesterol evidence is not convincing enough for me to recommend it for that purpose. Possible interactions, especially with medicines that affect blood clotting, also need attention. (Li et al.; Memorial Sloan Kettering)

How I Make These Decisions With My Patients

That brings us from the list of options to the person sitting across from me. I do not rank a treatment by whether it comes from a pharmacy or a supplement aisle. I rank it by what it can accomplish, how strong the evidence is, and what harm it might cause.

For prescriptions, I ask: How well does it work? Does it improve a blood-test result, prevent serious problems such as heart attacks and strokes, or help people live longer? How much does it help, over how many years, and in people like my patient? I want to know how much their actual chance of a problem might fall, not just a percentage that sounds impressive. Then I weigh side effects, effects on other medicines, and the demands of treatment.

I ask the same questions about supplements. What does the research show they can do? How much might they help, and what could go wrong? Does the bottle contain the same ingredients and amounts as the product studied, and are those amounts consistent from bottle to bottle? Where we do not have answers, I say so rather than assume benefit or safety.

Those questions guide my recommendations, not a fixed best-to-worst list for everyone. Better blood-test results, fewer heart attacks, and longer life are different findings. We then consider the patient’s risk, how quickly we need to act, and what they feel ready to do.

And although I have discussed the bottles first here, my office conversation usually starts somewhere else: the food on the plate.

Food before the supplement aisle

Supplements usually enter the conversation because a patient asks for something “natural.” My first response is to discuss food, not another bottle.

I use Dr. Andrew Weil’s anti-inflammatory diet, not a diet I developed. My 17-page illustrated eating guide is exactly that: a guide I created to help patients follow his recommendations.

I emphasize meals built mostly around whole plant foods. Some animal foods can fit. But when someone wants to lower cholesterol through daily habits, I ask them to view food as medicine: something we plan carefully, not simply an intention to “eat better.”

One visit is often not enough to make all those changes. As an integrative cardiologist, I am trained in motivational interviewing: a way of talking with patients about their own reasons for change and what feels possible. I listen to how they describe their habits and concerns. We choose a path they are ready to take, rather than making the whole plan an assignment due by the next visit.

That takes time. We may start with one meal, a change in the grocery cart, or a habit the patient feels able to sustain. At the next visit, we build on what happened and work through what got in the way.

When I show patients Dr. Weil’s food pyramid, the chocolate and wine near the top often catch their attention first. But a pyramid stands on a foundation: the broad base where the vegetables and fruits are.

That is where we start. Not at the tip, but with the foods that form the foundation of everyday meals. And wine’s appearance in the pyramid is not a reason to start drinking; Dr. Weil explicitly advises nondrinkers not to start. (Dr. Weil’s pyramid guide)

Urgency shapes the options

Food is central to my approach, but timing matters. “Secondary prevention” means preventing further problems in someone who already has cardiovascular disease. “Primary prevention” means preventing a first problem. I do not have the same conversation with someone who has already had a heart attack as with someone whose overall risk is low.

When a patient declines medicine, I explain my concerns and keep talking. If their overall risk looks more reassuring, we may agree on time to work intensively on daily habits, with regular checkups. When the risk is very high, I explain my recommendation more firmly and meet with them more often.

The right to make their own decision does not disappear when we disagree. Neither does my responsibility to explain the risk.

Some patients want more information. Some want time to try a plan. Others understand my recommendation but do not intend to take medicine. Those conversations need different responses. Repeating a warning more loudly is not a substitute for understanding the person.

What happens at the next visit

At each visit, we return to the plan. What did we agree to change? What became part of everyday life? What was difficult, and what needs to be more workable?

Then we look at the results. Making the changes and getting the hoped-for blood-test results are two different things. A disappointing number should not automatically become a judgment about effort.

If the changes have not happened, I ask what got in the way before making the plan harder. If they have, we look at what they achieved. When someone feels they have made all the changes they can keep up, we include that in the next discussion about medicine and dose.

During this closely followed lifestyle plan, I may repeat blood tests, including CRP, an inflammation marker, every three to six months. We revisit medication each time. The schedule and decisions are tailored to the person, not rules for everyone.

Some patients want to see how far they can climb through their own efforts. I help them judge their progress and what else they can keep doing. Accepting help is not failure, and the need to act may be more important than finishing the climb alone.

The aim is not to avoid a prescription at any cost. It is to make a plan while being clear about what the patient wants, what I recommend, and what the research can tell us.

The Decision We Make Together

I do not want patients to leave with a longer shopping list. I want them to understand why I recommend a plan, what we still do not know, and what we will check next.

For someone changing daily habits, we discuss both the changes and the results. For someone starting medicine, we discuss how they feel taking it as well as what the tests show. For someone declining my recommendation, the conversation stays open.

Useful questions include:

What about my risk makes you recommend this option now?
How much might this help me?
What would make waiting riskier?
What side effects, effects on my other medicines, costs, or daily difficulties should we discuss?
What will we check again, and when?

That is the decision between the prescription and the supplement: not which feels more natural, but what each can offer in a plan the patient understands and helps shape.

This article is for patient education. It is not a substitute for individualized medical advice. Cholesterol and cardiovascular risk management should be directed by your physician using validated risk assessment and current guideline-based therapy. Do not start or stop any medication or supplement without discussing it with your clinician, particularly if you take other prescriptions.

Key Sources

Dietary framework

Andrew Weil, MD. Anti-Inflammatory Diet & Pyramid.

Andrew Weil, MD. Dr. Weil’s Anti-Inflammatory Diet and Food Pyramid.

Medications

Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026;87(19):2624-2757.

Feingold KR. Cholesterol Lowering Drugs. Endotext. Updated April 23, 2026.

Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (IMPROVE-IT). N Engl J Med. 2015;372(25):2387-2397.

Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER). N Engl J Med. 2017;376(18):1713-1722.

Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol (ORION-10/11). N Engl J Med. 2020;382(16):1507-1519.

Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients (CLEAR Outcomes). N Engl J Med. 2023;388(15):1353-1364.

Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380(1):11-22.

Supplements: Blood-test results or symptoms

Jovanovski E, Yashpal S, Komishon A, et al. Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2018;108(5):922-932.

Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020;324(22):2268-2280.

Ried K. Garlic Lowers Blood Pressure in Hypertensive Individuals, Regulates Serum Cholesterol, and Stimulates Immunity: An Updated Meta-analysis and Review. J Nutr. 2016;146(2):389S-396S.

Kovacic S, Habicht SD, Eckert GP. Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis. J Nutr Sci. 2025;14:e72.

Supplements: Pharmacologically real

National Center for Complementary and Integrative Health. Red Yeast Rice: What You Need to Know.

Cohen PA, Avula B, Khan IA. Variability in strength of red yeast rice supplements purchased from mainstream retailers. Eur J Prev Cardiol. 2017;24(13):1431-1434.

Pharmanex, Inc. v. Shalala, 221 F.3d 1151 (10th Cir. 2000).

Ju J, Li J, Lin Q, Xu H. Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials. Phytomedicine. 2018;50:25-34.

NCCIH. Berberine and Weight Loss: What You Need To Know (interaction guidance).

Supplements: Modest add-ons

Gylling H, Plat J, Turley S, et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis. 2014;232(2):346-360.

Toth PP, Patti AM, Nikolic D, et al. Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study. Front Pharmacol. 2016;6:299 (2015 collection).

Zheng XX, Xu YL, Li SH, Liu XX, Hui R, Huang XH. Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials. Am J Clin Nutr. 2011;94(2):601-610.

Supplements: Limited, mixed, or negative evidence

Boden WE, Probstfield JL, Anderson T, et al. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy (AIM-HIGH). N Engl J Med. 2011;365(24):2255-2267.

Landray MJ, Haynes R, Hopewell JC, et al. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients (HPS2-THRIVE). N Engl J Med. 2014;371(3):203-212.

Unhapipatpong C, Julanon N, et al. An Umbrella Review of Systematic Reviews and Meta-analyses of Randomized Controlled Trials Investigating the Effect of Curcumin Supplementation on Lipid Profiles. Nutr Rev. 2025;83(8):1520-1536.

Szapary PO, Wolfe ML, Bloedon LT, et al. Guggulipid for the Treatment of Hypercholesterolemia: A Randomized Controlled Trial. JAMA. 2003;290(6):765-772.

Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA. 2006;295(19):2262-2269.

Li X, Long J, Gao Q, Pan M, Wang J, Yang F, Zhang Y. Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Rev Cardiovasc Med. 2023;24(8):234.

Memorial Sloan Kettering Cancer Center. Nattokinase (safety and interactions).

The Detail He Hadn’t Told Anyone

Dr. Sameer Azhak — Thu, 17 Sep 2026 17:28:39 GMT

Twenty-two years ago, during my cardiology fellowship, I was asked to see a young man who had been admitted after fainting.

By the time the cardiology service was called, he had undergone what physicians sometimes call, only half-jokingly, a “million-dollar workup.”

Blood tests. Chest X-rays. CT scans. MRI studies. An echocardiogram. Continuous cardiac monitoring.

The tests were not frivolous. Sudden loss of consciousness can signal a dangerous arrhythmia, a structural heart problem, a neurologic event, bleeding, infection, or any number of other serious conditions. The teams caring for him had done what they were supposed to do: they had looked carefully for the things no one can afford to miss.

But everything was normal.

The emergency department had found no answer. The internal-medicine team had found no answer. The imaging studies had found no answer. The laboratory results had found no answer.

And when no answer emerged, they called the specialist.

That specialist was me: the cardiology fellow, still learning, waiting to round with my attending physician at an inner-city hospital I will not name.

It was around 9:30 that evening. I remember carrying a late-night coffee as I walked down the hallway toward his room. The hospital had settled into its nighttime rhythm: dim lights, muted voices, the distant beep of monitors, the soft squeak of rubber-soled shoes against the floor.

He was awake in bed.

He looked tired, as anyone would after a day of needles, machines, questions, and uncertainty. He had been through an exhausting evaluation, and after all of it, no one had been able to tell him why he had collapsed.

Before I opened the chart or began my questions, I said something simple.

“Would you mind if I sat down while we talked?”

He nodded.

So I pulled up a chair.

Then we began at the beginning.

He told me how he had passed out. Much of it was already in the record: where he had been, when he had fallen, what the witnesses had seen, what he remembered before and after. It was a familiar story, at least at first. The kind of story that makes its way into a chart in fragments—useful fragments, but fragments nonetheless.

But the room was quiet. There was no one standing at the door waiting for the next task. No computer screen between us. No sense that he had to deliver his story quickly enough to earn the next question.

And because I was sitting beside him rather than standing over him, he told me something he had not told the paramedics, the emergency department, the medicine team, or anyone else.

It had been an unusually warm day for early spring.

He had gone out for a run.

When he finished, he was already tired. Then he met a woman in the park. They began talking. The conversation was pleasant, and he wanted it to continue. When she invited him to join her for another run, he did not want to say no.

So he went.

There was one important detail: he had not exercised regularly in about three months.

He had already pushed through one difficult run. He was out of shape, tired, and likely somewhat dehydrated. Then, wanting to impress someone—or perhaps simply not wanting to disappoint her—he went out again. He tried to keep up.

The next thing he remembered was waking up with EMS around him.

Suddenly, the story made sense.

Two strenuous runs back-to-back after months of inactivity, on an unexpectedly warm day, may not have been the wisest decision. But it was an entirely human one.

He had not hidden the detail because he was trying to mislead anyone. He had not considered it medically important. Perhaps he was embarrassed. Perhaps it seemed beside the point. Perhaps, in the rush and anxiety of the emergency department, no one had created enough space for the whole story to emerge.

The answer was not hidden in a CT scanner.

It was not waiting in an MRI image.

It was not buried in a laboratory value or an echocardiogram report.

The answer was in the story.

And the story surfaced because someone finally sat down long enough to hear it.

Modern medicine needs technology. It needs imaging, blood work, cardiac monitoring, specialists, and careful testing. Those tools save lives. They identify disease that cannot be diagnosed by conversation alone. They help us see inside the body when the body is unable to explain itself clearly.

But patients are never merely collections of symptoms, test results, and normal studies.

They are people. They have fears and pressures, relationships and obligations, pride and embarrassment, hopes and private motivations. They may leave out details because they are rushed. They may leave them out because they do not know what matters. They may leave them out because they fear being judged.

And sometimes they leave them out because no one has made room for them to speak.

The most valuable diagnostic tool in that room was not the monitor, the scan, or the laboratory test.

It was a chair.

For clinicians, that is the lesson: sit down. Look your patient in the eye. Ask one more question. Leave a moment of silence after the answer. Let the story unfold rather than forcing it into the narrow spaces of a checklist.

The detail that changes everything may not be in the chart.

And for patients, the lesson is equally important: your story matters. If something feels relevant—even if it seems embarrassing, trivial, or unrelated—say it. Ask for time. Ask for clarification. Ask to be heard.

You deserve to be heard.

Yes, I Recommend Supplements. Here's What I Wish Every Patient Knew About the Label.

Dr. Sameer Azhak — Thu, 17 Sep 2026 11:23:07 GMT

The Short Version

The Dietary Supplement Health and Education Act of 1994 — DSHEA — created a distinct legal framework for dietary supplements, which FDA generally regulates as a category of food rather than as drugs.
Most dietary supplements do not undergo FDA premarket approval for safety or effectiveness. Some products containing a new dietary ingredient require a premarket safety notification to FDA — which is not the same as FDA approval.
Most new prescription drugs must undergo FDA review and approval before marketing, based on evidence of safety and effectiveness for their intended use.
Supplements may make several regulated types of claims. The most common are structure/function claims describing support for normal body structure or function. A supplement cannot lawfully be marketed to diagnose, treat, cure, mitigate, or prevent a disease unless it satisfies the separate rules that apply to drugs or permitted disease-risk-reduction health claims.
The familiar FDA disclaimer is required when a label makes a structure/function claim or certain related claims — not on every supplement bottle.
Independent, product-specific certification from USP, NSF, or ConsumerLab can provide evidence about product quality, but it does not prove that a supplement will improve a specific health condition.

A Bit of History

On October 25, 1994, President Bill Clinton signed the Dietary Supplement Health and Education Act into law as Public Law 103-417. DSHEA amended the Federal Food, Drug, and Cosmetic Act and created a distinct statutory framework for dietary supplements in the United States (NIH Office of Dietary Supplements).

The law emerged during a period of significant debate about federal oversight of vitamins, minerals, herbs, and other nutritional products. The resulting statute generally treats dietary supplements as a category of food rather than as drugs. Drugs ordinarily require FDA review and approval before they can be marketed for a particular medical use. Dietary supplements generally do not. Instead, the manufacturer bears the responsibility for making sure its product is safe, properly manufactured, accurately labeled, and not marketed with unlawful claims (FDA: Questions and Answers on Dietary Supplements).

The statutory definition of a dietary supplement is broad: it can contain a vitamin, mineral, herb or botanical, amino acid, dietary substance used to supplement the diet, or a concentrate, metabolite, constituent, extract, or combination of these ingredients — everything from vitamin D3 and magnesium to probiotics, fish oil, and multi-ingredient blends (NIH ODS, DSHEA text).

Congress found in 1994 that approximately 600 US supplement manufacturers produced about 4,000 products. Today’s marketplace is vastly larger, though there is no authoritative government count of every supplement currently for sale. Industry sources estimated US supplement sales at approximately $69.3 billion in 2024 — an industry estimate rather than an audited government total (Nutrition Business Journal estimate, via Nutraceuticals World).

What DSHEA Actually Does

Three features of DSHEA matter most for patients and clinicians.

No routine FDA premarket approval

Unlike most new prescription drugs, dietary supplements generally do not go through a finished-product FDA approval process before they reach store shelves. There is no dietary-supplement equivalent of a New Drug Application.

That does not mean supplements are unregulated — the regulatory model is simply different. Manufacturers remain responsible for ensuring that products are not adulterated or misbranded, that they are manufactured according to applicable standards, and that label claims are truthful and not misleading. FDA may inspect facilities, monitor the marketplace, review labeling, issue warning letters, oversee voluntary recalls, and take other enforcement action. In limited circumstances, FDA also has mandatory-recall authority for dietary supplements when the statutory standard is met (FDA: Questions and Answers on Dietary Supplements; FDA: Questions and Answers Regarding Mandatory Food Recalls).

A different premarket pathway for new ingredients

Some supplements do require a premarket FDA notification. A New Dietary Ingredient, or NDI, is generally an ingredient that was not marketed in a US dietary supplement before October 15, 1994. A manufacturer intending to market a supplement containing an NDI generally must submit a notification to FDA at least 75 days before introducing the product into interstate commerce, unless a statutory exception applies. The notification must provide the basis for concluding that the ingredient, under the labeled conditions of use, can reasonably be expected to be safe.

This is an important safety requirement, but it is still not FDA approval. FDA may object to an inadequate notification, but the process does not involve the comprehensive premarket review required for a new prescription drug (FDA: New Dietary Ingredient Notification Process).

Manufacturers have affirmative quality obligations

It is not quite accurate to say supplement companies simply “police themselves.” Manufacturers carry the primary legal responsibility for compliance, governed by FDA rules. Companies that manufacture, package, label, or hold dietary supplements must comply with dietary-supplement current Good Manufacturing Practices (cGMPs), which are intended to ensure that a product meets specifications for identity, purity, quality, strength, and composition.

But cGMP compliance is not the same as FDA pre-approval. A product can be made in a compliant facility and still lack strong evidence that it improves a particular symptom, disease, or health outcome (FDA: Questions and Answers on Dietary Supplements).

What FDA Drug Approval Looks Like

The contrast becomes clearer when you look at the typical pathway for a new prescription drug. Not every product follows an identical pathway, but a typical new drug is first studied under an Investigational New Drug (IND) application and then evaluated through a New Drug Application (NDA) before marketing (FDA: The Drug Review Process — Ensuring Drugs Are Safe and Effective; FDA: The Drug Review Process — Continued).

The path generally includes preclinical laboratory and animal studies, an IND submission before most human trials, Phase 1 safety studies in roughly 20 to 80 participants, Phase 2 dose-finding studies in dozens to several hundred, Phase 3 effectiveness studies often involving hundreds to thousands, an NDA containing the full clinical and manufacturing package, formal FDA review, and post-marketing surveillance after approval.

Trial design, endpoints, and duration vary by disease and drug type. The key point is not that every drug study looks identical — it is that a new drug sponsor generally must provide FDA with evidence of safety and effectiveness before marketing.

A dietary supplement manufacturer generally does not conduct Phase 1, 2, or 3 clinical trials before selling a product. There is no supplement equivalent of an NDA and no routine FDA review team assigned to decide whether a finished supplement is effective before consumers can buy it. That is not a hidden loophole — it is the legal design of DSHEA.

Neither regulatory system is perfect. Drug development is expensive, slow, and cannot detect every rare or long-term safety issue before approval. The supplement system is faster and more permissive, but it does not ordinarily provide the same level of FDA premarket verification for a finished product.

What Supplement Claims Mean

One of the most useful skills a patient can develop is learning how to read the wording of a supplement claim. Supplements may make several kinds of regulated claims, and the legal category matters because each has different requirements.

Structure/function claims describe the role of a nutrient or dietary ingredient in supporting normal body structure or function — for example, “calcium builds strong bones,” “fiber helps maintain bowel regularity,” or “magnesium supports normal muscle function.” These claims do not require FDA pre-approval, but the manufacturer must have substantiation that the claim is truthful and not misleading, and must notify FDA of the claim’s text within 30 days after first marketing. Notification is not approval (FDA: Structure/Function Claims).

Health claims describe a relationship between a substance and reduced risk of a disease or health-related condition — for example, “adequate calcium intake may reduce the risk of osteoporosis.” This is a disease-risk-reduction health claim, subject to a different regulatory framework than structure/function claims. Depending on the claim, FDA authorization or carefully qualified wording may be required. It is different from saying a product treats existing osteoporosis — that would be a disease-treatment claim, generally placing the product in drug territory (Congressional Research Service Report R48623).

Disease claims are what a supplement cannot lawfully make. A product marketed to diagnose, treat, cure, mitigate, or prevent a disease may meet the legal definition of a drug because of its intended use. Language like “lowers blood pressure,” “treats atrial fibrillation,” “reverses coronary artery disease,” “prevents heart attacks,” or “cures diabetes” cannot lawfully appear on a supplement label without meeting the requirements that apply to drugs (FDA: Questions and Answers on Dietary Supplements).

A useful comparison:

ClaimLegal categoryGeneral regulatory meaning”Calcium builds strong bones.”Structure/functionMay be permissible if truthful, non-misleading, substantiated”Adequate calcium intake may reduce the risk of osteoporosis.”Health claimMay be permitted only under applicable health-claim requirements”Calcium treats osteoporosis.”Disease-treatmentGenerally a drug claim”Fiber helps maintain bowel regularity.”Structure/functionMay be permissible if properly substantiated”Fiber treats diverticulitis.”Disease-treatmentGenerally a drug claim

The familiar FDA disclaimer

When a supplement label makes a structure/function claim — or certain related claims — it must carry this disclaimer:

“This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

The disclaimer is not required on every supplement bottle. It appears when a manufacturer uses the types of claims that trigger the DSHEA disclaimer requirement.

The key phrase is not “no one has ever looked at this.” A company may have relied on studies, published research, or scientific reviews when making its claim. What the disclaimer means is more specific: FDA has not evaluated the claim before the product was marketed. The manufacturer is still legally responsible for having substantiation that an eligible claim is truthful and not misleading, but manufacturer substantiation is not the same as FDA premarket approval — and neither is automatically equivalent to high-quality clinical proof that the supplement improves a specific disease outcome (FDA: Structure/Function Claims).

What Third-Party Certification Means

Because supplements are not routinely FDA-approved before sale, independent product certification can be helpful. But it is essential to understand what a certification mark does — and does not — mean.

The most useful distinction is this: quality verification is not clinical proof of benefit. A supplement may contain the listed ingredient, match its label claim, and meet contaminant specifications, yet still have little meaningful evidence that it improves your particular symptom, diagnosis, or long-term health outcome.

USP Verified. The US Pharmacopeial Convention operates a voluntary Dietary Supplement Verification Program for selected finished products. To earn the USP Verified Mark, a manufacturer undergoes a facility audit for compliance with applicable Good Manufacturing Practices. USP verifies that a product contains the ingredients listed on its label in the declared potency and amount, and does not contain harmful levels of specified contaminants (USP Dietary Supplement Verification Program).

NSF certification. NSF certifies dietary supplements under standards evaluating specific quality and safety criteria — whether the product’s contents match label declarations and whether certain contaminants or undeclared ingredients are present at unacceptable levels. NSF Certified for Sport is especially relevant for competitive athletes because it includes testing to reduce the risk that a product contains substances prohibited in sports (NSF Product and Ingredient Certification).

ConsumerLab. ConsumerLab independently tests supplement products and offers a voluntary Quality Certification Program. Its testing may assess ingredient identity, quantity, selected contaminants, disintegration, or other quality characteristics. Its independent reviews can identify products that do not contain expected amounts of an ingredient or do not meet applicable quality expectations (About ConsumerLab.com).

USP, NSF, and ConsumerLab use different program structures, standards, sampling methods, and reporting practices. A consumer should verify what the particular mark on a specific product represents, rather than relying on a general quality claim by the brand. And none of these seals establish that a supplement treats disease, prevents disease, or produces a particular clinical benefit.

The quality question is: “Is this product reasonably consistent with its specifications?” The clinical-evidence question is: “Does this product improve a meaningful health outcome?” Those are separate questions, and patients deserve clear answers to both.

What This Means for You

Nothing in DSHEA makes supplements inherently bad. Some are useful, some have meaningful biological effects, and some are reasonable to consider for particular nutritional deficiencies, treatment goals, or patient populations. But the legal framework matters because it tells you what has — and has not — been independently verified before a product reaches the shelf.

Practical takeaways:

Read the wording carefully. “Supports,” “helps maintain,” and “promotes” commonly signal structure/function language. “Treats,” “cures,” “prevents,” “reverses,” and “lowers disease risk” call for closer scrutiny — they may be drug claims or health claims subject to separate rules.
Understand the disclaimer. If you see the familiar FDA disclaimer, FDA has not evaluated the statement before marketing. That does not prove the claim is false, but it does tell you the product has not gone through the drug-approval process.
Look for product-specific quality verification. USP, NSF, and ConsumerLab can provide useful information about identity, quantity, manufacturing controls, and selected contaminant testing. Verify the certification applies to the exact product and formulation you are considering.
Do not confuse purity with proof. A supplement can be accurately labeled and well manufactured yet still lack convincing evidence it improves a symptom, diagnosis, or meaningful clinical outcome.
Consider the dose. Evidence, risks, and interactions often depend on the actual dose and chemical form — not simply the ingredient name on the front label.
Bring supplements to your clinician. The actual bottles, a photo of the Supplement Facts panel, or a complete list with doses. Unreported supplement use can contribute to unexpected lab findings, adverse effects, and drug–supplement interactions.
Ask three separate questions. First: is this product likely to contain what it says it contains? Second: is there good evidence this ingredient, at this dose, helps someone like me? Third: is it safe with my conditions and medications?

The practical goal is not to fear supplements or assume they are ineffective. It is to recognize the difference between FDA approval, manufacturer responsibility, quality certification, and evidence of clinical benefit. A supplement may be legally sold without FDA premarket approval, manufactured to acceptable quality specifications, and carry a substantiated structure/function claim — yet still lack convincing clinical evidence that it improves a particular disease or patient outcome.

That is the story the label is trying to tell you. Once you understand it, you are in a much stronger position to decide what belongs in your cabinet — and what is worth discussing at your next office visit.

This article is educational and does not replace individualized medical advice. Do not start, stop, or change any supplement or medication without discussing it with your clinician.

Sources

DSHEA and dietary-supplement regulation

Dietary Supplement Health and Education Act of 1994, Public Law 103-417. NIH Office of Dietary Supplements. https://ods.od.nih.gov/About/DSHEA_Wording.aspx
Questions and Answers on Dietary Supplements. US Food and Drug Administration. https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements
New Dietary Ingredient Notification Process. US Food and Drug Administration. https://www.fda.gov/food/dietary-supplements/new-dietary-ingredient-ndi-notification-process
Food and Dietary Supplement Labeling Claims: FDA Regulation and Select Legal Issues. Congressional Research Service Report R48623. https://www.congress.gov/crs-product/R48623

Claims and disclaimers

Structure/Function Claims. US Food and Drug Administration. https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/structurefunction-claims

Drug approval

The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective. US Food and Drug Administration. https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fdas-drug-review-process-ensuring-drugs-are-safe-and-effective
FDA’s Drug Review Process: Continued. US Food and Drug Administration. https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fdas-drug-review-process-continued

FDA recall authority

Questions and Answers Regarding Mandatory Food Recalls. US Food and Drug Administration. https://www.fda.gov/media/117429/download

Independent quality programs

USP Dietary Supplement Verification Program. https://www.usp.org/verification-services/dietary-supplements-verification-program
NSF Product and Ingredient Certification. https://www.nsf.org/nutrition-wellness/product-and-ingredient-certification
About ConsumerLab.com. https://www.consumerlab.com/about/

Market context

The State of Supplements: US Market Approaches $70 Billion. Nutraceuticals World. https://www.nutraceuticalsworld.com/exclusives/the-state-of-supplements-u-s-market-approaches-70-billion/

The Cholesterol Transit Authority — Part 2

Dr. Sameer Azhak — Tue, 15 Sep 2026 11:03:41 GMT

The Short Version

Most lifestyle changes work through two broad pathways: they lower the number of ApoB-containing particles circulating, or they help the liver clear LDL more effectively. The changes are usually gradual, but they accumulate over time.
Soluble fiber is one of the more dependable dietary tools for modest LDL lowering. Oats, beans, lentils, psyllium, chia, and barley help alter bile-acid recycling in the gut.
Saturated fat matters, but replacement matters just as much. Swapping butter, fatty meat, or coconut oil for olive oil, nuts, seeds, and high-fiber foods is different from replacing them with white flour and sugar.
Fish belongs in a heart-healthy pattern. Fish-oil supplements mainly affect triglycerides and should not be mistaken for LDL-lowering treatment.
“Anti-inflammatory eating” is less a special diet than a familiar food pattern: plants, legumes, olive oil, nuts, fish, minimally processed food, and fewer sugary drinks and refined starches.
Fasting is useful for some people because it creates structure around eating. Its benefits depend much more on the overall pattern than on the length of the eating window.
Exercise improves cardiovascular health in ways the lipid panel does not fully capture. Aerobic work is especially useful for fitness, triglycerides, and blood pressure; strength work protects muscle, insulin sensitivity, and body composition.

A Quick Recap

In Part 1, we laid down the basic map. Cholesterol moves through the bloodstream inside particles called lipoproteins — a fleet of vehicles, each carrying an identifying tag called an apolipoprotein. Most of the particles relevant to atherosclerosis carry ApoB: VLDL and its remnants, IDL, LDL, and Lp(a).

The central prevention question is simple: how many of these particles are circulating, how long do they remain in the bloodstream, and how likely are they to enter and remain in artery walls?

Most cholesterol-lowering interventions work through one of two broad pathways. They either reduce the number of atherogenic particles in circulation, or they improve LDL clearance by the liver.

This article is about the parts of that system you can influence without a prescription.

What Food Can Change

Food does not affect cholesterol through one pathway. Different dietary choices can influence cholesterol absorption, bile-acid recycling, triglyceride production, insulin resistance, liver fat, LDL clearance, body weight, and the overall number of ApoB-containing particles circulating in the blood.

The effect of one meal is small. The dietary pattern repeated over months and years is what matters.

Soluble Fiber and LDL

Soluble fiber is the gel-forming fiber found in oats, barley, beans, lentils, psyllium, chia, flaxseed, apples, berries, and citrus. The best-studied forms are beta-glucan from oats and barley and psyllium husk.

Your liver uses cholesterol to make bile acids, which help digest fat. Most bile acids are normally reabsorbed in the intestine and returned to the liver for reuse. Soluble fiber partly interrupts that recycling. The liver, needing more bile, has to open more LDL depot stations to pull cholesterol out of circulation (Bakr & Farag, ACS Omega). Over time, that can help lower circulating LDL-C.

It is a modest effect, not a miracle. But it is one of the more dependable food-based ways to move LDL in the right direction. It works especially well as part of an eating pattern that also includes less saturated fat and more minimally processed food.

A practical goal is to add about 5 to 10 grams of soluble fiber daily, gradually, within an overall high-fiber diet. A cup of cooked oatmeal provides roughly 2 grams. A tablespoon of psyllium provides about 2 to 3 grams, depending on the product.

Start slowly. Fiber works best when your gut has time to adapt. Drink enough water, and ask your pharmacist how far apart to take psyllium from prescription medications.

Refined Carbohydrates and Triglycerides

Refined grains, added sugar, and sugary drinks do not affect every person the same way. But in the setting of insulin resistance, excess calorie intake, diabetes, or central weight gain, they can raise triglycerides and push the liver to send out more triglyceride-carrying VLDL particles (Siri-Tarino et al., AJCN).

That pattern often travels with lower HDL-C, higher triglycerides, and smaller, denser LDL particles.

Small LDL is not automatically dangerous, and large LDL is not automatically safe. The more useful question remains: how many ApoB-containing particles are circulating, and what is driving that number?

A reasonable rule of thumb is to choose intact whole grains more often than flour-based foods, eat beans and lentils regularly, and make sweetened drinks occasional rather than routine.

White bread, sweet coffee drinks, soda, juice, many snack foods, and desserts can all fit into a life. They simply work better as occasional food than as the foundation of a daily pattern.

Fish and Omega-3s

Fish and omega-3 fats are mostly a triglyceride story.

EPA and DHA, the long-chain omega-3 fats found in fatty fish, can reduce the liver’s production of triglyceride-rich particles and improve triglyceride clearance (Rimm et al., Circulation). The most consistent measurable effect is lower triglycerides.

LDL-C may go up, down, or stay the same with omega-3 products. That is one reason fish oil is not a primary LDL-lowering therapy. If LDL-C rises after starting a fish-oil supplement, it is worth reviewing LDL-C, non–HDL-C, and ApoB with your clinician rather than making assumptions based on LDL particle size alone.

For most people, fish twice a week is a useful default. Salmon, sardines, mackerel, herring, anchovies, and trout are all reasonable choices. The easiest version matters most: sardines on toast, salmon from the freezer, or grilled fish when you are out.

Fish on the plate and fish oil in a bottle are not interchangeable. Prescription omega-3 therapy has a role for selected patients with high triglycerides (Wilson et al., Circulation). Ordinary over-the-counter fish-oil supplements vary widely in dose, formulation, purity, and evidence. Part 3 will cover that distinction in more detail.

The Fat-Quality Question

The question I hear less often now is, “Should I avoid fat?”

The better question is: what kind of fat am I eating, and what is it replacing?

Saturated fat is concentrated in fatty cuts of meat, butter, full-fat dairy, coconut oil, and palm oil. For many people, a diet high in saturated fat raises LDL-C partly by reducing LDL-receptor activity in the liver (Feingold, Endotext). Trans fats remain worth avoiding altogether — they raise LDL-C and lower HDL-C.

The useful everyday change is to replace saturated fats with unsaturated fats: olive oil, avocado, nuts, seeds, walnuts, and fish. That substitution generally improves LDL-related measures. Replacing saturated fat with white flour, refined starch, or added sugar is a much less useful trade.

Coconut and palm oils are plant-derived, but that does not tell you enough about their effect on LDL-C. They are relatively high in saturated fat and generally raise LDL-C more than oils rich in unsaturated fat (Sacks et al., AHA Presidential Advisory, Circulation).

Keep olive oil close at hand. Make nuts and seeds routine rather than aspirational. Use butter, cream, and cheese deliberately, rather than automatically.

Plant-Forward Protein and Red Meat

The anti-inflammatory eating pattern I describe in my own book is not a proprietary diet. It is a practical version of the overlap between Mediterranean eating, DASH-style eating, and a mostly plant-forward plate.

It emphasizes beans, lentils, chickpeas, tofu, tempeh, nuts, seeds, vegetables, fruit, intact grains, olive oil, and fish. These foods help because they bring fiber, unsaturated fats, plant sterols, minerals, and better blood-sugar control. They also tend to crowd out foods that make LDL-C, triglycerides, and calorie balance harder to manage.

Deeply colored plants, extra-virgin olive oil, tea, coffee, cocoa, berries, and leafy greens contain polyphenols. These compounds may influence oxidative and inflammatory pathways, but the strongest reason to eat these foods is less glamorous: they make it easier to build a diet around foods that improve the overall metabolic picture.

A fair word about red meat: both unprocessed and processed red meats are associated with cardiometabolic risk, and the T2D signal for processed meat specifically is especially consistent across large cohort studies (Qian et al., Diabetes Care). Bacon, sausage, deli meat, hot dogs, and many cured meats belong in the uncommon category for most people.

Unprocessed red meat is a different conversation. A moderate portion of steak or lamb inside a fiber-rich, plant-forward pattern is not usually the main cardiovascular issue I see in the office. More often, the problem is a pattern built around refined carbohydrates, ultra-processed food, processed meat, sweetened drinks, and too few plants.

For many patients, the highest-yield change is not eliminating one food. It is making recognizable, minimally processed food the default again.

A Note on Fasting

Fasting is a topic where the enthusiasm often runs ahead of the evidence.

Time-restricted eating can help some people reduce late-night eating, simplify decisions around food, lose weight, or improve blood sugar. Those changes may improve triglycerides. LDL-C may improve, stay unchanged, or occasionally rise depending on the dietary pattern, amount of weight change, and individual biology (Gabel et al., Curr Atheroscler Rep).

Supervised prolonged-fasting programs have reported reductions in triglycerides, VLDL, and LDL, along with an increase in large HDL particles suggesting improved lipoprotein-associated atherogenic risk (Grundler et al., Eur J Nutr). But those studies do not mean prolonged fasting is a general treatment for high cholesterol, and they do not replace the value of a durable eating pattern.

Fasting is optional.

If it fits your life, helps you stop late-night snacking, and makes food choices easier, it can be a reasonable tool. If it worsens sleep, mood, hot flashes, hunger, binge-and-restrict behavior, or your ability to eat enough protein, it is not helping.

Most adults already have a natural overnight interval of roughly 12 hours between dinner and breakfast. That is a perfectly reasonable place to begin.

Fasting is a poor fit for people taking insulin or sulfonylureas, anyone who is pregnant or breastfeeding, anyone with an active or prior eating disorder, and anyone who develops binge-and-restrict cycles. If you have diabetes, kidney disease, liver disease, gout, or another complex medical condition, discuss fasting with your clinician before trying it.

What Exercise Changes

Exercise is the most under-prescribed cardiovascular therapy I know of.

It affects triglycerides, blood pressure, insulin sensitivity, fitness, body composition, sleep, mood, and vascular function — many of which matter even when LDL-C barely moves.

When muscles contract, they use more fuel. Regular activity improves the way the body clears triglyceride-rich particles from circulation and improves insulin sensitivity in muscle. That is why triglycerides are often the most responsive lipid measurement when someone becomes more active.

The larger point is that exercise changes cardiovascular risk through pathways that diet alone cannot reproduce.

Move Often

The foundation is movement you can repeat: walking, cycling, swimming, hiking, dancing, gardening, or anything else that gets you out of a chair and raises your heart rate.

Low-intensity movement may have a modest effect on the lipid panel, but it still matters because it displaces sedentary time and supports blood pressure, blood sugar, mood, mobility, and long-term function.

For most adults, the right starting point is not a fitness test. It is adding movement that feels realistic enough to continue next month.

Build Aerobic Fitness

For most adults, the familiar target remains 150 to 300 minutes a week of moderate aerobic activity, 75 to 150 minutes of vigorous activity, or a combination (Arnett et al., Circulation).

Moderate activity means your breathing and heart rate rise, but you can still speak in short sentences. Brisk walking, comfortable cycling, active gardening, recreational swimming, and moderate hiking all count.

Vigorous activity means conversation is difficult. Running, fast cycling, lap swimming, steep hiking, singles tennis, and hard rowing are examples.

Aerobic exercise tends to improve triglycerides most consistently. HDL-C may rise slightly. LDL-C can improve modestly, especially when exercise is paired with dietary improvement or weight loss (Mann et al., Sports Med).

Some people enjoy intervals or higher-intensity training because they build fitness efficiently. They can be useful, particularly when time is limited, but they do not replace the value of total weekly movement. The right dose is the amount you can recover from and repeat.

Strength Training Matters Too

Resistance training deserves its own place in a prevention plan.

Two or more weekly sessions that involve major movement patterns — squatting, hinging, pushing, pulling, carrying, and stepping — can preserve muscle, improve strength, support insulin sensitivity, and make daily life easier as you age.

You do not need maximal weights. You need enough resistance that the final repetitions are challenging while your form remains solid. The correct starting point will look very different for someone new to training, someone recovering from an injury, and someone who has lifted for years.

Resistance training can produce modest lipid improvements, but its larger cardiovascular contribution is indirect: more muscle improves glucose handling, makes physical activity easier, and supports a healthier metabolic environment.

A simple goal is resistance training at least twice a week, with gradual progression over time. If you are new to strength training, have osteoporosis, osteopenia, significant joint pain, prior injury, balance limitations, or pelvic-floor symptoms, getting a few sessions of professional instruction can be worthwhile.

The Bigger Exercise Benefit

The lipid-panel effects of exercise are often modest. Triglycerides tend to improve most consistently. HDL-C may rise slightly. LDL-C may change little.

That does not make exercise optional.

Its biggest payoff is the long-term effect on blood pressure, insulin sensitivity, body composition, cardiorespiratory fitness, endothelial function, and vascular resilience. These factors change how vulnerable your arteries are to the ApoB-containing particles that remain in circulation.

If exercise moved your LDL-C by zero and nothing else, it would still be one of the highest-value cardiovascular things you could do.

What’s Next

Diet and exercise are the foundation of prevention. For some people, that foundation is enough. For others, genetics, existing plaque, diabetes, chronic kidney disease, elevated Lp(a), or a high lifetime ApoB burden mean that lifestyle needs help.

Next Tuesday, Part 3 turns to medications and supplements. We will look at the treatments that have evidence for reducing cardiovascular events, the supplements that may produce modest laboratory changes, the products that are active enough to require caution and monitoring, and the ones I would generally leave on the shelf.

Key Sources

Diet

Bakr AF, Farag MA. Soluble Dietary Fibers as Antihyperlipidemic Agents: A Comprehensive Review. ACS Omega. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10357562/

Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Saturated Fat, Carbohydrate, and Cardiovascular Disease. American Journal of Clinical Nutrition. 2010. https://pmc.ncbi.nlm.nih.gov/articles/PMC2824150/

Wilson PWF, Blum CB, Brinton EA, et al. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation. 2019. https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000709

Rimm EB, Appel LJ, Chiuve SE, et al. Seafood Long-Chain n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: A Science Advisory From the American Heart Association. Circulation. 2018. https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000574

Feingold KR. The Effect of Diet on Cardiovascular Disease and Lipid and Lipoprotein Levels. Endotext. https://pubmed.ncbi.nlm.nih.gov/33945244/

Sacks FM, Lichtenstein AH, Wu JHY, et al. Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. Circulation. 2017. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000510

Qian F, Riddle MC, Wylie-Rosett J, Hu FB. Red and Processed Meats and Health Risks. Diabetes Care. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC6971786/

Fasting

Gabel K, Cienfuegos S, Kalam F, et al. Time-Restricted Eating to Improve Cardiovascular Health. Current Atherosclerosis Reports. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8218778/

Grundler F, Plonné D, Mesnage R, et al. Long-Term Fasting Improves Lipoprotein-Associated Atherogenic Risk in Humans. European Journal of Nutrition. 2021. https://pubmed.ncbi.nlm.nih.gov/33963431/

Exercise

Mann S, Beedie C, Jimenez A. Differential Effects of Aerobic Exercise, Resistance Training and Combined Exercise Modalities on Cholesterol and the Lipid Profile. Sports Medicine. 2014. https://pmc.ncbi.nlm.nih.gov/articles/PMC3906547/

Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000678

The Cholesterol Transit Authority — Part 1

Dr. Sameer Azhak — Tue, 08 Sep 2026 11:02:13 GMT

The Big Idea

Cholesterol has a public-relations problem. It gets talked about as if it were a poison sloshing through your bloodstream. It isn’t.

Every cell in your body needs cholesterol to build its outer wall. Your body uses it to make hormones such as estrogen and testosterone, vitamin D, and bile—the greenish fluid your liver sends into the gut to help digest fat.

The problem is not that cholesterol exists. The problem is how many of a specific kind of cholesterol-carrying particle—the kind that can enter and become trapped in artery walls—are traveling through your blood, and how long they stay there before your body clears them out. These are called atherogenic particles.

Because fat and cholesterol do not dissolve in blood, your body packages them into tiny vehicles called lipoproteins—bundles of fat and protein. Think of them as a city transit system: some vehicles run passenger routes carrying cholesterol from stop to stop, some run long-haul freight carrying triglycerides, and a cleanup fleet runs the reverse route home.

Each vehicle has a job, a route, and identifying tags on its surface that tell the body what it is and what to do with it. When there are too many atherogenic vehicles on the road for too many years, some enter the wall of your arteries and become trapped there. That slow buildup is called atherosclerosis. It is the process that quietly leads to heart attacks, strokes, and other vascular disease over decades.

That is the whole story in one paragraph.

The rest of this article—Part 1 of a three-part series—is a tour of the fleet, the tags on each vehicle, and how to read what is actually showing up on your lab report. Parts 2 and 3 will cover what food, exercise, medications, and supplements actually change about the traffic pattern.

The Six Vehicles

Each vehicle carries apolipoproteins on its surface—identifying tags that tell the body what the vehicle is, where it belongs, and what to do with it.

One tag, apoB, is especially useful because it marks nearly every particle capable of contributing to plaque.

Chylomicron — the local shuttle

The pickup out of the gut after a meal. Chylomicrons carry fat from what you just ate into circulation.

Intact chylomicrons are generally too large to enter artery walls. But their smaller leftovers, called chylomicron remnants, can contribute to plaque.

Main tag: apoB-48 — one per particle, the gut-made form of apoB.

Also carries: apoA-I, apoA-II, apoA-IV, apoA-V, apoC-II, apoC-III, and apoE.

VLDL — long-haul freight from the liver

VLDL carries triglycerides made or packaged by the liver to muscle and fat tissue.

As VLDL drops off triglycerides along its route, it shrinks into smaller, cholesterol-rich remnant particles. These remnants can enter artery walls. This is one reason persistently high triglycerides can matter for cardiovascular risk.

Main tag: apoB-100 — one per particle, the liver-made form of apoB.

Also carries: apoC-I, apoC-II, apoC-III, and apoE.

IDL — a VLDL at a fork in the road

IDL is a shrunken VLDL particle. It can return to the liver for clearance or continue along the route and become LDL.

Main tag: apoB-100

Also carries: apoC and apoE. ApoE acts in part as a “return to liver” signal.

LDL — the main passenger route for cholesterol

LDL carries cholesterol through the circulation to cells and tissues. It is the most common plaque-forming particle, but it is not the only one.

LDL, cholesterol-rich remnants, and Lp(a) can all enter and become retained in artery walls. LDL is usually the dominant source of this traffic.

Main tag: apoB-100 — one per particle. This is why an ApoB blood test is such a useful approximation of the number of LDL and other atherogenic vehicles in circulation.

HDL — the return route

HDL participates in moving cholesterol away from tissues and toward the liver.

Its role is biologically complex. A high HDL cholesterol number is not proof that a person is protected from cardiovascular disease, and medications that simply raise HDL cholesterol have not reliably prevented heart attacks or strokes.

Main tag: apoA-I — usually more than one per HDL particle and the defining protein of HDL.

Also carries: apoA-II, apoA-IV, apoC-I, apoC-II, apoC-III, and apoE.

Lp(a) — an LDL with an extra fitting

Lp(a), pronounced “L-P-little-a,” is an LDL-like particle with an extra protein attached to it.

Think of it as an LDL bus with an added piece bolted to the back. It carries cholesterol that can enter the artery wall, and its unusual structure may make it especially likely to promote plaque and clotting.

Lp(a) is largely inherited and usually remains fairly stable through adulthood. Most expert groups recommend measuring it at least once in adulthood because an elevated result changes how seriously the rest of the prevention plan should be taken.

Main tag: apoB-100 — the same one found on LDL.

Extra tag: apo(a) — attached to apoB-100 in a 1:1 ratio. Apo(a) helps explain why Lp(a) behaves differently from ordinary LDL.[^1][^2]

The Tag That Matters Most: ApoB

If you take one lab-report word away from this article, make it ApoB.

ApoB is the identifying protein carried by the particles most relevant to plaque: VLDL and its remnants, IDL, LDL, and Lp(a). Chylomicrons carry a related version of apoB, and their remnants can contribute too, but a routine ApoB test is mainly telling you about the atherogenic particles most people are worried about.

What the lab is measuring

Routine ApoB tests do not separately distinguish the liver-made apoB-100 from the gut-made apoB-48.

But under normal conditions—especially after fasting—nearly all of the ApoB measured in blood is apoB-100, the form found on VLDL, IDL, LDL, and Lp(a). That means the ApoB number on your report is, for practical purposes, a close estimate of the number of atherogenic particles most relevant to cardiovascular risk.[^3]

Two lab numbers that sound similar are measuring different things.

LDL cholesterol tells you how much cholesterol is being carried inside LDL vehicles.

ApoB tells you, more nearly, how many atherogenic vehicles are on the road.

A person can have an ordinary-looking LDL cholesterol value but still have a higher-than-expected apoB level because they have many cholesterol-poor LDL or remnant particles. This pattern is more common when triglycerides are elevated, insulin resistance is present, diabetes is present, or LDL-C and apoB do not agree with one another.

In those situations, apoB can provide a clearer estimate of atherogenic particle burden than LDL cholesterol alone.[^3][^4]

ApoB is not the whole risk picture. Blood pressure, diabetes, smoking, family history, chronic kidney disease, Lp(a), physical activity, diet, sleep, and—for selected patients—a coronary artery calcium scan all matter.

But ApoB is one of the most useful single numbers available, and many patients have never had it measured.

If ApoB is not available

Ask for non–HDL cholesterol.

Non–HDL cholesterol is simply total cholesterol minus HDL cholesterol. It measures the cholesterol carried in all of the major apoB-containing particles: VLDL, IDL, LDL, remnants, and Lp(a).

It is inexpensive, appears on nearly every standard lipid panel, and can be calculated from either a fasting or nonfasting sample. It often tracks well with ApoB and is especially useful when ApoB testing is unavailable, although it does not directly tell you the particle count.

The HDL fleet has its own major tag, called apoA-I. A high HDL cholesterol number can sound reassuring, but HDL biology is more complicated than “more is better.” High HDL-C alone is not proof that you are protected.

How to Read Your Lipid Panel

The most common reason a patient tells me their cholesterol is “fine” is that someone glanced at total cholesterol and said the word normal.

Total cholesterol is useful as a starting point, but it is rarely enough to guide a cardiovascular decision on its own. Here is what the report is actually telling you, line by line.

Total cholesterol

This is the sum of the cholesterol carried inside all lipoprotein particles, including LDL, HDL, VLDL, IDL, Lp(a), and remnant particles.

Because HDL cholesterol is included, total cholesterol can sometimes obscure the risk picture. A person with both high HDL-C and high LDL-C may have a total cholesterol level that does not immediately raise concern. Another person with low HDL-C and modest LDL-C may appear “borderline” on total cholesterol alone while having a relatively low apoB or non–HDL-C level.

Use total cholesterol as a starting glance, not as a decision by itself.

LDL cholesterol

LDL cholesterol is the cholesterol carried inside your LDL buses.

On many standard lipid panels, LDL-C is calculated rather than directly measured. Older reports often use the Friedewald equation. Newer Martin-Hopkins or Sampson/NIH equations are generally more accurate, especially when triglycerides are elevated or LDL-C is very low.

If triglycerides are above about 400 mg/dL, a fasting repeat panel is often helpful because the LDL calculation becomes less reliable. In that setting, non–HDL-C and ApoB can be especially useful.

LDL-C remains the number most guidelines are built around and the number many cholesterol medications are titrated against.[^5][^6]

HDL cholesterol

HDL cholesterol is the cholesterol carried inside the HDL cleanup fleet.

Higher HDL-C is associated with lower cardiovascular risk in large populations, but the relationship is not linear all the way up. Very high HDL-C is not necessarily better, and drugs that raise HDL-C have not reliably lowered heart attacks or strokes.

Think of HDL-C primarily as a risk marker and part of the overall metabolic picture—not as a number you should try to push upward with medication.

Triglycerides

Triglycerides are the main form of fat riding inside VLDL freight vehicles and, for a few hours after a meal, inside chylomicrons.

Elevated triglycerides can reflect insulin resistance, excess body weight, diabetes, refined-carbohydrate intake, excess alcohol, hypothyroidism, kidney disease, certain medications, or inherited lipid patterns.

Persistently elevated triglycerides often travel with more triglyceride-rich remnant particles in circulation, and those remnants can enter artery walls. Very high triglycerides also raise the risk of pancreatitis.

A fasting triglyceride below 150 mg/dL is generally considered normal, but the meaning of a result depends on the full metabolic and cardiovascular picture.

Non–HDL cholesterol

Non–HDL cholesterol is your total cholesterol minus your HDL cholesterol.

That one subtraction gives you the total cholesterol carried in all major atherogenic particles: VLDL, IDL, LDL, remnants, and Lp(a).

It is inexpensive, included on almost every standard lipid panel, and useful whether the blood sample was fasting or nonfasting. It often tracks well with ApoB and is especially valuable when ApoB testing is not available, although it does not directly measure particle number.

If ApoB is not available, non–HDL cholesterol is one of the most useful numbers to know.

ApoB

ApoB is not included on a standard lipid panel, so you usually have to ask for it.

It closely estimates the number of circulating atherogenic particles. It does not require fasting and is especially helpful when triglycerides are high, insulin resistance or diabetes is present, or LDL-C and non–HDL-C do not seem to tell the whole story.[^3][^4][^6]

Lp(a)

Lp(a) is not included on a standard lipid panel and must also be requested.

It should be measured at least once in adulthood because it is largely inherited and usually remains fairly stable.

In many expert statements:

Lp(a) below 30 mg/dL, or below 75 nmol/L, is considered lower risk
Lp(a) from 30 to 50 mg/dL, or 75 to 125 nmol/L, is considered an intermediate range
Lp(a) of 50 mg/dL or 125 nmol/L and above is considered high risk

Do not try to convert precisely between mg/dL and nmol/L. The two units are not interchangeable with one fixed formula because Lp(a) particle size varies substantially from person to person.

A high Lp(a) result does not mean disaster. It means your prevention plan—especially LDL-C and ApoB lowering—deserves more attention.[^1][^2][^7][^9]

Ratios

Total-cholesterol-to-HDL and LDL-to-HDL ratios are calculated automatically on many reports.

They can be useful for quick pattern recognition, but they can also hide important problems. A person can have a “great” ratio and still have a genuinely high ApoB or Lp(a).

Ratios are a supplement to the individual numbers, not a replacement for them.

A practical way to read the page

Start with LDL-C, non–HDL-C, and ApoB when it is available.

Then look at triglycerides. They can reveal whether triglyceride-rich lipoproteins and insulin resistance are contributing to the traffic pattern.

Then put all of it into the bigger cardiovascular picture: blood pressure, diabetes or prediabetes, smoking, kidney function, family history, Lp(a), age, sex, exercise, diet, sleep, and—when appropriate—coronary artery calcium.

Total cholesterol and HDL-C add useful context, but neither should dominate the interpretation.

Where Things Go Wrong

Most LDL buses are ultimately cleared by the liver.

The liver does this by putting docking ports on its surface that grab passing LDL particles and pull them in. These docking ports are called LDL receptors. Think of them as depot stations where the fleet gets pulled off the road for the night.

The more LDL-receptor stations the liver has open, the less time an LDL particle spends circulating in your blood. The less time it spends circulating, the less opportunity it has to enter and become trapped in an artery wall.

Anything that reduces the number of working depot stations—genetics, hypothyroidism, kidney disease, certain medications, and, for many people, a diet high in saturated fat—can leave more LDL particles sitting in traffic longer.

Anything that increases clearance—some dietary changes and most cholesterol-lowering medications—can reduce the time those particles spend circulating.

How strongly any individual person responds to these levers varies substantially.

What replaces saturated fat matters. Replacing it with unsaturated fats—such as olive oil, nuts, seeds, avocado, and many fish—usually lowers LDL-C more reliably than replacing it with refined carbohydrate.

Almost every cholesterol-lowering treatment works by pulling one of two levers:

Run fewer atherogenic vehicles
Open more LDL-receptor depot stations on the liver

That is the whole map.

What’s Next

You now have the map.

In Part 2, we will walk through what food and exercise actually change about the traffic pattern: which foods change which vehicles, why movement intensity matters, how body composition influences triglycerides and insulin resistance, and where the effects of lifestyle honestly sit next to the effects of medication.

In Part 3, we will cover the medications themselves and take an honest look at the supplements and herbals patients ask about most often—what each one does, what the evidence actually supports, and which ones are usually not worth the money.

Part 2 next Tuesday. Part 3 the Tuesday after.

This article is for patient education. It is not a substitute for individualized medical advice. Cholesterol management should be directed by your physician using validated risk assessment and current guideline-based therapy.

Key Sources

Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiology. 2019;4(12):1287–1295.
Soffer DE, et al. Role of Apolipoprotein B in the Clinical Management of Cardiovascular Risk in Adults: An Expert Clinical Consensus From the National Lipid Association. Journal of Clinical Lipidology. 2024.[^3][^8]
Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in Atherosclerotic Cardiovascular Disease and Aortic Valve Stenosis: A European Atherosclerosis Society Consensus Statement. European Heart Journal. 2022.[^9]
National Lipid Association. A Focused Update to the 2019 NLA Scientific Statement on Use of Lipoprotein(a) in Clinical Practice. 2024.[^1][^2]
Feingold KR. Guidelines for the Management of Dyslipidemia. Endotext [Internet]. 2026.[^5]
Blumenthal RS, Morris PB, et al. 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. Circulation. 2026;153(17):e1154–e1276.[^4][^6]

[^1]: https://www.lipidjournal.com/article/S1933-2874(24)00033-3/fulltext

[^2]: https://www.lipid.org/resource/a-focused-update-to-the-2019-nla-scientific-statement-on-use-of-lipoproteina-in-clinical-practice/

[^3]: https://pmc.ncbi.nlm.nih.gov/articles/PMC11734832/

[^4]: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423

[^5]: https://www.ncbi.nlm.nih.gov/books/NBK305897/

[^6]: https://professional.heart.org/en/science-news/2026-guideline-on-the-management-of-dyslipidemia

[^7]: https://www.acc.org/latest-in-cardiology/articles/2023/09/19/10/54/an-update-on-lipoprotein-a

[^8]: https://www.lipidjournal.com/article/S1933-2874(24)00240-X/fulltext

[^9]: https://academic.oup.com/eurheartj/article/43/39/3925/6670882

A Negative Trial Is Not a Closed Case: How to Read the HORIZON Result

Dr. Sameer Azhak — Sun, 06 Sep 2026 13:32:35 GMT

The short version

On September 4, Novartis announced that pelacarsen — the first drug ever designed to lower Lp(a), an inherited cardiovascular risk factor — did not reduce heart attacks, strokes, or cardiovascular deaths in its big clinical trial.
The drug did lower Lp(a) itself. It just didn’t translate that lowering into fewer events.
The trial, called Lp(a)HORIZON, enrolled 8,323 people who had already had a heart attack, stroke, or serious peripheral artery disease, and who had high Lp(a).
The trial’s design had real limits. It didn’t measure inflammation. It didn’t image patients’ plaque. It didn’t distinguish between the two very different kinds of Lp(a) particles people can carry. And it may not have run long enough for a lifetime disease to respond.
Two other Lp(a) drugs, from different companies, are still being studied. Their trials are ongoing.
For patients: nothing about your care changes today. High Lp(a) is still a risk factor worth knowing. It still means we treat everything else — cholesterol, blood pressure, lifestyle — more aggressively.
For the science: the Lp(a) story is bruised, not buried.

On September 4, 2026, Novartis announced that pelacarsen, the first drug ever engineered to lower a substance called lipoprotein(a), did not reduce heart attacks, strokes, cardiovascular deaths, or urgent heart procedures in its big Lp(a)HORIZON clinical trial. The drug did what it was designed to do at the chemistry level. It lowered Lp(a) substantially, just as it had in every earlier study. But that lowering did not translate into fewer cardiovascular events over the years the trial ran.

A lot of well-meaning coverage this week has already collapsed the story into “Lp(a) doesn’t matter” or “the Lp(a) hypothesis is dead.” Neither is true. I want to walk you through what HORIZON actually tested, what it didn’t test, and why I think the more interesting part of the story is still ahead of us.

What Lp(a) is, in one paragraph

Lp(a) — pronounced “L P little a” — is a cholesterol-carrying particle in your bloodstream. Everyone makes some. How much you make is set almost entirely by your genes, which is why Lp(a) runs in families and why diet and exercise barely move it. People with high Lp(a) have roughly two to four times the lifetime risk of heart attack and stroke that people with low Lp(a) have. For decades, we had no way to lower it. Pelacarsen was the first drug built specifically to try.

What the HORIZON trial did

HORIZON enrolled 8,323 patients who had already had one of three serious events: a heart attack, an imaging-confirmed stroke, or symptomatic peripheral artery disease (blockages in the leg arteries). Everyone also had a high Lp(a) — at least 70 mg/dL, with a typical enrolled value of about 108 mg/dL.

Each patient was randomly assigned to get either a monthly injection of pelacarsen or a placebo injection. Both groups also stayed on all their usual heart medications — statins, blood pressure pills, and so on. The average patient in the trial already had a well-controlled LDL cholesterol of about 65 mg/dL. Patients were followed for anywhere from four to about six and a half years, depending on when they enrolled.

The trial’s main question was straightforward: would people who got the drug have fewer heart attacks, strokes, cardiovascular deaths, or urgent heart procedures than people who got the placebo? The answer, in the topline data released last week, was no. The two groups came out about the same.

What HORIZON did not measure

This is the part I want you to sit with, because it shapes how much weight the negative result should carry.

HORIZON measured Lp(a) itself, and it collected the usual safety labs — blood counts, kidney function, liver enzymes. That was essentially it on the biology side. It did not measure inflammation markers like hsCRP. It did not measure Lp-PLA2 or oxidized LDL, both of which reflect the inflammatory damage happening in blood vessels. It did not measure the oxidized fatty acids that Lp(a) is thought to carry into the artery wall — even though an earlier, smaller pelacarsen study showed reductions in those markers of 37 to 88 percent.

And HORIZON did not image anyone’s arteries. No serial CT scans. No ultrasounds of the coronaries. No PET scans of vascular inflammation. Nothing to tell us whether pelacarsen actually changed the plaque in patients’ arteries.

Think of it this way. We ran a five-year trial on whether a new drug prevents heart attacks. It didn’t. But we never checked whether the drug did anything to the plaques that cause heart attacks, or to the inflammation that drives them. All we know is that the number on the lab report went down and the clinical events didn’t.

That’s a real gap. Compare it to how the cholesterol drug evolocumab was studied. In the GLAGOV trial, researchers put tiny ultrasound probes inside patients’ coronary arteries before and after treatment. They could actually see the plaque shrinking. In the HUYGENS trial, they used a different high-resolution imaging technique and saw the plaques becoming more stable and less inflamed. By the time evolocumab’s big outcomes trial reported that it prevented events, we already had a chain of evidence linking the drug to the artery wall. HORIZON gives us no such chain.

The units problem, and the isoforms problem

There’s one more thing HORIZON didn’t do that deserves its own section — because it may mean the wrong patients were enrolled.

Lp(a) can be reported in two different units, and those two units measure two different things.

Milligrams per deciliter (mg/dL) measures the weight of Lp(a) particles in your blood.
Nanomoles per liter (nmol/L) measures the number of Lp(a) particles in your blood.

Weight and number are not the same thing. Imagine measuring a crowd of people by their total weight versus by counting heads. If some of them are children and some are adults, weight and headcount give you very different answers. The 2022 European Atherosclerosis Society consensus and the 2024 National Lipid Association scientific statement both recommend measuring Lp(a) by particle number, in nmol/L. Particle number is what actually gets stuck in the artery wall. Weight is a rough substitute that can mislead you.

HORIZON enrolled patients based on weight — mg/dL — measured at a central lab. When the design paper mentions nmol/L values, those are just arithmetic conversions, not separate measurements.

Now to the second problem. Lp(a) particles are not all the same size. They have a tail called apo(a) that varies from person to person. Some people inherit small tails. Some inherit large ones. This isn’t just a cosmetic difference:

People with small tails carry more particles for the same weight — meaning their true Lp(a) count is higher than the weight number suggests.
People with small tails also seem to have Lp(a) that is more damaging to arteries, particle for particle. A large meta-analysis of 40 studies and 58,000 people found that people with small apo(a) tails had about twice the risk of coronary heart disease compared with people who had large tails.

HORIZON did not measure tail size. It did not sort patients by tail size. It did not analyze small-tail patients separately from large-tail patients. That means the trial mixed together two biologically different groups under a single weight-based cutoff.

Here’s what that could mean in practice. Picture two patients, both enrolled at exactly 90 mg/dL of Lp(a). The one with small tails may have been carrying a much higher number of much more dangerous particles. The one with large tails may have been carrying fewer, less dangerous particles. Both got the same drug at the same dose. Both counted equally in the analysis. If the drug’s benefit depends on how much of the dangerous biology a patient actually has — and there’s every reason to think it does — the small-tail patients may have shown a real benefit that got washed out by the large-tail patients until the average looked like nothing.

This is not a theoretical worry. It is a real reason a negative HORIZON does not close the question of whether pelacarsen works in the patients whose biology it was designed to address.

Why time may still change the answer

Cardiovascular trials are, in a real sense, races between the biology of the drug and the calendar of the trial.

Statins showed their benefit quickly — within a year or two — because they act on both cholesterol and vessel inflammation at the same time. Some other lipid drugs have needed longer.

Lp(a) builds up in artery walls over decades. The people in HORIZON had already accumulated a lifetime of plaque before their qualifying heart attack or stroke. Asking a monthly injection to reverse or even neutralize that burden in four to six years, on top of well-controlled cholesterol, is a demanding test. It’s entirely possible that a five-year curve looked flat while a ten-year curve would separate. It’s also possible that the trial needed younger patients, or patients earlier in their disease, or patients whose cholesterol wasn’t already so aggressively controlled that there was little event risk left to reduce.

Sometimes clinical trial curves overlap for years and then quietly begin to fan apart at the very end. When Novartis presents the full data at the American Heart Association meeting in November, three things will tell us how alive the Lp(a) hypothesis really is.

Did the “harder” version of the primary endpoint — heart attack, stroke, and cardiovascular death, without the softer “urgent procedure” count — move in favor of the drug?
Did the sicker patients, with even higher Lp(a) levels above 90 mg/dL, do better on the drug?
What was the on-treatment Lp(a) level, and how many patients got it down low enough to matter?

What the next generation of trials should do differently

If I could rewrite the Lp(a) research agenda from where we stand today, I would ask four things of the trials that follow.

Build in mechanistic endpoints. Take pictures of the plaques with serial CT or PET imaging in a subset of patients. Measure inflammation and oxidation markers before, during, and after treatment. A negative outcomes trial paired with positive plaque and inflammation data would tell a very different story from a negative outcomes trial with no biology at all.

Enroll on the right measurement. Use particle number (nmol/L), not weight (mg/dL). Sort patients by tail size. Analyze small-tail patients separately from large-tail patients. A trial built on the wrong measurement may weaken its own signal before the first patient is dosed.

Test the hypothesis earlier in the disease. HORIZON studied patients whose arteries were already badly damaged. Two other Lp(a) drugs — olpasiran from Amgen and lepodisiran from Lilly — are still being tested. Both use a newer technology that lowers Lp(a) more deeply and more durably than pelacarsen does. But those trials also enroll patients who have already had events. The truly definitive test would be a trial in high-Lp(a) patients earlier in life, before the first heart attack.

Take follow-up seriously. Event-driven trials that stop after five years are efficient. They are not always long enough for a disease that took fifty years to build.

Where this leaves us in the office

For patients I care for with a high Lp(a), nothing about the HORIZON result changes what I do this month.

Elevated Lp(a) is still an independent, inherited, causal cardiovascular risk factor. Knowing your Lp(a) still matters, because it changes how aggressively we treat everything else — cholesterol, blood pressure, inflammation, the lifestyle levers. A high Lp(a) still means the LDL target should be lower, the blood pressure target tighter, the calcium score more closely watched.

What has changed is our timeline for having a targeted therapy — a drug I can point to and say, “This lowers your Lp(a) and lowers your risk.” That answer is turning out to be more complicated than a single trial can settle. The Lp(a) story is bruised. It is not buried. And the next two trials, with better drugs, longer follow-up, and I hope more careful measurements built into the design, will tell us far more than HORIZON did about what to do with a number we can now measure but still cannot fully treat.

The honest posture, for now, is patience. We have the first real answer. And we have every reason to keep asking the question.

This article is educational and reflects the author’s clinical perspective. It is not medical advice, and it is not a substitute for evaluation and treatment by your own physician. If you have questions about your Lp(a) level or cardiovascular risk, please discuss them with your doctor.

For women-specific cardiovascular content, see the sister publication The Menopause Heart.

The Cholesterol Transit Authority

Dr. Sameer Azhak — Sun, 06 Sep 2026 12:16:48 GMT

Cholesterol has a public-relations problem. This week, on The Integrative Cardiologist, I want to fix it: first with a walking tour of the whole map, then with three Tuesday articles on how food, exercise, medication, and supplements change the traffic.

Cholesterol is often discussed as though it were a poison sloshing through the bloodstream. It is not.

Every cell in the body needs cholesterol to build its outer membrane. Your body uses it to make hormones such as estrogen and testosterone, to produce vitamin D, and to manufacture bile acids — the fluid the liver releases into the intestine to help digest fat.

The problem is not cholesterol’s existence. The problem is exposure: how many cholesterol-carrying particles are circulating, how long they remain in the bloodstream, and whether they enter and become trapped inside artery walls.

Last week’s article on the five calcium scores was about what we can see after years of arterial wear, inflammation, and repair. This article is about the traffic that comes first: the particles in the blood, the factors that make them more likely to accumulate in artery walls, and the levers that can reduce that burden over time.

Where “Good” and “Bad” Cholesterol Came From

Most people arrive at a cholesterol discussion with the same basic vocabulary: LDL is “bad” cholesterol and HDL is “good” cholesterol.

Those labels did not come from marketing. They grew out of decades of observation, including the Framingham Heart Study. In 1948, the US Public Health Service began following roughly 5,200 adults in Framingham, Massachusetts, to understand why heart attacks and strokes occurred in some people and not others. Their children later joined the study. Then their grandchildren. It became one of the most influential long-term records in cardiovascular medicine.

By the 1970s, Framingham investigators had shown that higher LDL cholesterol tracked with greater coronary risk, while higher HDL cholesterol tracked with lower risk. The shorthand stuck.

LDL became the “bad” one. HDL became the “good” one.

But the labels were always incomplete.

LDL is not “bad” because the body made a mistake by producing it. LDL is a normal transport particle. It carries cholesterol through the bloodstream for ordinary biological purposes. HDL participates in cholesterol transport as well, but a high HDL cholesterol number is not a guarantee of protection, and medications that raise HDL-C have not reliably reduced cardiovascular events.

The modern view is more useful.

Atherosclerosis is not passive grease collecting in a pipe. The artery wall is alive. Its inner lining — the endothelium — responds to blood pressure, smoking, diabetes, kidney disease, inflammation, genetics, and decades of metabolic stress.

But the essential first step is that particles carrying ApoB — including LDL, VLDL remnants, IDL, and Lp(a) — enter the artery wall and become retained there. Once trapped, they can be modified, recognized by the immune system, and set off a chronic inflammatory process that becomes plaque.

So LDL is not a moral villain. It is a normal particle that becomes harmful when too many ApoB-containing particles circulate for too many years and repeatedly gain access to the artery wall.

The artery wall matters, and so does the traffic. Atherosclerosis develops when ApoB-containing particles repeatedly enter and remain in an arterial environment made more vulnerable by high blood pressure, smoking, diabetes, kidney disease, inflammation, genetics, and time.

Cholesterol Does Not Travel Freely

Fat and cholesterol do not dissolve well in blood. So the body packages them into tiny particles called lipoproteins — bundles of fat and protein that travel through the circulation.

Some carry fat absorbed from a meal. Some carry triglycerides made by the liver. Some carry cholesterol to tissues. Some participate in moving excess cholesterol back toward the liver.

Each particle has a job, a route, and an identifying protein on its surface — an apolipoprotein — that helps determine where it goes and how the body handles it.

The metaphor has limits, but it is useful to think of these particles as vehicles in a transit system. The key prevention question is not whether any one vehicle is “evil.” It is whether there are too many artery-capable vehicles on the road, for too long.

The Fleet — At a Glance

There are six particles worth knowing.

Chylomicrons are large particles made by the intestine after a meal. They carry dietary fat from the gut into circulation. The intact particles are generally cleared quickly, although their remnants can matter when triglycerides are persistently elevated.

VLDL, or very-low-density lipoprotein, is made by the liver. It carries triglycerides to muscle and fat tissue. As VLDL unloads triglyceride, it becomes smaller and more cholesterol-rich. Those remnant particles can enter the artery wall.

IDL, or intermediate-density lipoprotein, is a short-lived middle stage in the transition from VLDL to LDL. It is also an ApoB-containing particle that can contribute to atherosclerosis.

LDL, or low-density lipoprotein, is the most familiar cholesterol-carrying particle. It delivers cholesterol to tissues throughout the body. When LDL particle burden is too high, it becomes a major driver of plaque formation.

HDL, or high-density lipoprotein, participates in cholesterol transport back toward the liver and has other biologic functions. But a higher HDL cholesterol number does not automatically mean lower cardiovascular risk.

Lp(a) is an LDL-like particle with an additional protein attached. It is largely inherited, can independently raise cardiovascular risk, and is especially prone to retention in the artery wall. It is worth measuring at least once in adulthood.

The Tag That Matters: ApoB

Every VLDL, remnant particle, IDL, LDL particle, and Lp(a) particle carries one ApoB tag on its surface.

That makes ApoB useful. Measuring ApoB gives an estimate of how many potentially artery-entering particles are circulating in your blood.

Your routine lipid panel reports the amount of cholesterol inside LDL particles — your LDL cholesterol, or LDL-C. ApoB answers a different question: how many ApoB-containing particles are actually circulating?

Those are not always the same story.

Two people can have the same LDL cholesterol level but very different ApoB levels. One person may have fewer, cholesterol-rich LDL particles. The other may have many more particles, each carrying less cholesterol. The second person has more opportunities, day after day and year after year, for particles to enter and remain in the artery wall.

This is especially relevant when triglycerides are elevated, insulin resistance is present, diabetes or metabolic syndrome is part of the picture, or LDL-C and the rest of the metabolic story do not seem to match.

LDL cholesterol remains an important number and a central treatment target. But ApoB can add useful information, particularly when the situation is metabolically complicated.

If ApoB is not available, non-HDL cholesterol — total cholesterol minus HDL cholesterol — is present on almost every standard lipid panel and is a helpful, inexpensive surrogate for the cholesterol carried by atherogenic particles.

The practical takeaway is simple: the cholesterol inside each particle matters, but the number of ApoB-containing particles tells us how many chances there are for cholesterol-carrying particles to enter and remain in the artery wall.

Two Main Levers

Most interventions that reduce LDL-related risk work through one or both of two pathways.

First: reduce the number of ApoB-containing particles in circulation. That can involve improving diet quality, reducing excess saturated fat, lowering refined-carbohydrate intake when triglycerides are elevated, losing weight when appropriate, improving insulin sensitivity, and using medications that reduce hepatic cholesterol production or intestinal cholesterol absorption.

Second: improve clearance of LDL from the bloodstream. The liver removes LDL through LDL receptors. Think of them as depot stations. The more receptors available and functioning, the faster LDL can be removed from circulation.

Statins increase LDL-receptor activity. PCSK9-targeting therapies help prevent LDL receptors from being degraded. Other interventions can support the same overall clearance pathway.

The metaphor is imperfect, but it is useful: less atherogenic traffic entering circulation and better traffic removal both reduce lifetime exposure of the artery wall to ApoB-containing particles.

Where Things Go Wrong

Some conditions leave LDL particles circulating longer than they should. Genetics, hypothyroidism, kidney disease, certain medications, and a diet high in saturated fat can all contribute.

Other factors increase the number of triglyceride-rich particles the liver produces. Insulin resistance, diabetes, central weight gain, alcohol excess, and diets high in refined starches and added sugars can raise triglycerides and worsen the overall metabolic pattern.

Then there are inherited conditions that set a high baseline regardless of how well someone eats or exercises. Familial hypercholesterolemia and elevated Lp(a) are two important examples. They are why some people with excellent lifestyles still need medication.

That is not a failure of effort. It is biology.

What Diet and Exercise Can Change

Food does not act on cholesterol through one pathway. Some choices affect cholesterol absorption. Some affect bile recycling. Some influence triglyceride-rich particles, insulin resistance, body weight, or the liver’s ability to clear LDL.

The most reliable dietary foundation is familiar: more vegetables, fruit, beans, lentils, intact whole grains, nuts, seeds, and minimally processed foods; more unsaturated fats from olive oil, nuts, seeds, avocado, and fish; and less reliance on processed meats, sugary drinks, refined carbohydrates, and foods high in saturated fat.

Soluble fiber from oats, beans, psyllium, barley, lentils, apples, berries, chia, and flax can help lower LDL cholesterol. It binds bile acids in the intestine, which encourages the liver to draw on cholesterol and increase LDL-receptor activity. Psyllium and oat beta-glucan are among the most useful and low-risk non-prescription tools for modest LDL lowering.

Replacing saturated fat with unsaturated fat also matters. Olive oil, nuts, seeds, avocado, and fish generally improve LDL-related measures when they replace butter, fatty or processed meats, and other major sources of saturated fat. The substitution is what matters. Adding olive oil to an otherwise highly processed diet is not the same intervention.

Refined carbohydrates and sugary drinks often show up first in the triglyceride number. In people with insulin resistance, diabetes, central weight gain, or a genetic tendency toward high triglycerides, a pattern high in sweet drinks, sweets, refined flour, and heavily processed starches can worsen triglycerides and metabolic health.

Fatty fish is a good protein choice, especially when it replaces processed or fatty meat. For people with very high triglycerides, prescription omega-3 therapy may be appropriate, but a prescription product is not interchangeable with an over-the-counter fish-oil supplement or a couple of servings of salmon each week.

Exercise provides benefits that food alone cannot. Regular movement improves blood pressure, insulin sensitivity, triglyceride clearance, fitness, body composition, sleep, and long-term cardiovascular resilience. A practical goal remains at least 150 minutes a week of moderate-intensity aerobic activity, plus resistance training at least twice weekly.

Fasting is more modestly useful than the internet suggests. A comfortable overnight eating window helps some people reduce late-night eating, improve weight regulation, or improve blood sugar. It is not required for cardiovascular prevention, and whether it improves a lipid panel depends heavily on the quality and quantity of food inside the eating window.

Part 2 will cover these diet, exercise, and fasting questions with specific targets, references, and honest caveats.

What Medications Actually Do

When diet, exercise, and time are not enough — because of genetics, existing plaque, diabetes, chronic kidney disease, familial hypercholesterolemia, or a high lifetime cardiovascular risk — medications provide additional ways to lower ApoB-containing particle burden.

Statins reduce the liver’s own cholesterol production. In response, the liver increases LDL-receptor activity and removes more LDL from the bloodstream. They are the most studied cholesterol-lowering medicines in cardiovascular prevention and reduce heart attack, stroke, and cardiovascular death in appropriately selected patients.

Ezetimibe reduces cholesterol absorption in the intestine. It is often used with a statin when additional LDL lowering is needed or when a person cannot tolerate higher statin doses.

PCSK9-targeting therapies include injectable antibodies given every few weeks and inclisiran, an siRNA therapy given twice yearly after its initial doses. These treatments help preserve LDL receptors and can produce major LDL reductions. They are commonly considered for people with established cardiovascular disease, familial hypercholesterolemia, very high LDL despite maximally tolerated therapy, or selected cases of statin intolerance.

Bempedoic acid reduces cholesterol production upstream from where statins work. It can be particularly useful for people who cannot tolerate statins or need additional LDL lowering.

Icosapent ethyl is prescription-strength purified EPA, a specific omega-3 formulation shown to reduce cardiovascular events in selected high-risk patients with elevated triglycerides. It is not the same as an over-the-counter fish-oil supplement.

Starting medication is not a failure of diet. It is another way to reduce the lifetime traffic that damages arteries.

An Honest Word About Supplements

Patients ask about supplements every day. Some are genuinely useful. Some have modest effects. Some are heavily marketed with claims their evidence does not support.

The short version is this: soluble fiber, especially psyllium and oat beta-glucan, is among the most useful low-risk, non-prescription tools for modest LDL lowering.

Plant sterols may provide a small additional LDL reduction for some people. They can be reasonable as an add-on, but they should not be confused with a proven substitute for statins or other medications that reduce cardiovascular events.

Red yeast rice deserves special caution. It may work because some products contain monacolin K, a compound chemically identical to lovastatin. In other words, it can act like a statin because it is, pharmacologically, a statin exposure. Product contents can vary substantially. It can cause muscle symptoms, liver-enzyme abnormalities, medication interactions, and other adverse effects. It deserves medical supervision, not a “natural” free pass.

Berberine is promising but inconsistent across preparations and studies. It can affect blood sugar, may modestly improve lipid measures in some people, and has real potential for medication interactions and gastrointestinal side effects. It is not a substitute for guideline-based therapy when medication is indicated.

Aged garlic extract may have modest effects in some studies, but the results are mixed. Curcumin remains an interesting compound for research, but it should not be presented as a proven cardiovascular-prevention supplement. Niacin, once widely promoted for HDL and cholesterol management, did not improve cardiovascular outcomes when added to statin treatment in major modern trials and produced meaningful side effects.

The central rule for the supplement aisle is simple: a product that changes a laboratory number is not automatically proven to prevent a heart attack or stroke.

Part 3 will cover ten commonly discussed supplements — what they may do, what they probably do not do, and which ones I would generally skip.

What This Means for Your Next Visit

If you take nothing else from this Sunday overview, take these six questions into your next appointment:

Ask whether ApoB would add useful information to your lipid assessment, especially if triglycerides are elevated or you have insulin resistance, diabetes, metabolic syndrome, or a mismatch between LDL-C and your overall risk picture.
Ask for an Lp(a) measurement at least once in adulthood if you have never had one.
Ask whether high-sensitivity CRP, or hsCRP, would add useful information in your case. It is a nonspecific marker of systemic inflammation, not a direct measurement of inflammation inside your arteries, but a persistently elevated level can sometimes help refine cardiovascular risk.
Take blood pressure, waist circumference, physical activity, sleep, blood sugar, and smoking status as seriously as the cholesterol numbers. They are cardiovascular numbers too.
If the decision about medication is unclear, ask whether a coronary artery calcium score would help. CAC is most useful as a decision tool when risk is uncertain — not as routine testing for everyone.
Ask directly whether your current numbers warrant medication and, if you already take medication, whether the dose and treatment plan fit your actual risk rather than simply the laboratory reference range.

The question is not simply, “Is my LDL normal?”

A better question is: “Given my full risk profile, is my lifetime exposure to ApoB-containing particles low enough to protect my arteries over the next twenty to thirty years?”

That is the central framework for this series.

What’s Coming This Week

Tuesday 9/8/26 — Part 1: The Framework
A closer look at the six particles, the ApoB tag, and how to read your own lipid panel through this map. Where each number comes from, what it tells you, and what it cannot tell you.

Tuesday 9/15/26— Part 2: How Diet, Fasting, and Exercise Change the Traffic
Which foods affect which parts of the lipid system. Why exercise matters beyond the scale. Where fasting can help, and where it is oversold.

Tuesday 9/22/26 — Part 3: Medications and Supplements — What the Evidence Actually Supports
A practical tour of the prescriptions that reduce heart attack and stroke risk, plus an evidence-based look at the ten supplements patients ask about most: useful options, modest add-ons, and products I would generally avoid.

If a term in today’s overview raised a question you want answered in greater depth, one of the next three articles will probably address it. If not, reply to the Tuesday emails. Your questions will help shape future posts.

This article is for patient education. It is not a substitute for individualized medical advice. Cholesterol management should be directed by your clinician using validated risk assessment and current guideline-based therapy. Do not start, stop, or change any medication or supplement without discussing it with your healthcare professional.

Sources

Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the Epidemiology of Cardiovascular Diseases: A Historical Perspective. Lancet. 2013.
Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High Density Lipoprotein as a Protective Factor Against Coronary Heart Disease: The Framingham Study. American Journal of Medicine. 1977.
Ross R. Atherosclerosis — An Inflammatory Disease. New England Journal of Medicine. 1999.
Libby P. Inflammation and the Pathogenesis of Atherosclerosis. Vascular Pharmacology. 2024.
Glavinovic T, et al. Physiological Bases for the Superiority of Apolipoprotein B Over LDL Cholesterol and Non-HDL Cholesterol as a Marker of Cardiovascular Risk. Journal of the American Heart Association. 2022.
National Lipid Association. Role of Apolipoprotein B in the Clinical Management of Cardiovascular Risk in Adults: An Expert Clinical Consensus.
Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. 2019.
Boden WE, et al. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. New England Journal of Medicine. 2011.
Landray MJ, et al. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. New England Journal of Medicine. 2014.
Piercy KL, et al. The Physical Activity Guidelines for Americans. JAMA. 2018.
National Center for Complementary and Integrative Health (NIH). Red Yeast Rice.

Five Signs of Risk for Heart Disease in The Mirror

Dr. Sameer Azhak — Fri, 04 Sep 2026 00:35:49 GMT

Before the ultrasound, before the calcium scan, before the lab draw, physicians made their living from inspection. Long before I could order a coronary CT, the cardiologists who trained me were reading the patient at the door: the earlobe, the eyelid, the ring around the iris, the color of the skin at the nape of the neck. Half of the finding was already in the room by the time the stethoscope came out.

Most of those clues live above the collarbone, which means your bathroom mirror sees them before I do. What follows are five things I look at on a patient’s face, and, roughly in the order you would notice them washing up in the morning, five things you can look at on yours.

None of the signs below is proof of heart disease. None of them is enough, by itself, to change your care. They are flags.

Think of the real drivers of cardiovascular risk as ingredients in a recipe. The familiar ones (high blood pressure, high cholesterol, smoking, diabetes, insulin resistance, a sedentary lifestyle, a poor diet, a strong family history of early heart disease, and chronic low-grade inflammation, which we sometimes measure with a high-sensitivity CRP test) are the ingredients that, when they collect in the same bowl, eventually bake the cake we are trying to avoid: a heart attack or a stroke. No single ingredient bakes the cake. The more of them accumulate in one person, the closer that person gets.

The five findings below are not the ingredients. They are visible clues on the outside of the bowl that an ingredient may already be inside. Early corneal arcus points at a lipid disorder. Acanthosis nigricans points at insulin resistance. Xanthelasma may point at how the body handles cholesterol at the tissue level. Persistently bleeding gums point at a chronic inflammatory state. A diagonal earlobe crease points at something we are still trying to understand.

None is a diagnosis. None is a reason to go request a specific test. Each is, at most, a reason to book a check-up and let your primary care physician decide what, if anything, is worth looking into.

Patient stories in this piece are composites; identifying details have been changed. The accompanying images were generated with AI software to illustrate composite clinical findings rather than photograph any specific patient.

1. A diagonal crease across your earlobe

The first time I noticed Frank’s sign on my own was in a 62-year-old accountant who had come in to the clinic for a routine heart checkup. No chest pain, walked three miles a day, took no medications. His earlobes carried a shallow, symmetric diagonal wrinkle I recognized only because a senior colleague had drawn it on a napkin for me years earlier during my training. The calcium score I later ordered from his age, family history, and lipids, not from the earlobe, came back elevated.

A diagonal crease running from the opening of the ear canal down and back toward the outer edge of the earlobe.

Turn your head slightly and look at your earlobe. A diagonal wrinkle that runs from the opening of the ear canal at about a 45-degree angle down and back toward the outer edge of the lobe is called Frank’s sign, after Sanders T. Frank, the American physician who first described it in 1973.

When you pool 12 studies and 5,000 people, people with the crease had roughly four-fold higher odds of coronary artery disease than people without it. That number is loud. It comes largely from patients who were already inside a cardiology setting (hospitals, catheterization labs, chest-pain clinics), where the prior probability of disease is high before the earlobe is even looked at.

Ask the same question in the general population and the answer shrinks. The Copenhagen City Heart Study followed nearly 11,000 adults for an average of 23 years. After adjusting for age, sex, cholesterol, blood pressure, diabetes, smoking, and family history, the crease was associated with about a 9 percent increase in ischemic-heart-disease risk. A separate diagnostic-accuracy review reached the same practical conclusion: the crease shifts the probability only slightly and should not, by itself, change what tests a person gets.

Bilateral creases, one on each ear, appear to carry a stronger association than a one-sided crease, at least in patients referred for coronary angiography.

Why would a wrinkle on the ear correlate with heart disease at all? No one is entirely sure. The leading hypothesis is that the earlobe sits at the far end of the ear’s blood supply, a small fatty flap with comparatively sparse vasculature and physiologically lower oxygen levels (autopsy series). That could make it prone to age-related, low-grade injury of the same type that is quietly damaging small vessels elsewhere in the body. Small biopsy studies have reported fragmentation of elastic fibers and thickening of small-vessel walls under creased earlobe skin, and one autopsy series found microscopic fibrosis and nerve changes at the base of the crease (Elliott et al.; autopsy series). These are real observations. They do not prove that ear-vessel injury and coronary injury are the same process, and part of what looks like small-vessel change on histology may simply be ordinary sun-related skin aging. Shared effects of aging, cardiometabolic risk factors, and connective-tissue biology are all still on the table.

The crease is not a diagnostic test. Plenty of people with it have clean coronaries, and plenty of people without it still develop heart disease. It is a flag on the door, not a note from the doctor. If you see one, especially on both ears, book the check-up you have been postponing.

2. Yellow plaques on your eyelids

A patient of mine once found her own xanthelasma in the visor mirror of her car, on the drive home from a lipid panel her physician had called normal. She sent me a photograph the next morning. Her LDL was in range; her HDL was not. The plaque did not send her to imaging by itself. It joined her family history, her HDL, and her age in a conversation that eventually did.

Xanthelasma: soft, yellowish plaques on the eyelids, most often near the inner corner by the bridge of the nose.

Xanthelasma are soft, yellowish, slightly raised patches on the upper or lower eyelids, most often near the inner corner by the bridge of the nose. Up close they look almost like a smear of yellow wax under the skin, which is close to what they are: macrophages that have swallowed cholesterol and settled where the skin is thinnest.

Their significance is easy to underestimate, because about half of people with xanthelasma do not have obviously high cholesterol on a routine lipid panel, though many still have subtler abnormalities, most often a low HDL. And yet the Copenhagen City Heart Study, nearly 13,000 people followed for up to 33 years, found that xanthelasma independently predicted heart attack, ischemic heart disease, and death, even after adjusting for cholesterol and triglycerides. The same study found no independent association with ischemic stroke.

My working interpretation is that xanthelasma may reflect something about how a particular person handles cholesterol at the tissue level that a standard lipid panel does not capture. Residual confounding and other pathways cannot be excluded, and this is still an area of active work.

One practical note. Cosmetic removal clears the plaque. It should not be assumed to change cardiovascular risk. The dermatologist takes the wax off the eyelid. Your primary care physician deals with what put it there.

If you see one, bring it up at your next visit, not your next cosmetic consult.

3. A pale ring around the colored part of your eye

A 38-year-old marathon runner sat across from me last winter and asked why his eyes looked older than his face. He had a soft grayish ring at the outer edge of each iris. His father had died of a heart attack at 47. His LDL, when we checked it, was 244. On the criteria we use for familial hypercholesterolemia, he scored as definite. Which meant the more important conversation was not really about him. It was about his brother, his sister, and his two children, who all needed a lipid panel of their own.

Corneal arcus: a grayish ring at the outer edge of the iris, formed by lipid depositing in the peripheral cornea.

Lean in close and look at the outer edge of the iris where it meets the white of the eye. A grayish-white, blue-white, or yellowish ring at that border is called corneal arcus. It is lipid, depositing in the peripheral cornea.

The interpretation depends almost entirely on age. In older adults, corneal arcus is largely an age-related change, and once you account for age the Framingham cohort found that arcus, by itself, no longer predicts cardiovascular disease.

Corneal arcus before age 45 is a different matter. It is a recognized criterion in the Dutch Lipid Clinic Network scoring system for familial hypercholesterolemia, an inherited condition where lifetime cholesterol exposure runs high from a young age and where treating early meaningfully changes outcomes. If a first-degree relative has been diagnosed, cascade screening (a lipid panel on parents, siblings, and children) is the highest-yield thing that finding can do. Arcus in anyone under 50 is still worth mentioning to your doctor as a possible clue to a lipid disorder, even outside the formal FH criteria.

One more thing to know. If the ring shows up on only one eye, that asymmetry has been associated with narrowing of the carotid artery on the opposite side. The mechanism is counterintuitive: the narrowed artery sits on the side of the eye without the ring, because reduced flow on that side keeps the lipid from depositing there. It is rare. It is worth mentioning specifically.

Under 50 and see either pattern? Treat it the way you would treat a xanthelasma. Book the visit.

4. Dark, velvety skin at the nape of your neck

A teenage patient once told me his mother kept scrubbing the back of his neck because she thought he was not showering. He was. The skin at the nape was velvety, brownish, and would not come off. His labs showed the picture of insulin resistance, and his BMI was in a range no one had thought to worry about. He was the exception, and that is part of why I remember him: most of the acanthosis I see is in people carrying extra weight. His story is the reminder that the skin finding can arrive first.

Acanthosis nigricans at the nape of the neck, with several small skin tags along the same crease.

Turn a bit and look at the back of your neck, at the folds under your jaw, and in your armpits. Brownish-to-black, thickened, velvety patches, the kind of finish that can make skin look dirty even after you have scrubbed it, are acanthosis nigricans. Small, soft, stalk-like skin tags (acrochordons) often keep them company along the same folds. On darker skin the color contrast is subtler, so look for the change in texture rather than the change in shade.

Both are visible clues to insulin resistance, the state in which the body has to make more and more insulin to keep blood sugar in range. Acanthosis nigricans is closely tied to hyperinsulinemia, and dermatologists have described it as a clinical stand-in for laboratory-measured insulin resistance, though the same review is careful to note that acanthosis is neither necessary nor sufficient for the diagnosis and that obesity itself is a stronger determinant. Skin tags are also nonspecific and occur commonly in people without any metabolic issue at all.

Insulin resistance is one of the central pathways linking abdominal weight gain to high blood pressure, fatty liver, unfavorable cholesterol patterns, and type 2 diabetes, most of which are relevant to the heart. In women, acanthosis nigricans can also be part of the picture of polycystic ovary syndrome.

One different scenario, worth naming plainly. Acanthosis that appears rapidly, spreads extensively, or is itchy in an adult can, rarely, be a paraneoplastic sign of an internal cancer, most commonly of the stomach or another abdominal organ. That pattern needs a same-week appointment, not a routine one.

In every version of this story, the destination is the same doctor. Only the timeline changes.

5. Your gums when you brush

The last thing most of us do at the mirror is brush our teeth, and the sink gives an honest verdict. Occasional bleeding after a change in floss technique is common and reversible. Persistent bleeding on brushing, gums that have receded up the tooth, and teeth that feel loose are the visible face of periodontal disease.

Inflamed, bleeding gum tissue at the margin between gum and tooth: the visible face of periodontal disease.

Of all five signs in this article, this is the one where it is easiest to overstate the case. Let me walk up the ladder honestly and stop where the evidence stops.

What is reasonably well established is that people with periodontitis have, on average, modestly higher levels of inflammatory markers like C-reactive protein and interleukin-6 than people with healthy gums. Treating gum disease is associated with a short-term reduction in CRP that is variable across trials, appears to fade by a year, and has not been shown in patients who already have cardiovascular disease. In the Tonetti randomized trial, intensive periodontal treatment improved endothelial function (how well small blood vessels relax and open) for several months.

What is not established is the final rung: that treating gums prevents heart attacks and strokes. No randomized trial has yet shown a reduction in hard cardiovascular events after periodontal treatment. Mendelian randomization studies, a genetic technique that can strengthen causal inference, have on the whole not supported a causal relationship between periodontitis and coronary disease or stroke. The American Heart Association’s 2025 update is explicit: gum disease is an associated risk marker for heart attack, stroke, atrial fibrillation, and heart failure, but a direct cause-and-effect relationship has not been proven, and shared drivers (smoking, diabetes, chronic inflammation, socioeconomic circumstances) may explain part of the overlap.

So where does that leave the mirror? Persistently bleeding gums are a visible clue that a chronic, low-grade inflammatory state may be present, and that some of the same drivers that damage gum tissue may also be acting on artery walls elsewhere. They are not proof of heart disease. Treating them is not a proven way to prevent it. But they are not “normal” either, and they belong on the list of reasons to see a dentist promptly and to mention the finding at your next primary care visit.

One safety note. Bleeding gums that are new, heavy, or accompanied by easy bruising, nosebleeds, or bleeding from other sites, especially in a patient on warfarin, a direct oral anticoagulant, or a strong antiplatelet regimen after a stent, need a same-week appointment rather than a routine one.

How to use these five

None of these signs, by itself, causes a heart attack. None of them is a causal risk factor, meaning something you could change and thereby change your risk. Each is a flag: a visible clue that a real risk factor may already be in the bowl.

A diagonal earlobe crease. The accumulated wear-and-tear of ordinary cardiovascular risk factors may already be at work. The underlying mechanism is still debated.
A xanthelasma. The body may be handling cholesterol in a way a routine lipid panel does not fully capture.
Corneal arcus before 45. A formal criterion for familial hypercholesterolemia. Arcus in anyone under 50 is a broader clue worth mentioning.
Acanthosis nigricans at the nape. A well-recognized clue to insulin resistance, with the caveats above.
Persistently bleeding gums. A clue to chronic low-grade inflammation, one of the modifiable contributors to cardiovascular risk over time, though treating the gums has not been shown to lower cardiac risk.

The real ingredients (high blood pressure, an unfavorable cholesterol pattern, smoking, diabetes, insulin resistance, a sedentary lifestyle, a poor diet, a strong family history of early heart disease, and chronic low-grade inflammation) are what actually bake the cake when enough of them collect in the same bowl. The five findings in this article are not enough, on their own, to bake anything.

They are the flags you can see for free every morning without a blood draw or a scan. Each one points to an ingredient a check-up can look for.

If you notice one, especially corneal arcus before 50, a xanthelasma at any age, new acanthosis nigricans, or long-standing bleeding gums, that is a legitimate reason to book a visit with your primary care physician, who can weigh it against the rest of your history and decide what, if anything, is worth testing.

The mirror does not diagnose anything. What it can do is show you a flag, and give you the chance to have that conversation a year earlier than you otherwise would.

In prevention, a year is often the whole margin.

If cardiovascular risk for women in and around menopause is what you came here for, that conversation lives at our sister publication, The Menopause Heart.

The Integrative Cardiologist is a free patient-education publication and is not a substitute for individualized medical advice. Nothing here constitutes a diagnosis or a recommendation to start, stop, or change any medication or treatment. If you notice a new or worsening physical finding, please speak with your own physician.

Five Calcium Scores, Five Different Plans

Dr. Sameer Azhak — Tue, 01 Sep 2026 12:01:55 GMT

By Sameer Azhak, MD, FACC

At 58 Robert was 4 years away from the age his dad died. Calcium score 340, LDL 165, he came in to be seen. I could feel the tension when I walked in to greet him. He still had his coat on. The printout was folded into quarters in his shirt pocket, and he had folded and unfolded it enough times that the crease had gone soft.

He had read the number to his wife over the phone from the parking lot of the imaging center. By the time he sat down across from me he had already done what most people do, which is search the number, land on a survival curve built from a population he has never met, and decide that 340 is a sentence with a date attached to it.

It is not. And the reason it is not is the whole subject of this letter. Robert is not one of the five patients I am going to walk you through today. He is every patient who has ever come into my office holding one of these reports.

I have been ordering coronary calcium scans for most of my career, and I have watched the same test do two different jobs depending on what the patient walks out of the office holding. Without context, the number is what they think about at two in the morning. With a plan around it, the same number can be the most useful piece of information they have ever received about their own body. Same scan, same score, different interpretation.

So let me do here what I do in the room. Five patients from my practice. Five scores. Five different plans. The patients are composites, with identifying details changed and the physiology kept honest.

What the number in Robert’s pocket actually counts

One paragraph on the picture itself, because it changes how the score lands. Think of arterial plaque the way you think about spackle. When the wall of an artery gets injured, the body patches it. Early on, that patch is wet spackle — soft, lipid-rich, unfinished, easy to knock loose. Over years, the body cures the patch. Calcium moves in, the patch hardens, and what was soft becomes stone. What the scanner sees is a repair reaching completion.

The calcium scan photographs the cured spackle. The scanner counts every coronary speck at 130 Hounsfield units or higher, multiplies the area of each speck by a weighting factor tied to its peak density, and adds it all up. That sum is the Agatston score, and the density weighting runs from 1 for a lesion in the 130 to 199 range up to 4 for anything 400 and above. The scan takes about ten seconds of breath-hold, uses no contrast, and delivers roughly the radiation of a mammogram.

So the number in Robert’s shirt pocket is a count of finished repairs. Hold that. Everything below follows from it.

Frank at 1,247, and the stress test that lied

Frank is 78. Retired postal supervisor, widowed two years, lives alone in the house he raised his kids in. His score came back at 1,247. He had walked six minutes on a Bruce protocol treadmill test the week before, and the nuclear images from that study had been read as normal. He came to see me because he had noticed, over the previous month, that walking the empty garbage cans back up to the street left him more winded than it used to. Not chest pain. Just a fatigue at the end of the driveway that hadn’t been there in June.

Six minutes on a Bruce is a short study, and a normal perfusion scan in a 78-year-old with a calcium score above 1,000 is a combination I do not take at face value. Nuclear perfusion imaging compares blood flow across territories of the heart. It looks for a relative defect — one wall darker than its neighbor. When all three coronary arteries are narrowed to roughly the same degree, every wall dims together, the relative comparison finds no defect, and the study reads out as normal. Cardiologists call this balanced ischemia. It is a well-documented false-negative pattern in triple-vessel disease, and it is exactly the kind of miss a very high calcium score is designed to catch.

A Journal of Nuclear Medicine study looked at exactly this scenario — patients with normal SPECT imaging and a calcium score above 1,000 who went on to cardiac catheterization. The added diagnostic yield was substantial, and the mechanism was not always balanced ischemia in three-vessel disease. Sometimes a single vessel was severely narrowed and the nuclear study had simply missed it. For me, a normal stress test in a patient with a 1,247 is not an ending. It is the next question.

I laid the two paths out for Frank in the office. One was a CT angiogram, non-invasive, contrast in a peripheral vein, a definitive answer for whether obstructive disease was there. The other was a diagnostic catheterization, invasive, definitive for both anatomy and treatment in the same setting if a lesion needed a fix. He chose the cath. He wanted the answer and, if there was a fix, he wanted it in the same visit. He had three-vessel disease. He is now three months out from bypass surgery and back to walking the trash cans up the driveway without stopping.

The calcium score and the stress test ask different questions. The stress test asks whether the heart muscle is short of blood right now. The calcium score asks how much repair work is written into the walls of the arteries. When the two disagree, the calcium score is often the one telling you the truth.

Tony walked thirteen minutes

Tony is 65. Two hundred and thirty pounds at five feet nine, built like a man who has been in a gym six days a week for forty years. Retired firefighter, part-time strength coach. He has been on testosterone for twelve years and used anabolic steroids in his forties. His calcium score came back at 1,159, which arrived in his inbox at 6 AM and cost him his morning.

The number, in isolation, put him in the same statistical bin as Frank. In the MESA analysis, a score of 1,000 or higher carried a 4.7-fold adjusted risk of cardiovascular events compared with a zero. Treated from the number alone, Tony would be on maximum medical therapy, a low-dose aspirin conversation, and a rescan schedule.

Then Tony walked thirteen minutes on the same Bruce protocol Frank had done six minutes of. Thirteen minutes on a Bruce is a full-length study. The nuclear imaging was normal. No perfusion defect, no post-stress wall motion change, ejection fraction preserved through recovery. In most practices Tony’s evaluation would have stopped there. I sat down with him and laid out the same two paths I had offered Frank. He knew his exercise capacity, and he knew that a 1,159 with a decade of steroid history was not a number he was going to sleep on. He chose the cath. The coronaries showed mild luminal irregularities. Diffuse calcification of the arterial wall. No narrowing that would justify a stent, no lesion that would justify a bypass.

Two facts about Tony matter. First, anabolic steroids and long-term supraphysiologic testosterone are associated with accelerated arterial calcification independent of the usual risk factors. His 1,159 was, in part, a signature of his pharmacology, not solely a signature of his cholesterol. Second, his exercise capacity was extraordinary and his nuclear study was a full-length, well-powered negative. Balanced ischemia is a threat when the stress test is short and inconclusive. It is a much smaller threat when the patient walks thirteen minutes and the images are clean.

Tony still owned every finished repair on that scan. His plan is aggressive lipid management, tightening of his testosterone protocol in coordination with the physician who prescribes it, and a rescan schedule that lets us watch how the number moves without treating him as if he were about to have an event tomorrow.

Frank and Tony had almost the same number and almost the same reading on their nuclear studies. Their catheterizations found nearly opposite anatomy. Tony’s story argued against the aggressive interpretation the number alone would have earned him.

Marcus, the zero, and the stent he needed anyway

Marcus is 42. Six feet, three hundred and ten pounds. Type 2 diabetes for four years, blood pressure 148/92 on two medications, LDL 113, triglycerides 240, waist circumference the size of a truck tire. Metabolic syndrome, by every classical definition. He had seen an advertisement on the radio for a $99 calcium score at a local imaging center, self-referred, paid out of pocket, and had the scan done on a Saturday morning. It came back zero. The report landed in his inbox with a one-line note that the study was normal.

He came to see me two weeks later because his zero had not made the other thing go away. For the past month he had been getting a pressure in his chest, mid-sternum, when he walked up the two flights of stairs to his office. It went away by the time he sat down at his desk. He had not told his wife. He had not told his primary care doctor. He told me because his cousin, who was his age and heavier than he was, had died of a heart attack four months earlier, and because the zero on his printout and the pressure in his chest did not fit together in a way he could reconcile alone.

He was right that they did not fit. He was wrong about which one to trust. If the calcium score alone had guided the plan, Marcus would have walked out of that imaging center reassured. He had none of the finished repairs the machine was built to detect. His arteries, from the scanner’s point of view, looked clean.

A zero does not cover soft plaque. The scanner cannot see it. Soft plaque is the wet stage, before the calcium arrives, when the cap is thin and the core is lipid-rich and the lesion is the kind most likely to rupture and cause a heart attack. In a 42-year-old with metabolic syndrome, an LDL of 113, and new exertional symptoms, the pretest probability of soft plaque is high, and a calcium score is the wrong tool to rule it out. In the Western Denmark Heart Registry, among symptomatic patients age 40 or younger who turned out to have obstructive coronary disease on CT angiography, 58 percent had a calcium score of zero. In a young symptomatic patient, soft plaque hides from the scanner often.

So Marcus got a stress test. It was positive. Anterior ischemia, exactly where the LAD supplies the heart. Catheterization showed a ninety percent narrowing in the mid-LAD, non-calcified plaque, the widow-maker distribution. He got a stent that afternoon.

Marcus’s zero was accurate. His arteries had not calcified any of the repair work yet. But the injury was there, the plaque was there, and the calcium score is not the test that finds it in a patient like him. The calcium score is a good test for asymptomatic risk stratification and a bad test for a symptomatic patient. No negative calcium score has ever bought a patient of mine an exit from a real symptom.

Marcus’s plan looks like every plan I write for a patient in his situation. Aggressive management of the metabolic syndrome — glucose, blood pressure, weight, sleep, inflammation, and lipids together, not one at a time. High-intensity statin. Dual antiplatelet therapy for the stent, aspirin and a P2Y12 inhibitor for the year the interventionalist and I agreed on. And a slower conversation, over the next year, about the deeper drivers of the injury that put a stent in the heart of a 42-year-old.

The zero was true. It just answered a question I had not fully asked.

Michael, 275, and a spreadsheet

Michael is 54. Real-estate appraiser, thin, runs three miles most Saturdays, LDL 168, HDL 51, triglycerides 118, blood pressure 132/84, hs-CRP 2.4, non-smoker, no diabetes. His primary care doctor calculated a 10-year PREVENT risk of 6.2 percent, which is intermediate, and the two of them decided a scan would settle the question. It came back at 275.

Michael has never taken a statin. He came in with a printout, a spreadsheet of his last five lipid panels, two weeks of home blood pressure readings taken the way I teach it — sit five minutes, rest and breathe, check three times in a row, log the lowest of the three — and a specific ask, which was to be talked out of medication. That home BP method, along with the rest of the natural-first approach to blood pressure, is written up in my book, Lower Your Blood Pressure, available on Kindle now with the paperback releasing October 20.

His 275 sits in the 100 to 299 band, and the 2026 ACC/AHA dyslipidemia guideline treats a score in that band as a marker of established atherosclerosis and moves the LDL target down accordingly. His percentile in the MESA reference tool is above the 75th for a 54-year-old man, which by itself crosses the same threshold. Two independent readings of his scan land in the same place.

Then I told him what the number meant in real terms. In the CAC Consortium follow-up, participants with a score in the 1 to 399 range carried roughly a twofold higher risk of coronary heart disease death compared with a zero after adjustment for the usual risk factors. That is Michael’s trajectory without treatment. The higher the risk you are starting from, the more a statin saves you. A 275 has more to gain from the same LDL reduction than a 25 does.

Michael pushed back where I expected him to. He runs, his weight is fine, and what he wanted to know was whether the running could carry the number the rest of the way. Lifestyle bends risk. It does not close a hundred-point LDL gap. The distance from 168 to where a 275 needs him to be is not a distance running has ever moved anyone.

We added the two together. He started a moderate-intensity statin, kept the running, added two days of resistance work, and we tightened the anti-inflammatory side of the plate. His three-month LDL came back at 71. His hs-CRP came down to 1.1. His real question was never about pills. His real question was whether the number meant he had a disease. It did. So we treated it.

A quick piece of history, because it changes the next patient

Before I introduce Ellen, I want to tell you where the calcium score came from, because the timing explains why the same number now means two different things.

In March of 1990, a Miami Beach cardiologist named Arthur Agatston and a radiologist named Warren Janowitz published a short paper in the Journal of the American College of Cardiology titled “Quantification of coronary artery calcium using ultrafast computed tomography”. The scanner they used was electron-beam CT, a machine fast enough to freeze the moving heart in an era when ordinary CT could not. Multidetector CT eventually replaced it, but the formula they proposed — area of each speck multiplied by a density factor, summed across all three coronary territories — survived intact. Every calcium score you have ever seen is still an Agatston score.

Lovastatin, the first statin the FDA approved, cleared in 1987. Agatston’s paper appeared in 1990. The scan that shows us plaque was invented into a world where the drug that stabilizes plaque had just barely arrived. For the first decade of calcium scoring, we were quantifying a disease process we could only partly treat. The aggressive treatment thresholds in the 2026 guideline are the product of thirty-six years of watching what happens to the number when a real drug meets a real repair. The scan is old technology. The interpretation is where the field has moved, and the interpretation is what the next patient’s story turns on.

Ellen, on treatment for fifteen years

Ellen is also 54. Similar build and roughly the same weekly mileage on the treadmill. Her first-ever calcium score came back at 275 too. She has been on atorvastatin 40 mg since her late thirties because her LDL ran above 220 in her twenties and a strong family history landed her under a lipid specialist’s care early. Her LDL on treatment is 62, her hs-CRP is 0.6, and her Lp(a) is 40 nmol/L.

Same number as Michael, same demographic, different plan.

The first thing I did was slow the room down, because a 275 on a treated patient looks like a treatment failure and it almost never is. I gave her the two sentences I give every long-term statin patient who gets a first-time positive scan.

One: your score is a count of the repairs your body finished. It is not a count of the repairs your body started.

Two: those repairs cured harder on a statin than they would have without one.

That is the statin paradox in one exchange. Statins pull lipid out of the soft core of a plaque and let the repair finish. Serial imaging studies show statin therapy associated with higher plaque density and lower low-attenuation and fibro-fatty plaque volume, and the Heinz Nixdorf Recall investigators documented the same accelerated calcification signal in statin-treated participants. The Agatston score, remember, weights each lesion by peak density. A patch that hardens without growing at all can score higher than the same patch would have scored while it was still soft. Ellen is not looking at fifteen years of runaway disease. She is looking at fifteen years of successful repair that the scanner can now see because it has cured to the density the machine was built to detect.

I do not tell Ellen the calcification itself is what protects her. I tell her what I can defend at the bedside. Her LDL is 62. Her hs-CRP is 0.6. Her Lp(a) at 40 nmol/L sits on the reassuring side of the risk cutoff. The number on her scan is a picture of repairs her body finished on a drug that helped them finish. Her clinical risk profile is what drives her plan, and by that profile she is exactly where I want a 54-year-old with her genetics to be.

Michael and Ellen have the same score and different risks. Michael’s 275 is a snapshot of untreated disease. Ellen’s is a snapshot of treated disease. The scanner does not distinguish between the two, so the physician has to.

For the untreated patient the same number means start. For the treated patient it means do not confuse the density of a successful repair with the failure of one.

Ellen kept her atorvastatin. Ellen’s plan is Ellen’s plan: an NMR lipoprofile to resolve the LDL into particle number and size, an eye on the Lp(a) where it already sat on the reassuring side of the cutoff, and continuation of the work that had brought her hs-CRP to 0.6 — anti-inflammatory eating, sleep, and stress management alongside the drug. Her plan was written in her thirties. Her scan confirmed it.

What none of the five scores said

Every one of those numbers was silent on the same four things, and I would rather say them plainly than let a reader discover them the hard way.

The score does not measure narrowing. It counts calcium. Blockage is a separate question with separate tests. Frank had a very high score and severe blockage. Tony had a very high score and almost no blockage. Same number, different angiograms.

The score does not measure soft plaque. It is blind to exactly the lesions most likely to rupture, which is why Marcus’s zero did not close the question in a symptomatic 42-year-old with metabolic syndrome. A zero from an asymptomatic 60-year-old with good numbers is a strong negative finding. A zero from a symptomatic 42-year-old with metabolic risk factors is the wrong test at the wrong time.

The score does not overrule symptoms. A zero in an asymptomatic person is powerful. A zero in a person with chest pain or exertional dyspnea is useful but not absolute. In a pooled analysis, a zero calcium score ruled out obstructive disease in 97 percent of patients with stable chest pain and 98 percent with acute chest pain. Those are strong numbers. They are not 100. Symptoms get evaluated on their own terms.

And the score does not tell you what caused it. The number counts the repairs. It says nothing about what kept injuring the wall in the first place. That answer comes from a blood draw and a conversation: LDL and apoB, Lp(a), blood pressure, fasting insulin and A1c, hs-CRP, sleep, and how much of the day is spent in a low-grade inflammatory state. The calcium score is where the workup starts, not where it ends. It tells me the fire has been burning. It does not tell me where the pilot light is.

Before you close this

The score counts the patches, not the leaks. It does not tell you whether the artery you are looking at is a Frank or a Tony, whether a zero is a Marcus, or whether a 275 is a Michael or an Ellen.

Five numbers, five plans, one test that was never designed to deliver a verdict.

What I am after in every one of these plans is the same three things. Calm the fire. Shrink the spackle bucket. And if there is a lot of sticky spackle, shrink the bucket a lot and the fire absolutely has to be out.

If you have a score, look up two things next to it: your absolute number and your percentile for your age and sex. A zero with symptoms does not answer the symptom. A first-time positive scan on a long-term statin is not a treatment failure until Ellen has been read again. And a score above 1,000 with a normal stress test is a set of results that only makes sense when you look at all of it together, the way I looked at Frank’s.

A few questions patients ask me. Can I lower my score? Not reliably; stabilizing what it represents is the goal. Should I rescan? Not for at least 3 to 5 years, and only if the result would change what we do. Does a high score mean I need a stress test? Not by itself, and not in the absence of symptoms.

If you are sitting with a folded printout in your pocket right now, the feeling you are having is the correct feeling, and it does not have to last. It usually takes about two visits for a frightening number to become a working number.

There is a younger healthier version inside of you and we are going to set them free together.

I will be here when the numbers come back.

Sameer Azhak, MD, FACC is a board-certified cardiologist with fellowship training in integrative medicine through the Andrew Weil Center. He writes The Integrative Cardiologist and its sister publication, The Menopause Heart. Reader mail reaches him at hello@theintegrativecardiologist.com.

This article is for educational purposes only and does not constitute medical advice or create a physician-patient relationship. Please consult your own physician before making changes to your treatment.

Medical Disclaimer & Privacy Policy

Dr. Sameer Azhak — Sat, 22 Aug 2026 04:19:47 GMT

Medical Disclaimer

This publication is written by Sameer Azhak, MD, FACC, a board-certified cardiologist. It is provided for general educational and informational purposes only. It is not medical advice, is not a substitute for professional medical care, and does not create a physician-patient relationship between you and Dr. Azhak, Cordate Press, or Integrative Cardiology LLC.

Do not start, stop, delay, or change any treatment, medication, or supplement based on what you read here. Always consult your own physician about your specific medical situation. Dr. Azhak is licensed only in New Jersey; nothing here constitutes the practice of medicine in any other jurisdiction.

If you think you may be having a medical emergency, call 911 or go to the nearest emergency department immediately.

Please do not send protected health information or clinical questions by email or in comments — those channels are not HIPAA-secure. For the full, canonical disclaimer and privacy policy — including how subscriber data is handled by Substack and this publication — see drazhak.com/medical-disclaimer and drazhak.com/privacy.

Contact

For general questions (not clinical), use the contact form at drazhak.com. For patient care, please schedule with Heart & Vascular Associates at (973) 942-1141.

This page will be kept up to date. Last updated: August 2026.

Welcome to The Integrative Cardiologist

Dr. Sameer Azhak — Wed, 19 Aug 2026 19:28:29 GMT

If you take one thing from this letter, take this: most heart disease is preventable, and prevention is a lot bigger than a pill.

I’m Dr. Sameer Azhak — a board-certified cardiologist and Fellow of the American College of Cardiology. For more than twenty years I’ve been the person patients come to after the cholesterol result, after the calcium score, after the sleepless night on Dr. Google. I trained conventionally at Seton Hall’s cardiovascular fellowship, and then, because I kept running into questions that cardiology alone couldn’t answer, I completed a fellowship in Integrative Medicine at the Andrew Weil Center for Integrative Medicine at the University of Arizona.

That combination is what this publication is about.

What “Preventative Cardiology, Integrated” actually means

I don’t call myself an integrative cardiologist — that’s not a real board, and I care about accuracy. What I do is combine two disciplines that usually live in separate hallways:

• Conventional cardiology: the trials, the labs, the imaging, the medications. The evidence base that has cut heart-attack mortality in half in my lifetime.

• Integrative medicine: nutrition, sleep, stress physiology, mind-body medicine, supplements when they’re indicated (and honesty when they aren’t).

Neither one, on its own, is enough. A statin without a plate that isn’t inflaming you every day is a rescue mission. A perfect Mediterranean diet without a look at your genetics (Lp(a), crp, homocysteine, ldl particle size and number, APO B) is a blind spot. This letter is where I bring both into the same conversation, in plain English, without the wellness hype and without the pharma-brochure minimalism.

What we’ll cover

Here’s the running docket:

• The numbers that matter. LDL (particle size and number), ApoB, Lp(a), hs-CRP, homocysteine, coronary calcium — what to ask for, when, and how to read the result.

• Food as cardiology. Anti-inflammatory eating, the real Mediterranean pattern (not the marketing version), and the shortlist of foods with the best evidence for your arteries.

• Blood pressure. What the number actually means, when to treat, and the lifestyle levers that move it the most.

• Cholesterol without the fear. Statins, Injectables, other pills, natural strategies, and when each is appropriate.

• Supplements. What has real data behind it, what doesn’t, and what to spend nothing on.

• The physiology of stress and sleep — and why cardiology has stopped ignoring them.

• How to read your own tests. Echocardiogram, stress test, CT calcium score, coronary CTA — how a cardiologist reads them, translated for you.

If you’ve been told “your numbers are fine” but something feels off, or “you should be on a statin” without anyone explaining why, or “just eat healthier” without anyone telling you what that means — this letter is for you.

What you won’t get here

• No fear-mongering. Cardiology can be sold as a horror movie. I refuse.

• No supplement affiliate links. If I recommend something, it’s because the evidence recommends it — not because someone paid me to say so.

• No replacement for your own doctor. This is education, not care. Nothing here creates a doctor-patient relationship. Bring what you learn here to your own physician.

A note on the sister publication

If you are a woman navigating perimenopause or menopause, your cardiovascular story has a chapter that gets its own letter: The Menopause Heart. Same author, same evidence-first tone, focused on the specific hormonal and vascular shifts that happen after 40. Cross-subscribe if you want both — I write them as companions.

What happens next

I’ll be publishing regularly — expect the first substantive article within the week. If you’re reading this because you already know me, thank you for being here from day one. If you found this letter through a search or a friend, welcome; the archive will grow quickly.

Two small favors:

1. Hit subscribe. It’s free. It’s how new posts find you.

2. Send this to one person whose heart you care about. That’s how this publication grows, and how better cardiology reaches more people.

Your heart is doing something remarkable right now — roughly 100,000 beats today, without a single conscious instruction from you. Let’s give it the care it deserves.

— Dr. Sameer Azhak

Board-certified cardiologist · Andrew Weil Center Integrative Medicine

Wayne, New Jersey